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HIV-1 Reverse Transcriptase (RT) is entirely responsible for conversion of viral RNA into 
dsDNA in the host cell cytoplasm, making it an attractive drug target.  Nonnucleoside RT 
Inhibitors (NNRTIs) are highly effective in the treatment and prevention of HIV, yet their 
mechanism of action remains unknown.  Furthermore, NNRTI resistance mutations arise from 
therapy, complicating treatment, yet the mechanism(s) of how these mutations inhibit 
polymerization by RT is unclear.  In Chapter 2, we examine the role of NNRTI on the dynamics 
between RT and its Template/Primer (T/P) substrate using a combination of single-molecule and 
bulk fluorescence techniques which provide an unprecedented glimpse into the dynamics of RT-
T/P interaction as well as the intramolecular conformation of RT itself while bound to its 
substrate. We show that efavirenz, an NNRTI, causes RT to relinquish its grip on the T/P 
substrate via “molecular arthritis," accompanied by increased shuttling on the substrate, reducing 
time spent in a polymerase-competent configuration. The K103N mutation relieves the arthritis 
in the fingers and thumb sub-domains of RT, enabling the efavirenz-bound enzyme to form a 
stable polymerase-competent complex.  We demonstrate that relief of molecular arthritis is likely 
caused by disruption of a salt bridge between K101 and E138, residues at a key hinge site in the 
RT heterodimer. The data suggests a unique mechanism of resistance that is mediated by 
interplay between intramolecular conformational changes in RT and intermolecular dynamics of 
the RT-template/primer-dNTP complex.  In chapter 3, we discuss ongoing experiments to probe 
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 5 
the intramolecular dynamics of RT on the T/P substrate in response to NNRTIs.  Combining 
time-resolved measurements of interdomain distances within RT as it binds and responds to 
NNRTIs in real time with atomistic molecular dynamics simulations of RT, we are attempting to 
characterize on-pathway structural intermediates of NNRTI-induced conformational change.  
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PROLOGUE 
“Strengths 
 None 
Weaknesses 
 
 Single molecule FRET studies of reverse transcriptase in combination with computational 
analysis will not have the resolution to improve or develop new inhibitors. 
 
 The approach will not provide a clear understanding of the effects of drug resistant 
mutations on inhibitor binding affinity. 
 
 While studies of this type have value for our understanding of large scale protein 
motions, they are not, at least at this point, sufficiently detailed to provide practical 
information for the development of better drugs” 
 
 
 
Reviewer 1, NIH R21 Study section 
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1.0  INTRODUCTION 
Approximately 34 million people worldwide are infected with human immunodeficiency virus 
(HIV), the etiological agent of acquired immunodeficiency syndrome (AIDS), causing 1.7 
million deaths in 2011 alone (UNAIDS, 2012).  There are two subtypes of HIV: HIV-1 and HIV-
2, with HIV-1 being the most common and virulent strain.  Standing for “major,” the M group of 
HIV-1 is responsible for over 90% of clinical cases of HIV worldwide and can be further 
subdivided into subtypes A-K, which are classified according to their predominant clinical 
presentation in various regions around the world (Sharp and Hahn, 2011).  Currently the most 
popular drug target against HIV/AIDS, HIV-1 Reverse Transcriptase (RT) transcribes retroviral 
(+)RNA into human cDNA, a crucial step in the retroviral life cycle.  There are currently thirteen 
FDA approved RT Inhibitors (RTIs) which are typically administered as highly active 
antiretroviral therapy (HAART), i.e., in combinations with 2 or more other RTIs (Menéndez-
Arias, 2013). Although these regimens are highly effective, new drug-resistant mutations are 
constantly arising which can greatly reduce the efficacy of RTIs, posing a challenge to 
researchers attempting to design more efficacious RTIs (Esposito et al., 2012; Le Grice, 2012).  
It is therefore imperative to understand the mechanism(s) of inhibition of this remarkably 
versatile enzyme in detail, including an understanding of the molecular mechanism(s) of RTI 
resistance.   
 17 
1.1 HIV-1 LIFE CYCLE 
HIV-1 hijacks the host cell in order to replicate (Sluis-Cremer and Tachedjian, 2008).  Upon 
fusion with a CD4+ T-lymphocyte, mediated by gp41 and gp120 on the viral envelope and CD4 
and either the CXCR5 or CCR5 coreceptors on the cell surface, the viral envelope fuses with the 
host cell membrane, releasing the viral capsid into the cytoplasm.  This capsid packages two 
copies of the same remarkably simple (+) ssRNA genome (see Figure 1.1).   
 
Figure 1 Organization of the HIV-1 genome.   
The schematic indicates the relative distribution of genes from 5’-3’, including the three major genes, gag, pol, and 
env, as well as regulatory (tat and rev) and accessory (vif, vpr, vpu, and nef) genes, flanked by the long terminal 
repeat (LTR) regions designated R, U5, and U3.  RT, encoded by the pol gene, is highlighted in red, indicated next 
to the coding sequences for protease (PR) and integrase (IN).  Figure adapted from Menendez-Arias, 2013.  
 
The HIV-1 genome consists of several open reading frames (ORFs) flanked by long 
terminal repeat sequence (LTR), designated U5, R,  and U3, a 5’ cap (Gppp) and a 3’ poly(A)tail 
(see Figure 1.1). These ORFs encode the three structural genes, gag, pol, and env, as well as 
regulatory (tat and rev) and accessory genes (vif, vpr, vpu, and nef; see figure 1.1). For the 
purposes of this review, we will focus on pol, the gene which encodes the Pol polyprotein 
consisting of the enzymes RT, integrase (IN), and protease (PR) (see Lee et al., 2012 for more 
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information). PR is required to cleave components of the Gag polyprotein, but is also required to 
cleave RT.  IN is required to integrate the dsDNA product of RT into the host cell genome. 
 The 640 bp LTR flanking the HIV-1 genome contains enhancers and promoters 
necessary for transcription (Esposito et al., 2012).  Particularly important for the life-cycle of 
HIV-1 RT, the 18 nt PBS, or primer binding site, is a sequence in the U5 region which is 
complementary to 18 nt of the tRNALys, required to prime reverse transcription initiation (see 
Figure 1.2).  
HIV-1 RT is an RNA- or DNA-dependent DNA polymerase and also contains 
ribonuclease H (RNase H) activity, containing all the necessary enzymatic activity for 
conversion of HIV-1 ssRNA into dsDNA, which is then inserted into the human genome with IN 
(Figure 1.2) (Sarafianos et al., 2009; Sluis-Cremer and Tachedjian, 2008). Reverse transcription 
(Hu and Hughes, 2012) is initiated at the 3’-end of cellular lysyl-tRNALys,3, which hybridizes to 
the primer binding site (PBS) on the HIV-1 genome. RNA-primed RT elongates until the 5’-end 
of the HIV-1 RNA is reached (Initiation), forming minus-strand strong-stop DNA. Employing 
the RNase H activity of RT, the remaining HIV-1 genomic RNA is cleaved to allow the 
nascently synthesized DNA to circularize and hybridize with the repeat sequence (R) at the 3’end 
of the HIV-1 ssRNA. After this strand transfer, the nascent DNA strand is further elongated by 
RT. RT hydrolyzes the remaining RNA but leaves behind a purine-rich sequence named the 
polypurine tract (PPT), which subsequently serves as a primer for the initiation of second strand 
DNA synthesis. RT then elongates the PPT primer. The RNase H activity of RT removes all 
remaining RNA, including the tRNA primer and the PPT. Strand transfer takes place by PBS 
sequence homology. DNA polymerization and strand-displacement followed by further DNA 
elongation results in an integrase-competent dsDNA, which is flanked by LTR at both ends.  
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This dsDNA is then a substrate for integrase, which catalyzes the insertion of dsDNA into the 
human genome (Sluis-Cremer and Tachedjian, 2008). 
 
 
 
Figure 2. Reverse Transcription.   
Schematic of the multistep process of conversion of viral RNA (red) into integrase-competent dsDNA (bottom) for 
insertion into the human genome.  Figure adapted from Sluis-Cremer and Tachedjian, 2008. 
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1.2 HIV-1 REVERSE TRANSCRIPTASE: STRUCTURE AND FUNCTION 
Able to efficiently catalyze DNA polymerization on a variety of substrates (i.e., RNA/DNA, 
DNA/DNA) and also possessing RNase H activity, RT is an astonishingly versatile enzyme 
(Sarafianos et al., 2009), perhaps due in large part to its modular structure.  
 RT is a 110 kD heterodimer composed of two subunits: p66 (560 aa long) and p51 (440 
aa long) (Divita et al., 1993a).  Both subunits are a product of proteolytic processing of a gag-pol 
polyprotein by HIV-1 protease (PR).  In p51, the RNase-H domain (residues 550-560) has been 
cleaved, resulting in a structure that shares secondary structural elements with p66.  However, 
since the overall tertiary structure is spatially configured differently than p66, p51 only plays a 
scaffolding role for p66, the only subunit in the RT heterodimer to possesses polymerase and 
RNase H activity (Jacobo-Molina et al., 1993; Kohlstaedt et al., 1992). 
 Like other DNA polymerases, RT is shaped like a right hand (Kohlstaedt et al., 1992).   
Its subdomains are accordingly named: fingers (residues 1-85 and 118-155), thumb (residues 
237-318), palm (residues 86-117), and connection (319-426) subdomains (see Figure 3).  In the 
apo structure of RT (e.g., Rodgers et al., 1995) the thumb and fingers domains are nearly in 
contact, and the thumb resides in the nucleic acid binding cleft (see Figure 7, left for a view of 
unliganded RT) (Esnouf et al., 1995; Rodgers et al., 1995). To accommodate T/P substrates in 
the nucleic acid binding cleft, the thumb must extend outward.  Pre-steady-state kinetic analysis 
showed that binding to the T/P and dNTP substrates is a two step process involving initial entry 
of the T/P into the nucleic acid binding cleft and a slow step dependent on conformational 
change of the enzyme to accommodate cognate dNTP, which can increase the overall binding 
affinity to the T/P substrate (KruhØfter et al., 1993).  The resultant binary complex contains a 
T/P substrate simultaneously spanned by a polymerase and an RNase H approximately 18 bp 
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apart.  Remarkably, RT is able to flip on template/primer substrates and can reside in different 
relative orientations based on the composition of the template/primer alone (Abbondanzieri et al., 
2008). 
 
           
Figure 3. Structure of RT. 
RT is pictured as a solvent-accessible surface area model (taken from PDB ID: 1RTD).  The DNA/DNA 
template/primer  is shown as cartoon.  The p51 subdomain is colored in grey, and the p66 subdomain is subdivided 
into thumb (green), fingers (red), palm (purple), connection (wheat), and RNase H (blue) domains.  The polymerase 
active site is colored in yellow.  
 
RT clamps down on the incoming nucleotide with its fingers (Huang et al., 1998), 
specifically, via the Lys65, Arg72, Asp113, and Ala114 residues of the e β3- β4 loop (Le Grice, 
2012). Structures of RT complexed with a DNA/DNA template/primer that has been dideoxy 
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terminated at the 3’-end (to create a dead-end complex in the presence of cognate dNTP) 
identified the binding site of dNTP:  Asp113, Tyr115, Phe116, and Gln151 (Huang et al., 1998).  
In agreement from pre-steady-state kinetics data and based on data from other polymerases (Kati 
et al., 1992; Kirmizialtin et al., 2012), it was proposed that fingers clamping of dNTP is a rate-
limiting prerequisite to catalysis (Sarafianos et al., 1999).  Pre-steady-state kinetic analysis 
showed that dNTP incorporation rates depend upon the composition of the T/P substrate, and 
suggested that RT can bind T/P substrates in productive or nonproductive complexes in terms of 
dNTP incorporation, and that the T/P must isomerize in order for the RT-T/P complex to be 
converted into a productive one (Wöhrl et al., 1999). It was further shown that the rate-limiting 
step of fingers bending is on the order of milliseconds and that the conformational change itself 
governs dNTP specificity (Kirmizialtin et al., 2012).    
The bending of the fingers clamp precisely positions dNTP for incorporation, which is 
coordinated with the positioning of the growing primer by the “primer grip,” composed of the 
β12-β13 hairpin (Jacobo-Molina et al., 1993). Finally, formation of a nascent phosphodiester 
bond on a growing primer (i.e., DNA polymerization) is coordinated by the catalytic triad in the 
palm subdomain (D110, D185, D186; part of the conserved YXDD motif), which is a conserved 
process amongst polymerase and is dependent upon two divalent metals (Steitz, 1998).  The 
process of nucleotide addition ends in release of pyrophosphate, which is accompanied by 
fingers domain opening. In order for processive replication to continue, the T/P substrate needs 
to translocate 1bp with respect to RT, a process which is possibly linked potential energy stored 
in the YMDD loop, akin to a loaded springboard (Götte et al., 2010; Sarafianos et al., 2002).  
 
 23 
1.3 REVERSE TRANSCRIPTASE INHBITORS 
The US Food and Drug Administration (FDA) has approved 13 RTIs for the treatment of HIV-1 
infection, although only 11 of these are currently used (see below). These inhibitors, all of which 
bind at or near to the DNA polymerase active site of the enzyme, can be classified into two 
distinct groups: (1) the nucleoside and nucleotide RT inhibitors (NRTIs) and (2) the 
nonnucleoside RT inhibitors (NNRTIs) (Arts and Hazuda, 2012).  
First-line antiretroviral therapy (ART) for the treatment of HIV-1 infection typically 
includes two NRTIs in combination with an NNRTI or a protease inhibitor. NRTIs and NNRTIs 
are also routinely used in second-line and salvage ART therapies. HIV-1 resistance to all of the 
FDA-approved NRTIs and NNRTIs has been documented. An understanding of the mutations 
associated with RT inhibitor (RTI) resistance, the antagonistic or complementary interactions 
between RTI resistance mutations, and the mechanisms of HIV-1 resistance to RTIs is of critical 
importance for the development and formulation of effective ART therapies. Of concern, there 
has been a significant increase in circulating and transmitted NNRTI drug resistance in resource-
limited settings due to the extensive use of NNRTIs in prevention and treatment strategies for 
HIV-1 infection. Despite this increase in NNRTI drug resistance, the next generation 
diarylpyrimidine NNRTIs, dapivirine, etravirine and rilpivirine, will be increasingly used in 
resource-limited settings. As such, there is a continued need to monitor and understand NNRTI 
resistance (Esposito et al., 2012; Menéndez-Arias, 2013; Sluis-Cremer and Tachedjian, 2008). 
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1.4 NRTIS 
The NRTIs are analogs of naturally occurring dNTPs that lack a 3’-hydroxyl group on the ribose 
sugar/pseudosugar. They were the first drugs used to treat HIV-1 infection and they remain 
integral components of nearly all antiretroviral (ART) regimens. To exhibit antiviral activity, 
NRTIs must be metabolically converted by host-cell kinases to their corresponding triphosphate 
forms (NRTI-TP).  
The NRTI-TP inhibit HIV-1 RT DNA synthesis by acting as chain-terminators of DNA 
synthesis (Goody et al., 1991).  Eight NRTIs have been approved for clinical use, namely 3’-
azido-3’-deoxythymidine (zidovudine, AZT), 2’,3-dideoxyinosine (didanosine, ddI), 2’,3’-
dideoxycytidine (zalcitabine, ddC), (-)--2’,3’-dideoxy-3’-thiacytidine (lamivudine, 3TC),  2’-
deoxy-2’,3’-didehydrothymidine (stavudine, d4T), (1S,4R)-4-[2-amino-6-(cyclopropyl-amino)-
9H-purin-9-yl]-2-cyclopentene-1-methanol succinate (abacavir, ABC), (R)-9-(2-
hosphonylmethoxypropyl) adenine (TFV, tenofovir), and 5-fluoro-1-[(2R,5S)-2-
(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine (emtricitabine, FTC) (Figure 1.3). ddC is less 
potent than the other NRTIs, has inconvenient dosing schedules, and is associated with serious 
adverse events. For these reasons it is now rarely used to treat HIV-1 infection. Similarly, the 
World Health Organization advocated that d4T should be phased out of use because of its long-
term, irreversible side-effects. However, d4T is still used in first-line therapy in developing 
countries due to its low cost and widespread availability.  
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Figure 4. Chemical structures of FDA-approved NRTIs   
1.4.1 NRTI Resistance 
NRTI-associated resistance mutations can be broadly categorized into two groups depending on 
their phenotypic mechanism of resistance (Selmi et al., 2003; Sluis-Cremer and Tachedjian, 
2008).  The mutations K65R, K70E, L74V, Q151M (in complex with A62V, V75I, F77L and 
F116Y) and M184V increase the selectivity of RT for incorporation of natural dNTP substrate 
versus the NRTI-TP (Deval et al., 2002, 2004a, 2004b, 2004c; Feng and Anderson, 1999; Selmi 
et al., 2001, 2003; Sluis-Cremer et al., 2007). This resistance mechanism has been termed NRTI-
TP discrimination. In comparison, the mutations M41L, D67N, K70R, L210W, T215F/Y and 
K219Q/E are typically referred to as thymidine analog mutations (TAMs). These mutations 
augment the ability of HIV-1 RT to excise a chain-terminating NRTI-monophosphate (NRTI-
ddC AZT d4T ABC 
ddI TFV FTC 3TC 
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MP) from a prematurely terminated DNA chain (Arion et al., 1998; Meyer et al., 1999). This 
resistance mechanism has been termed NRTI-MP excision. 
 
Figure 5. Residues involved in NRTI resistance   
Structures of RT taken from a) the TTP-bound ternary complex (PDB ID: 1RTD) or b) an AZT-terminated primer in 
the P-site (PDB ID: 1N6Q) are shown, highlighting the residues (sticks) associated with NRTI resistance. 
1.5 NNRTIS 
The NNRTIs are a group of amphiphilic compounds that bind to a hydrophobic pocket in HIV-1 
RT that is proximal to but distinct from the polymerase active site called the NNRTI Binding 
Pocket (NNRTIBP), which is not formed unless an NNRTI is bound (Kohlstaedt et al., 1992; 
Sluis-Cremer et al., 2004). Because the binding pocket is a full 10 Å away from the polymerase 
active site and are noncompetitive with dNTP or template/primer binding (Divita et al., 1993b), 
NNRTI are considered classical allosteric inhibitors of HIV-1 RT DNA polymerization reactions 
(Seckler et al., 2011; Temiz and Bahar, 2002).   The precise mechanism of inhibition by NNRTI 
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(discussed further in section 1.5.1) remains to be entirely understood (Esposito et al., 2012; 
Ivetac and McCammon, 2009; Sluis-Cremer and Tachedjian, 2008), but proposed mechanisms 
have included restriction of thumb flexibility (Kohlstaedt et al., 1992), distortion of the catalytic 
triad (Ren et al., 1995), primer grip repositioning (Das et al., 1996), repositioning of primer (Das 
et al., 2012), and loosening of the thumb/fingers clamp on template/primer substrates (Liu et al., 
2008). 
FDA-approved NNRTIs include 11-cyclopropyl-4-methyl-5,11-dihydro-6H- 
dipyrido[3,2-b:2′,3′-e][1,4]diazepin-6-one (nevirapine; NVP), N-[2-({4-[3-(propan-2-
ylamino)pyridin-2-yl]piperazin-1-yl}carbonyl)-1H-indol-5-yl]methanesulfonamide (delavirdine; 
DEL), (4S)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-2,4-dihydro-1H-3,1-
benzoxazin-2-one (efavirenz; EFV), 4-[6-Amino-5-bromo-2- [(4-cyanophenyl)amino] pyrimidin-
4-yl]oxy-3,5-dimethylbenzonitrile (etravirine; ETV) and 4-{[4-({4-[(E)-2-cyanovinyl]-2,6-
dimethylphenyl}amino)pyrimidin-2-yl]amino}benzonitrile (rilpivirine; RIL). The efficacy of 
delavirdine is lower than that of the other NNRTIs, especially EFV, and it also has an 
inconvenient dosing schedule. These factors have led the U.S. Department of Health and Human 
Services (DHHS)  to recommend against its use as part of initial therapy.  
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Figure 6. Chemical structures of FDA-approved NNRTIs   
 
Despite their widespread use and remarkable efficacy, the mechanism(s) behind inhibition of 
reverse transcription by NNRTIs remains unclear. 
1.5.1 Mechanism of action of NNRTIS 
The mechanism of action of NNRTIs is controversial (Ren and Stammers, 2008; Sarafianos et 
al., 2009).  One possible mechanism is distortion of the catalytic triad (Ren et al., 1995), 
rendering an inactive polymerase.  It has also been postulated that NNRTIs are responsible for 
repositioning the primer grip, eliminating the coordination of primer to the catalytic triad  (Das et 
al., 1996).   Recently, there has been evidence that NNRTIs cause loosening of the thumb/fingers 
clamp on template/primer substrates (Liu et al., 2008), as well as repositioning of primer (Das et 
al., 2012).  
NVP EFV 
ETV 
DEL 
RIL 
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 One persistent observation from the solved crystal structures of RT in the presence of 
NNRTIs is the hyperextension of the thumb domain and a further opening of the fingers domain 
accompanied by a marked decrease in flexibility, also known as “molecular arthritis.” (see 
Figure 6), which appears to be closely related to the existence of a hinge region between the p51 
and p66 subdomains (Bahar et al., 1999; Ivetac and McCammon, 2009). Restriction of thumb 
flexibility was considered a key element in the inhibition mechanism (Kohlstaedt et al., 1992).  
Although it is unclear whether molecular arthritis is functionally tied to inhibition of 
polymerization, there is evidence that it affects the grip on the template/primer substrate.  Liu 
and colleagues found that, while cognate dNTP stabilizes the polymerase competent 
configuration, NNRTI destabilizes this configuration, regulating the sliding dynamics of RT on 
the T/P, indicating that modulation of the grip on the T/P substrate itself by NNRTIs may alter 
RT-T/P dynamics, disfavoring the polymerase mode (Liu et al., 2008).   It is furthermore 
possible that the function of molecular arthritis is to reposition the catalytic triad in a polymerase 
incompetent configuration, as was observed in large, multicopy simulations of apo and NNRTI-
bound RT (Ivetac and McCammon, 2009). 
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Figure 7. Molecular arthritis. 
The structures of apo WT RT (left; PDB ID: 1DLO) and WT RT bound to efavirenz (right; PDB ID 1FK9).  
Structures are represented by solvent-accessible surface area.  The p51 subunit is colored in grey and the p66 subunit 
is colored according to crystallographic B-factors.   
 
Until recently, there only existed structures of RT complexed with dsDNA 
template/primer (T/P) mimic substrates (mostly DNA/DNA, DNA/PPT) or structures of RT 
complexed with NNRTIs, however there was no structure of a ternary RT-T/P-NNRTI complex.  
It has historically been a challenge to find order in the electron density maps of RT-T/P in the 
presence of NNRTIs. Recently, however, a structure of RT crosslinked to a  DNA/RNA T/P 
substrate and bound to neviripine (NVP) was elucidated (Das et al., 2012), wherein the authors 
observed a distortion of the primer grip accompanied by thumb hyperextension and a 5.5 Å shift 
of the 3’-end primer away from the active site, dNTP binding site distortion, and a reduction in 
RT-T/P contacts.  These newly solved structures primarily resemble bunches of grapes and long 
tubes (Deejay Smumilo, personal communication).  Soon after, structures of RT bound to several 
DNA/RNA T/P substrates in the presence of NVP and EFV were solved without the use of 
crosslinking agents (Lapkouski et al., 2013). The structure showed that NNRTIs pushed RT 
toward a degradative/RNase H-competent mode (as opposed to a polymerase competent mode) 
in the context of a hybrid substrate, which is consistent with the findings of Radzio and Sluis-
Cremer, 2008, which indicated that EFV accelerates RNA degradation.  
 
Perhaps counterintuitively, it has been demonstrated that some NNRTIs  act as potent 
chemical enhancers of HIV-1 RT heterodimerization (Tachedjian et al., 2001; Venezia et al., 
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2006).  To date, efavirenz was found to be the most potent enhancer of RT heterodimerization, 
whereas nevirapine has a weak effect and delavirdine has no effect at all (Tachedjian et al., 
2001).  While there doesn’t appear to be a correlation between the impact of NNRTI-mediated 
enhancement of RT heterodimerization and the defects in RT polymerase function (Xia et al., 
2007), recent studies have demonstrated effects of some potent NNRTIs, (e.g., efavirenz, 
dapivirine and etravirine) on the late stages of HIV replication (Tachedjian et al., 2005; 
Figueiredo et al., 2006).   
1.5.2 NNRTI Resistance 
Typically, HIV-1 resistance to NNRTIs correlates directly with mutations of one or more RT 
residues in the NNRTI-binding pocket. Mutations associated with resistance to NVP and EFV 
include L100I, K101E/P, K103N/S, V106A/M, Y181C/I/V, Y188C/L/H, G190A/E/S and 
M230L (Stanford University HIV Drug Resistance Database: http://hivdb.stanford.edu/). 
Although ETV and RIL have been reported to have higher in vitro genetic barriers to resistance 
than EFV or NVP (Andries et al., 2004; Azijn et al., 2010), 17 mutations in HIV-1 RT have been 
associated with decreased virologic response to ETV (V90I, A98G, L100I, K101E/H/P, V106I, 
E138A, V179D/F/T, Y181C/I/V, G190A/S and M230L) (Vingerhoets et al., 2010), and 15 
mutations with decreased virologic response to RIL (K101E/P, E138A/G/K/Q/R, V179L, 
Y181C/I/V, H221Y, F227C, and M230I/L) (Anta et al., 2013). In general, these NNRTI 
resistance mutations can affect inhibitor binding in a number of ways. (1) They can remove one 
or more favorable interactions between the inhibitor and NNRTI-binding pocket. For example, 
the Y181C mutation eliminates π-stacking interactions between this residue and the aromatic 
ring of the NNRTI pharmacophore (Ren et al., 2001). (2) They can introduce steric barriers to 
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NNRTI binding. For example, the G190E mutation introduces a bulky side-chain which may 
prevent NNRTI binding by sterically interfering with functional groups, such as the cyclopropyl 
ring of NVP (Huang et al., 2003; Yap et al., 2007). (3) The mutations may introduce or eliminate 
inter-residue contacts in the NNRTI-binding pocket, which interfere with the ability of other 
residues in the pocket to fold down over the NNRTI (Sluis-Cremer et al., 2004).  
 
Figure 8. Residues involved in NNRTI resistance   
1.5.3 K103N 
A major focus of this dissertation, K103N is the most commonly reported NNRTI-resistance 
mutation (Ren and Stammers, 2008).  It confers high level resistance to a wide range of NNRTIs, 
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notably efavirenz (EFV) and neviripine (NVP) (approximately 20-fold reduction in 
susceptibility) (Clotet, 1999).  Despite its devastating effects on susceptibility to first-gen 
NNRTIs, the mechanism of resistance by K103N remains unclear.  Observations from the first 
structures (Hsiou et al., 2001; Ren et al., 2001) of K103N RT indicated that neither K103 nor the 
mutant N103 residue make any contacts with EFV or NVP (although K103 can H-bond with 
DEL) (Ren and Stammers, 2008). 
 
Figure 9. K103N RT Structure 
The structures of RT harboring Lys103 (WT RT, purple sticks) to Asp103(K103N RT, pink sticks) are shown 
superimposed.  The secondary structure surrounding the NNRTIBP is also shown for the p66 (green) and p51 
(wheat) subunits.  
 
It was initially proposed that the K103N mutation was responsible for adding an extra H-bond 
with Y188 in the NNRTIBP, stabilizing the apo form of RT(Hsiou et al., 2001), however, the H-
bond is relatively weak compared to NNRTI binding. It was later inferred from a K103N/Y181C 
K103N 
EFV 
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double mutant that this H-bond was possibly mediated by a Na
+ 
ion and water molecules in the 
NNRTIBP (Das et al., 2007).    
Unlike first generation NNRTIs, the next generation diarylpyrimidine NNRTIs, etravirine 
(TMC125) and rilpivirine (TMC278) are effective against K103N RT (Andries et al., 2004; 
Azijn et al., 2010; Lansdon et al., 2010; Rawal et al., 2012).  At the moment, it is unclear what 
advantage these inhibitors have over single-moiety NNRTIs, and whether the strengthened H-
bond network conferred by K103N is broken by this new class of NNRTIs. 
1.6 METHODS BACKGROUND 
1.6.1 Single-molecule Total Internal Reflection Fluorescence Microscopy (TIRFM) 
Traditional spectroscopy employs bulk solutions of fluorophore-labeled biomolecules, however, 
bulk averaging of signals, a result of acquiring signal from many unsynchronized kinetic 
processes occurring simultaneously, makes spectra from these techniques difficult to interpret.  
In order to eliminate bulk averaging, we observe individual, surface tethered, fluorophore-
labeled molecules with single-molecule total internal reflection fluorescence microscopy 
(TIRFM; Fagerburg and Leuba, 2011). 
TIRF is an illumination scheme which relies on the difference in refractive indices of 
water and glass to reflect photonic light off of the interface of those surfaces while sending an 
evanescent wave of matching frequency into the sample (see Figure 10; Axelrod, 1989).  The 
wave decays exponentially as Iz = Ioe
-z/d
, where Iz is the intensity at distance z from surface, Io is 
the intensity at the interface, and d is the penetration depth, only penetrating ~100 nm deep.  A 
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low background, high contrast technique, TIRFM effectively eliminates excitation of other 
molecules in solution besides the small illuminated patch under observation.  We use prism-
based TIRFM in these studies, which is ideal for single-molecule experiments (Fagerburg and 
Leuba, 2011).  See Figure 10 for a schematic of TIRFM. 
Biomolecules of interest are tethered to homemade quartz flow cells through biotin-
streptravidin-biotinPEG linkages.  To reduce nonspecific binding of proteins to the surface, flow 
cells are surface passivated by PEGylation (Roy et al., 2008).  Molecules are deposited on the 
surface at optimal surface density (typically ~100 molecules per 512x512 pixel field of view) 
and imaged with a highly sensitive electron multiplying CCD (EMCCD) camera.  The vacuum-
sealed camera CCD is thermoelectrically and liquid cooled to -90C to minimize dark current, or 
signal arising from non-photonic sources such as heat.  Photostability of the fluorophores is 
maximized with oxygen scavengers (to extend the pre-bleaching observation lifetime of the 
molecule to the minutes scale) and triplet state quenchers (to eliminate photoblinking).   
Small regions on the slide surface (~100 μm x 50 μm) are then excited with the 
appropriate excitation wavelength. Molecules can optionally be excited by donor excitation (532 
nm) or acceptor excitation (647 nm) diode lasers. To solely monitor the fluorescence of Cy3 (as 
in PIFE), we simply illuminate our sample with the green (532 nm) laser and collect its emission. 
Alternately, to collect FRET data, we excite the donor and separately collect ID and IA (see 
Figure 10). Using Alternating Laser Excitation (ALEX; Lee et al., 2005), we are additionally 
able to probe the integrity of the acceptor dye by directly exciting it with acceptor excitation. 
Fluorescence emission is collected through a 60x 1.2NA water-immersion objective and 
first passes through a 550LP filter to remove scattered donor-excitation laser light. The 
fluorescence emission is next split into two separate paths via a DualView
TM
 unit (Optical 
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Insights, Inc.) which uses a 610 nm dichroic mirror to split the emission into two fields: emission  
shorter than 610 nm is sent through the donor signal path and additionally filtered by a 580/40 
nm bandpass filter, while wavelengths longer than 610nm are sent through the acceptor signal 
path, it is also filtered by a 660LP filter. The resultant signals are finally imaged onto separate 
halves of a thermoelectrically cooled EMCCD (Andor iXon).  The resultant images represent 
diffraction limited spots, i.e., are a point spread function (PSFs) limited by the optics of the 
system with a maximum resolution of ~250 nm.  The crux of single-molecule spectroscopy, 
however, is to accurately localize the signals of the surface-tethered molecules by fitting the 
PSFs with 2D Gaussian functions and localizing their origin.  Integrating this function extracts 
the time-resolved intensity from a single fluorophore.  In single-molecule FRET experiments, the 
two wavelength-separated projected regions are then superimposed onto each other using linear 
transformation as well as functions which account for small amounts of warping and/or 
aberration in the respective field (Hinterdorfer and Van Oijen, 2009).  
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Figure 10. Schematic of single-molecule TIRFM. 
The setup described in the text is shown in schematic form.  Left: TIRF optics.  Negotiated by a dichroic mirror, 
coherent donor excitation (Dex) and Acceptor excitation (Aex) laser beams are directed through a prism (coupled to 
the slide with index-matching oil) and  into the sample.  The schematic shows theoretical biomolecules harboring a 
Cy3/Cy5 (green/red) FRET pair.   Donor emission (Dem) and Acceptor Emission (Aem) are then projected onto the 
EMCCD.  Right: example image, with donor signals on the left, and acceptor signals on the right.  Below is a 
theoretical donor and acceptor trace resulting from donor excitation (red and green), as well as an acceptor trace 
resulting from acceptor excitation (pink).  Trace shows anticorrelated behavior indicative of FRET, as well as 
photobleaching of both dyes. 
 
Acquiring image stacks at speeds of up to 30 ms/frame for a 512x512 pixel region and 15 
ms/frame for a 512x256 pixel region, we are then able to simultaneously observe hundreds of 
individual fluorescence intensity trajectories per region, making TIRFM a robust technique for 
monitoring many kinetic processes in parallel and at high temporal resolution.  
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1.6.2 Fluorescence Anisotropy 
Fluorescence anisotropy (Lakowicz, 2006) takes place in a standard bulk spectrofluorimeter 
which includes linear polarizers mounted to motorized stages.  Circularly polarized fluorescence 
excitation and emission can be linearly polarized in the vertical or horizontal axes by these filters 
according to their relative orientation. Polarized excitation of a fluorescent sample results in 
polarized fluorescence. Gradually, polarized fluorescence emission returns to unpolarized 
fluorescence, depending on the timescale of rotational diffusion; rapidly tumbling fluorophores 
and/or dye-labeled DNA with small hydrodynamic radii quickly depolarize, whereas slowly 
tumbling molecules with large hydrodynamic radii slowly depolarize.  Anisotropy, the ratio of 
the polarized-light component to the total light intensity, is related to the speed of depolarization 
by the equation  
                                                                        r=ro/(1+τ/θ)                                                  (1.1)   
where τ is the fluorescence lifetime of the fluorophore (typically on the range of nanoseconds) 
and θ is the rotational correlation time of the molecule the fluorophore is bound to, defined as the 
average time the complex takes to rotate 1 radian, which can vary from picoseconds to hundreds 
of nanoseconds depending on the hydrodynamic radius of the molecule under study.   
 
 39 
 
Figure 11. Schematic of fluorescence anisotropy experiment 
A basic “L format” setup for anisotropy is shown.  Two optical polarizes (ovals) are placed in the path of the 
excitation beam and the orthogal emission beam.   
 
In the lab reference frame, we define light intensity, e.g., IVV is with both excitation and 
emission polarizers oriented vertically; IHH is for excitation and emission polarizers oriented 
horizontally, while  IHV uses a horizontal excitation polarizer and the emission uses a vertical 
polarizer, etc. Average anisotropy <r> is calculated as  
                                       <r>= (IVV-G·IVH )/(IVV+2·G·IVH)                                          (1.2) 
where the “G factor,” G, is defined as G=IHV/IHH and is measured on a per-experiment basis. The 
rotational correlation time θ is related to both the volume of a rotating sphere V and the 
molecular weight of the complex M by the equation (Lakowicz, 2006): 
θ=ηV/RT = ηM·(v+h) /RT                             (1.3) 
where η is the solution viscosity, R is the gas constant, T is the temperature, v is the specific 
volume, and h is the hydration in ml/g.    
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1.6.3 Molecular mechanics and molecular dynamics simulations 
Grounded in theoretical physics, molecular models are a way of describing molecular 
systems to facilitate their analysis (Leach, 2001; Schlick, 2010). Quantum mechanical models 
are often used for very small systems since they can offer an extremely accurate prediction of 
multiple variables for a molecular system. These methods, however, are extremely 
computationally demanding and currently not amenable to the description of biomolecular 
systems. To study large systems, we must neglect quantum effects and approximate molecular 
motions and interactions with Newtonian physics. The Born-Oppenheimer approximation, which 
is invariably assumed for any type of molecular model, states that since the mass ratio of nuclei 
to electrons is so large, the electrons can instantaneously adjust to the positions of the nuclei.  
Separating the motions of nuclei and electrons, the energy of a molecule can then be considered 
as a function of its nucleus only. This means that we can view a large molecule as a network of 
nuclei-centered masses (atoms) connected essentially by springs (bonds) which can interact with 
each other in a closed system, responding by stretching, bending, and rotating about these bonds.  
This approach is known as molecular mechanics since it is based in classical mechanics, but is 
also known as the force-field or potential energy method.    Most atomic coordinates use a 
Cartesian coordinate system, and atomic coordinates are usually determined by X-ray 
crystallography or Nuclear Magnetic Resonance (NMR). Many biological molecules can be 
found in the RCSB Protein Data Bank (http://www.rcsb.org/pdb/), and at the time of this writing 
there were 44,320 structures deposited in the Data Bank. A force field is a way to describe the 
potential energy of a molecule as a function of its coordinates. To develop an empirical 
description of the atomic potentials of a molecule, known as a parameter set, experimentalists 
can assign values to molecule-specific parameters by measuring their equilibrium values with 
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various spectroscopic methods, and these parameters can be further optimized with high-level 
quantum mechanical calculations. The functional form of a simple empirical force field is 
usually described as the sum of all intramolecular and intermolecular potentials: 
 
 
                                                
 
 
                                                      
 
 
                                                
 
                                                            (1.4)   
Where V(r
N
) is the total potential energy as a function of the coordinates (r) of N atoms.   
Based on Hooke’s law, bonds, angles, and torsions are described as masses connected by 
springs with a harmonic potential. The energy of an atom bonded to another atom varies with the 
square of the displacement from the reference bond l0. The deviation of angles also contributes to 
an atomic potential as the square of angle displacement to the reference angle θ0.  Torsion here is 
defined as the energy barriers associated with the twisting of a molecule, and is usually defined 
for 4 interconnected atoms. For the torsional potential, Vn is considered the barrier height of the 
torsional energy, where n is the multiplicity of the function or the number of minimum points in 
the potential as the bond is rotated through 360°, and γ is the phase factor that describes the angle 
at which the torsional energy goes to zero. The nonbonded term includes a Lennard-Jones or 6-
(bonds) 
(angles) 
(torsions) 
(nonbonded) 
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12 potential, and a Coulombic potential. The Lennard-Jones potential models van der Waals 
interactions, and describes atoms interacting at distance r, with a repulsive term that changes as r
-
12
 and a term for attraction that changes as r
-6 
, with a well depth ε and a collision diameter σ.  
The second term in the nonbonded term is a potential for two charges that is modeled after 
Coloumb’s law, which describes two charges q, separated by distance r, where ε0 is the 
permittivity of free space. Charges are distributed as partial charges on each atom so that the 
total charge of the molecule is 0. Using the nonbonded potential, every atom is able to “feel” 
every other atom in a simulation. 
In Chapters 2 and 3, we implement molecular dynamics simulations to study biological 
molecules.  Molecular dynamics simulations, as is implied by the name, simulate the time-
dependant dynamics of molecules.  Since we now have described the potential energy for a set of 
atomic coordinates, it is straightforward to see how we can simulate interactions of these 
potentials in time.  Molecular dynamics is a deterministic method, meaning we can predict the 
final configuration of the system with the knowledge of the initial variables.  In a typical 
simulation, initial velocities are randomly assigned to each coordinate for a specified temperature 
such that there is no overall momentum P in the system: 
                                                                                                               (1.5) 
Velocities are randomly selected from a Gaussian or Boltzmann distribution at a desired 
temperature, which gives the probability (p) that an atom i has the velocity vx in the x direction at 
temperature T: 
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                                                                       (1.6)
 
Where the temperature T for the system can be calculated as: 
                                                                                                      (1.7) 
Knowing the masses, velocities, and potential energy of each atom in the system, we can 
numerically integrate Newton’s familiar second law to describe changes for the system in time : 
                                                                                                                   (1.8) 
At each step, the vector sum of the force on each atom (the negative first derivative of the 
potential function with respect to the coordinates) can be computed for each atom along with the 
current positions and velocities, and the new positions and velocities are described for a short 
time step (δt) ahead.  The force on a particle changes with position (as dictated by the force 
field), resulting in a many-body problem that cannot be solved analytically.  Using finite 
difference integration and discretizing the time steps, we can calculate the accelerations of 
particles from the forces, combining them with the positions and velocities at time t to calculate 
the positions and velocities at time t + δt, assuming that the force has stayed constant over the 
length of the time step.   There are many finite difference integration methods, and all of them 
assume that the positions, velocities, and accelerations can be approximated as a Taylor series.  
Commonly, a leap-frog Verlet integrator is used, using the following definitions: 
                                                                                      (1.9)
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                                                                               (1.10) 
First, the velocities v(t+1/2δt) are calculated from the velocities at time t-1/2δt and the 
accelerations at time t.  Positions r(t+δt) are calculated from the velocities together with the 
positions at time r(t) using equation (5).  The velocities at time t can then be calculated using 
                                                                            (1.11) 
So the velocities ‘leap’ over the positions to give their values at t+1/2δt, and the positions 
leap over the velocities giving their new values at t+δt.  The more accurate velocity Verlet 
integrator used in Chapter 2 and 3 calculates new positions, velocities, and accelerations of 
atoms simultaneously and uses the following definitions: 
                                                                             (1.12) 
                                                                        (1.13) 
which requires three stages since calculating the new velocities requires accelerations at 
time t and t+δt.  Velocities at time t + 1/2δt are calculated: 
                                                                                         (1.14) 
Next, forces are calculated from the current positions, which gives a(t+δt).  Finally, the 
velocities at time t+δt are calculated by: 
                                        
                                 (1.15) 
After many iterations, the result is a trajectory for a system, or the propagation of atomic 
coordinates through time.  Most molecular dynamics simulations tend to use a 1 femtosecond 
(fs) time step, since this is approximately one tenth of the period of the highest frequency 
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vibration in the system, the covalent bond between oxygen and hydrogen.  Any larger, and the 
time step used would overlook these vibrations.  The SHAKE algorithm is widely used to impose 
constraints on covalent hydrogen bonds during every time step, essentially freezing this motion 
and allowing an acceptable time step of 2fs.  Both simulations in Chapters 2 and 3 define the 
system as a canonical NVT ensemble: a constant number of atoms, volume, and temperature.  
Volume can be controlled by imposing boundaries on the system.  In all simulations in Chapter 2 
and 3, periodic boundary conditions are used, which describe the simulation as one ‘unit cell’ 
with an infinite number of adjacent images of the same cell surrounding it, allowing atomic 
interactions between cells in order to simulate bulk phase. Desired temperature for the 
simulations in Chapters 2 and 3 is achieved with a Langevin heat bath, which adds random noise 
to the system until a desired temperature is reached and can be adjusted by a thermostat which 
checks the temperature at defined intervals during the simulation. Also, the calculation of 
nonbonded atomic interactions can be very expensive.  Usually, the program keeps a running list 
of all atoms which interact through space, and calculates nonbonded forces only between those 
atoms.  Cutoff schemes to truncate this list, and to bring the Lennard-Jones potential and the 
Coulombic potential to zero at some finite distance are commonly used in the simulations in 
Chapters 2 and 3 since the ‘real’ potential only gets infinitesimally close to zero as interatomic 
distance increases.  Lastly, Accelerated Molecular Dynamics (AMD; Hamelberg et al., 2004) is 
implemented in all simulations herein. AMD is a method of adding a biasing potential to the 
overall dihedral potential term in order to make it shallower, effectively facilitating sampling 
while maintaining the native free energy landscape of the system.  
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2.0  QUANTIFYING THE DYNAMIC INTERACTIONS BETWEEN HIV-1 RT AND 
ITS TEMPLATE/PRIMER (T/P) SUBSTRATE WITH SINGLE-MOLECULE AND 
BULK FLUORESCENCE SPECTROSCOPY 
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) are an attractive drug class since 
they are highly effective against RT in a specific and, thus, relatively nontoxic manner.  
However, NNRTI-resistant strains are continually emerging, highlighting an urgent need to 
understand the mechanism(s) underlying drug resistance. In RT, K103N is one of the most 
common mutations arising from efavirenz-based treatment regimens, yet the mechanism by 
which K103N confers efavirenz resistance is unknown. We show that efavirenz causes RT to 
relinquish its grip on the template/primer substrate via “molecular arthritis," accompanied by 
increased shuttling on the substrate, reducing time spent in a polymerase-competent 
configuration. The K103N mutation relieves the arthritis in the fingers and thumb sub-domains 
of RT, enabling the efavirenz-bound enzyme to form a stable polymerase-competent 
complex.  We demonstrate that relief of molecular arthritis is likely caused by disruption of a salt 
bridge between K101 and E138, residues at a key hinge site in the RT heterodimer. Our data 
suggests a unique mechanism of resistance that is mediated by interplay between intramolecular 
conformational changes in RT and intermolecular dynamics of the RT-template/primer-dNTP 
complex. 
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2.1 INTRODUCTION 
In this study, we wished to characterize the dynamics of RT on its T/P.  In order to accomplish 
this, we used a single molecule TIRFM technique known as Protein Induced Fluorescence 
Enhancement (PIFE; Hwang 2011) to monitor dynamics of individual complexes. This technique 
has the advantages over the use of Förster Resonance Energy Transfer (FRET) to measure RT 
dynamics as previously reported (Liu et al., 2008) since it has a shorter distance sensitivity (~0-4 
nm for PIFE vs. ~5-8 nM for FRET), does not perturb the structure of RT with fluorophore 
labeling and corequisite site-directed mutagenesis, and, by restricting the fluorophore to the 
nucleic acid substrate, allows for the use of physiologically relevant concentrations of RT 
without saturating the CCD detector.   
 We furthermore devised a technique to measure the mobility of RT on its template/primer 
(T/P) substrate which should be extensible to any protein-DNA system.  Using this technique, we 
are able measure two simultaneous quantities: 1) the relative effect of NNRTIs on RT mobility 
and 2) the binding affinity of NNRTIs.  Of particular importance to researchers in the RT field 
will be the second application, since there are few biophysical techniques able to measure the 
binding affinity directly, which is made more difficult due to the insolubility of NNRTIs (e.g., 
isothermal calorimetry cannot be used due to the high concentrations of NNRTI required). 
To understand the mechanism of NNRTI resistance by K103N, we combined these novel 
techniques with single-molecule Forster Resonance Energy Transfer (FRET) to measure, in 
unprecedented detail, the changes in RT-T/P dynamics, dNTP affinity, and intramolecular FRET.  
Using this combination of approaches, we were able to demonstrate that the NNRTI resistance 
mutation K103N works by alleviating molecular arthritis, mediated by two crucial residues at the 
intersubunit hinge site in RT. 
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2.2 MATERIALS AND METHODS 
2.2.1 Template/Primer (T/P) constructs 
All oligonucleotides were ordered from IDT.  Oligonucleotides were resuspended to 200 M in 
buffer (50 mM Tris-HCl pH 7.5, 25 mM NaCl) and annealed by mixing at a 1.2:1 biotin-
Template:Primer ratio (ensuring all Primer-Cy3 signals were Template-bound), heated at 94°C 
for 5 minutes on a heating block, and allowed to cool on the block for 1 hour before freezing at   
-20°C. 
To facilitate analysis, the T/P substrate used in this study is identical to that in PDB 
1RTD, with the addition of an extended template for tethering purposes.  The sequences used 
were:  
Template: 5’-biotin-GGGTTTGCTAAGCACCGGCGCCCGAACAGGGACTG   
Primer (PIFE): 5’-Cy3-CAGTCCCTGTTCGGGCGC-3’-ddC 
Primer (FRET): 5’-CAGTCCCTGTTCGGGCGC-3’-ddC 
For experiments involving T/P lengthening, we used the following sequences: 
Template_2: 5’-biotin-GGGTTTGCTAGAGAGCGGCGCCCGAACAGGGACTG 
Primer (+2b): 5’-Cy3-CAGTCCCTGTTCGGGCGCCGCT-3’-ddC 
Primer (+4b): 5’-Cy3-CAGTCCCTGTTCGGGCGCCGCTCT-3’-ddC 
The following were used in the anisotropy experiments: 
Template: 5’-GGGTTTGCTAAGCACCGGCGCCCGAACAGGGACTG   
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Primer (Anisotropy): 5’-Fluorescein-CAGTCCCTGTTCGGGCGC-3’-ddC 
 
2.2.2 RT expression, purification, and labeling 
WT and mutant RT were expressed and purified as previously described (Brehm et al., 2008; 
Radzio and Sluis-Cremer, 2008).  FRET constructs were prepared by mutating endogenous 
cysteines C38 and C280 to serines and introducing cysteines into codons 250 (thumb) and 139 
(fingers) with site-directed mutagenesis.  These positions were chosen due to their optimal 
separation distance (~5 nM), ideal for reporting FRET in the quasi-linear response regime, and 
also for their high degree of solvent accessibility (both residues reside in solvent-exposed loops 
in WT RT; see Figure 5a).  We then labeled the resultant C38S/C280S/T139C/D250C RT 
simultaneously with equimolar amounts of Cy3- and Cy5-maleimides (GE Healthcare) at pH 8.0 
according to the manufacturer instructions.  
2.2.3 Single-molecule Total Internal Reflection Fluorescence Microscopy (TIRFM) 
Single-molecule TIRFM was performed on an Olympus IX-71 configured with prism-based 
TIRF illumination geometry and imaged with an Andor iXon 897 back-illuminated electron 
multiplying CCD (EMCCD).  Donor and acceptor emission signals were separated by a 610 nm 
dichroic longpass mirror, a 580/40 nm bandpass filter and a 660 nm longpass filter and 
subsequently imaged. 
 
 50 
2.2.4 Protein Induced Fluorescence Enhancement (PIFE) Experiments 
PIFE data was acquired on a 512x256 pixel region of an Electron Multiplying CCD (EMCCD, 
Andor Technologies) at 30 ms/frame. T/P molecules were surface tethered to the PEGylated flow 
cell via a biotin:streptavidin:biotin-PEG linkage. Concentrations of T/P used were typically 20 
pM for an optimal surface density of ~100 molecules per field of view. 250 nM RT was 
introduced to the flow cell and incubated for 5 minutes, followed by a wash step with 5X volume 
of imaging buffer.  The power of the 532 nm excitation beam was typically ~8 mW.  
Fluorescence intensity traces which visibly fluctuated and also exhibited single-step 
photobleaching were selected for analysis (typically 25%-50% of all molecules, as many had not 
bleached yet and also possibly since many molecules remained in high PIFE states throughout 
observation time).  PIFE traces were then rescaled to “fold intensity” (as in Figure 13a-c) by 
fitting each trajectory to two Gaussian functions and dividing the data by the fitted average of the 
lowest peak in order to rescale it to 1-fold.  PIFE histograms (e.g., Figure 13d) were constructed 
by binning many PIFE traces into 50 bins and fitting with two Gaussians to extract the average 
fold intensity increase.  Data from Figure 20 (red circles) was constructed of the average of 3 of 
such values. Data was also rescaled for use with the vbFRET program, and fluctuating 
fluorescence intensity traces were fit to idealized states.  Idealized dwell times aggregated into 
cumulative residence time distributions (employed to eliminate any bias from choice of bin 
number), and these distributions were fit with single exponential functions to calculate shuttling 
rates.  
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2.2.5 Single-molecule Förster Resonance Energy Transfer Experiments 
For FRET data, unlabeled T/P was surface tethered by introducing ~2M T/P into the flow cell, 
ensuring a dense “carpet” of unlabeled substrates for RT to bind.  FRET-pair labeled RT was 
subsequently introduced at concentrations of ~40 pM.  Using this method, we were able to avoid 
the problem excess background noise typical of saturating the EMCDD with relatively higher 
(nM range) fluorophore-labeled protein concentrations.  Based on the relative distribution of 
donor and acceptor intensities in the observed field of view with TIRFM, dual-labeling 
efficiency was approximately 5-10% for all final constructs (data not shown). FRET data was 
acquired at 100 ms/frame, and peak choice was thresholded on Cy5 intensity such that only 
molecules exhibiting FRET were chosen. Eapp was calculated as IA/(ID+IA), where ID and IA 
respectively denote background-corrected donor and acceptor intensities. Noting that Eapp should 
remain the same value regardless of the relative arrangement of Cy3 or Cy5 on D250C/T139C, 
Eapp histograms were subsequently constructed from all traces resulting in donor and acceptor 
photobleaching (see Supplemental Figure 3a), fit with 25 bins each, and fit with single Gaussian 
functions (see Supplemental Figure 3b). Data in the Results section is reported as the mean ± std 
of these fits.  All analysis of single-molecule data was performed using custom-written 
MATLAB scripts (see Appendix). 
 
2.2.6 Accelerated Molecular Dynamics (AMD) Simulations 
All Molecular Dynamics (MD) simulations were performed in NAMD with atomic coordinates 
of the ternary complex (PDB: 1RTD) modified at the 5-end of the primer with coordinates of 
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first excited state of Cy3 optimized at the CIS/6-31G(d,p) level (Courtesy David Norman). 
Systems were solvated in a 125 Å x 96 Å x 96 Å periodic box of TIP3 waters, ionized with 25 
mM NaCl, and loaded with the CHARMM27 force field including Cy3 parameters courtesy of 
Arjan van der Vaart.  In their article, Spiriti et al. (Spiriti et al., 2011) stiffened the dihedral 
parameters of the polymethine chain connecting the heterocyclic rings to explicitly prevent 
excessive Cy3 isomerization. Upon request, Spiriti and van der Vaart generously provided the 
original dihedral parameters for the linker, which are herein provided in the Supplemental 
Information. For simulations which lengthened the distance between the 5’-Cy3 and RT, the 
DNA duplex was rotated 35.3° and translated 3.4  Å upstream along its principle axis for each 
increase in 1 bp of separation (initial configurations shown in Supplemental Figure 2a), and 
periodic boxes were grown as necessary (total size ranging from ~100,000-125,000 atoms). 
Systems were subjected to 100,000 steps of conjugate gradients minimization, heated to 300 K in 
increments of 30 K over the course of 1 ns, and allowed to equilibrate for an additional 1 ns in an 
NPT ensemble with traditional MD. Simulations were subsequently continued using AMD, a 
method of enhanced sampling which enabling us to capture Cy3 isomerization events, for an 
additional 50 ns each. For every system simulated, the NAMD parameters for AMD 
implementation, accelMDE and accelMDalpha, were defined as accelMDE=Vd +4·Nres and 
accelMDalpha=4·(Nres/5),  where Vd is the average of the dihedral potential over the course of 
the 1 ns of MD equilibration after heating, and Nres is the number of residues in the system. For 
the MD portion, 0.05 kcal/mol·Å
2
 harmonic constraints were added to every Cα and DNA P 
atom. All constraints within 25 Å of Cy3 were subsequently removed for the AMD portion.  All 
simulations were run with 2 fs time steps (employing the SHAKE algorithm), Particle-mesh 
Ewald electrostatics, a Langevin Thermostat set to 300 K, and a Langevin Barostat set to 
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1.01325 atm. Trajectories were analyzed with VMD.  Cy3 was defined as the dihedral angle 
between the Cy3 atoms C5A,C5B,N1A, and N1B.  All AMD simulations were performed in 
triplicate for each condition.      
2.2.7 Anisotropy Experiments 
Anisotropy experiments were performed as previously described on a Cary Eclipse 
spectrofluorimeter using 485 nm excitation and 520 nm emission, with T/P-fluorescein 
concentrations (400uL volumes) of ≤5 nM.  Anisotropy values were collected with an integration 
time of 0.25 s for three consecutive readings, and each value represents the average of 3 
independent experiments.  
 
2.2.8 Buffer components and small-molecule ligand concentrations 
All experiments were performed in 50mM Tris-HCl pH 7.5, 25 mM NaCl, and 5 mM MgCl2. 
TIRFM experiments additionally contained 0.1 mg/ml glucose oxidase, 0.02 mg/ml catalase, 
0.4% wt/v β-d-glucose, and 2 mM Trolox for photoprotective purposes.  Unless otherwise 
indicated (e.g., with titrations), TTP was held at 50 M in all TIRFM experiments and 100 M 
in all anisotropy experiments, and EFV concentration was held at 500 nin all experiments, 
ensuring saturated binding conditions for both ligands. 
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2.3 RESULTS 
2.3.1 PIFE-based assay of RT-T/P shuttling dynamics in the context of polymerization  
In order to measure RT dynamics on its T/P substrate, we employed a single-molecule technique 
based on Protein Induced Fluorescence Enhancement (PIFE), a phenomenon recently 
characterized as a distance-dependent enhancement of the intensity of a fluorophore due solely to 
its relative proximity to protein (Fischer et al., 2004; Hwang et al., 2011). To probe RT shuttling 
on T/P as previously reported (Liu et al., 2008), we designed a T/P reporter construct consisting 
of a 5’-biotinylated Template annealed to a Primer with a 5’-Cy3 with a 3’-ddC (Figure 12).  
 
 
Figure 12. Schematic of PIFE assay of RT shuttling 
In our shuttling assay, the T/P reporter construct is composed of a 5’-Cy3 labeled, 5’-dideoxy terminated Primer 
(red) a 5’-biotinylated Template (black) is surface tethered to a PEGylated flow cell (see Methods), incubated with  
RT, and washed to eliminate unbound RT.  PIFE occurs when RT is proximal to the terminal Cy3. 
 
The 3’-dideoxy nucleotide allowed us to add the next correct dNTP without enzymatic primer 
extension by RT, resulting in a nonproductive ternary complex. The T/P substrate was surface 
tethered to a PEGylated quartz flow cell and visualized at the single-molecule level with Total 
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Internal Reflection Fluorescence Microscopy (TIRFM), and the resulting fluorescence intensity 
traces were normalized for PIFE analysis (see Methods section).  In the absence of RT, the 
majority (>95%) of T/P intensity trajectories exhibited no observable fluctuations (Figure 13a). 
After incubating the T/P with RT and subsequently washing the flow cell with 5X volume 
imaging buffer to eliminate signal from RT association and/or dissociation events, we observed 
fluctuating PIFE signals with gradual transitions between 1- and 2-fold intensity from the 
majority (>75%) of the fluorescence traces (Figure 13b), indicative of RT shuttling on the T/P. 
Upon addition of TTP, the next correct dNTP, we observed the stabilization of the PIFE signal 
into two discrete low and high states (Figure 13c), resulting in an average intensity increase of 
~1.6-fold (Figure 13d).  In agreement with our single-molecule experiments, we also observed 
concentration-dependent PIFE in bulk (Figure 14).  
 
 
Figure 13.  Probing the polymerase-competent mode with PIFE 
Representative PIFE traces for the indicated experimental conditions.  Fluorescence intensity is normalized to a fold 
scale, with the lowest intensity set to 1-fold  a) T/P-Cy3 in the absence of RT.  b) WT-T/P.  and c) WT RT-T/P-
dNTP.  d) Representative PIFE histogram. PIFE signals (n=106) were binned into 50 bins and fit with two 
Gaussians. The fitted means (n=3) of similar histograms were then used for the final average (e.g., for the 1.58 ± 
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0.07 point in Figure 19 for the ternary complex).  Observation time was set to 10 s for all traces for a direct 
comparison between traces.  
 
 
Figure 14.  Bulk PIFE shows RT-T/P association 
Bulk PIFE experiments were carried out on a standard spectrofluorimeter (see Methods).  PIFE is represented as the 
Cy3 emission intensity at 570 nm at the given RT concentrations, normalized by the intensity at [RT] = 0.  Points 
represent n=3 independent experiments; error bars indicate s.e.m. 
 
To better understand the origin of the high PIFE signal we observed, we performed 
Accelerated Molecular Dynamics (AMD) simulations on the crystal structure of the RT-T/P-
dNTP complex (Huang et al., 1998; PDB ID 1RTD) modified with a terminal Cy3 and placed in 
explicit solvent (see Methods section) while monitoring θCy3, the dihedral angle between the 
planes of the heterocyclic rings of Cy3 (Figure 16, left).  Contrary to the case of T/P in the 
absence of RT, where the terminal Cy3 had a high degree of conformational freedom, Cy3 was 
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observed to closely interact with RT in a nonspecific manner, confining the conformational space 
explored by Cy3 (Figures 15 and 17).  
  
Figure 15.  Cy3 Interacts with RT 
The RT-T/P complex is shown, highlighting the nonspecific interaction of Cy3 with RT. The conformation of Cy3 is 
drawn every 0.1 ns for a  50 ns AMD simulation. 
 
This interaction with RT markedly changed the distribution of θCy3, enhancing the 
photoactive cis isomer of Cy3 (Figure 16, right). In the case of the ternary configuration, RT 
increased the overall time Cy3 spent in the cis conformation from 39.2% ± 3.3% to 60.4% ± 
6.0% for an average relative increase of 1.54 ± 0.15 fold (± s.e.m., n=3 50 ns simulations).  
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Figure 16.  Interaction with RT stabilizes the cis conformation of Cy3 
Left: Definition of θCy3, the dihedral angle between the planes of the heterocyclic rings of Cy3. Right: distributions 
of θCy3 in the presence (red) or absence (black) of RT.  The distributions represent data from 3 AMD simulations 
each.  The cis isomeric state is highlighted in green. 
 
Figure 17.  Representative simulation data 
AMD simulations with (left) and without (right) RT are shown. Top: Cy3 configurations from every 0.1 ns drawn.  
Bottom: Representative data over 50 ns simulations tracking θCy3 is shown.  Histograms of θCy3 were binned, and the 
percentage of time spent in the cis conformation is shown.  For the data in Figure 17, n=3 of such simulations were 
combined into one histogram for each condition (i.e., T/P +/- RT). 
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In order to accurately quantify the relationship between the PIFE signal we observed and 
the position of RT on the T/P relative to the terminal Cy3, we next extended the distance of the 
terminal Cy3 1 to 5 bp away from the starting configuration and performed similar AMD 
simulations as above (Figure 18). The simulations revealed an inverse relationship between the 
distance of RT to Cy3 and the enhancement of the cis isomer (Figure 1g, red circles). We also 
performed similar PIFE experiments, wherein we lengthened the T/P either 2 bp or 4 bp 
upstream (relative to the 3’ end of the primer) of the original ternary configuration (Figure 1g, 
top).  
  
 
Figure 18.  Starting configuration of RT-T/P in AMD simulations 
The starting configuration of the RT-T/P complexes in the AMD simulations are shown, where ori stands for origin 
at the ternary complex (PDB ID 1RTD), and +1-5 represents primers translated 1-5 bp upstream as discussed in the 
Methods section. 
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Figure 19.  Extracting fold-intensity values 
Left: Representative fitted histograms from RT-T/P (red), RT-T/P + 2bp (green), and RT-T/P + 4 bp (blue).  Points 
represent bin centers, and lines represent composite fits from two-component Gaussian fits.  Right: Individual 
Gaussian peaks from curve fits of RT-T/P (red), RT-T/P + 2bp (blue), and RT-T/P + 4 bp (black).  The averages of 
n=3 such peaks were used for the data presented in Figure 19. 
 
Similar to the result for the simulations, we observed a distance dependence on the fold 
increase in Cy3 intensity in analogous PIFE experiments (Figure 20, black squares; see also 
Figure 19). Comparing the distance dependence on the experimental fold enhancement of Cy3 
intensity with that of the enhancement of the cis isomer in the simulations revealed markedly 
similar trends (R=0.92).  Particularly striking was the similarity between the experimental PIFE 
signal for the ternary complex (1.58 ± 0.07) and the fold enhancement of the cis isomer for the 
ternary configuration in the simulations (1.54 ± 0.15), leading us to conclude that the high PIFE 
signal observed upon incorporation of the next correct dNTP was a result of RT stably residing 
in polymerase-competent configuration. 
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Figure 20.  Accurate identification of the polymerase competent configuration 
Top: schematic of extension experiments.  Cy3 was extended from 1 to 5bp away from RT in the polymerase 
competent state. Bottom: Fold intensity changes from PIFE experiment (squares, left y-axis) are compared to the 
fold increase in the cis isomer of Cy3 (red circles, right y-axis)  
2.3.2 Efavirenz alters shuttling dynamics of WT, not K103N, RT 
With the ability to accurately identify the polymerase-competent RT-T/P configuration, we 
probed the effect of efavirenz (EFV) on the shuttling dynamics of both WT RT and K103N RT 
with respect to residence time in the polymerase mode via dwell-time analysis of PIFE traces 
(see Methods).  
In the absence of EFV, the ternary complex displayed a stable, high PIFE state (Figure 
21a, left) as discussed above, with relatively few transitions observed per trace, (Figure 21c, left, 
blue). Upon infusion with EFV, RT spent relatively shorter times in the polymerase mode 
(Figure 21a, right), displaying many more transitions away from this state (Figure 21c, left, red).  
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In contrast, PIFE traces for the K103N RT-T/P-dNTP complex (Figure 21b) were 
indistinguishable to those of WT RT in either the absence (Figure 21b, left) or presence (Figure 
21b, right) of EFV and displayed a similar number of transitions in both cases (Figure 2c, right). 
Using dwell-time analysis (see Methods), we calculated the rates to and from the polymerase 
mode, karrival and kdeparture, respectively, and the results are summarized in Figure 21d.  While 
addition of EFV to the WT RT-dNTP complex (Figure 21d, left) resulted in significant ~5- and 
~6-fold increases in karrival and kdeparture, respectively, addition of EFV to the K103N RT-dNTP 
complex (Figure 21d, right) resulted in an insignificant ~2.5-fold change in karrival  and a 
comparatively smaller ~2-fold change in kdeparture.  Taken together, these results suggest that EFV 
destabilizes the polymerase-competent mode in WT, but not K103N RT.  
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Figure 21.  EFV destabilizes the polymerase mode in WT, but not K103N, RT 
Representative PIFE traces are shown for a) WT RT-T/P-dNTP or b) K103N-RT-T/P-dNTP in the absence (left) or 
presence (right) of EFV. c) Transition histograms showing the average number of transitions per trace WT RT-T/P-
dNTP (left) or K103N RT-T/P-dNTP (right) in the presence (red) or absence (blue) of EFV. c) Rates of arrival from 
or departure to the polymerase competent state for WT RT-T/P-dNTP (left) or K103N RT-T/P-dNTP (right) in the 
presence (red) or absence (blue) of EFV.  Error bars represent the mean +/- s.e.m. of n=3 fits from analysis of 3 
groups derived from  n=630 and  n=573 total molecules for WT RT-T/P-dNTP in the respective absence or presence 
of EFV, and n=926 and  n=725 total molecules for K103N RT-T/P-dNTP in the respective absence or presence of 
EFV.   
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2.3.3 Development of a novel anisotropy-based assay to simultaneously report relative 
mobility and NNRTI binding affinity 
We next asked whether presence of dNTP or EFV could alter the affinity of RT for its T/P 
substrate. Using fluorescence anisotropy with a T/P substrate identical to that used in the PIFE 
experiments but with a terminal 5’-flouorescein on the primer in place of the 5’-Cy3, we 
performed titrations of WT RT and recorded anisotropy binding curves in the presence or 
absence of saturating concentrations of EFV and/or dNTP (see Methods section). Interestingly, 
neither ligand significantly affected the binding affinity of RT for T/P, with the dissociation 
constant Kd in the ~10 nM range for all cases.  Furthermore, we unexpectedly observed large 
changes in the absolute anisotropy accompanying the presence of various ligands (Figure 22). 
 
 
Figure 22.  Small molecule ligands do not affect RT-T/P affinity 
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Bulk anisotropy binding curves.  Anisotropy from T/P-fluorescein is monitored during [RT] titration in the presence 
of the ligands indicated.  All Kd values of RT for T/P remained in the ~10 nM range regardless of ligand. 
 
 To understand the source of these observed differences, we calculated the anisotropy 
values expected for various sphere sizes and also for the molecular weight (MW) of the complex 
(Figure 23) and made two observations: first, due to the large size of the complex, the response 
of anisotropy to the spherical size of the complex falls outside of the quasi-linear regime for the 
value expected for the MW,  which largely ruled out the possibility that, e.g., increases in the 
effective hydrodynamic radius due to a broader occupancy of RT on the substrate were 
responsible for increases in anisotropy. Second, the anisotropy we calculated is much lower than 
that expected for this complex based on the MW (Figure 23, top right), which is likely due to the 
contribution from the fast tumbling of fluorescein (Figure 23, bottom right).  
 
Figure 23.  Changes in hydrodynamic radius are insufficient to explain changes in anisotropy 
Left: spherical approximation of RT-T/P.  Top right: Anisotropy calculated according to first principles calculations 
(see section 1.6.2. for more info).  Arrows point to the anisotropy expected for a sphere of r=4.83 nm and the 
anisotropy expected for the molecular weight (MW) of the complex, assuming a hydrated sphere.  The dependence 
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of the rotational correlation time θ is also shown in blue (right y-axis).  The experimental range for RT-T/P 
experiments (i.e., Figure 22) is highlighted in pink.  Lower right: A schematic of fast (due to fluorescent dye) and 
slow (due to the protein-DNA complex) tumbling with corresponding θfast and θslow are shown.  The equation for 
anisotropy (r) including the linear combination from fast and slow tumbling is shown on the right. 
 
We next considered a model where RT was able to interact with the fluorescein as it 
shuttled on the T/P substrate (Figure 24, left). In this model, changes in a theoretical standard 
deviation σ2 of the distribution of RT on the T/P, starting from the polymerase-competent 
position, are related to changes in the observed anisotropy due to interactions of RT with the 
fluorescein, which is expected to confine the dye and increase anisotropy (Figure 24, right).  
Using this model, we were able to derive the expected distributions of RT on the T/P from the 
absolute anisotropy value of each case in the saturated condition.  The calculated σ2 for the cases 
of the indicated complexes (Figure 24, right, dotted lines) were then used to render the normal 
distributions shown in the left panel of Figure 24. Compared to the RT-T/P-dNTP complex, 
which has a tight distribution around the polymerase mode as expected, addition of EFV to RT 
resulted in a broad distribution on the T/P substrate, consistent with our PIFE results. Therefore, 
we considered absolute anisotropy as a proxy measurement for RT mobility on the T/P. 
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Figure 24.  Simplified model of RT shuttling reveals origin of anisotropy changes 
Left: A model of RT (oval) shuttling on its T/P substrate (blue) is presented, including putative interaction with the 
terminal fluorescein (labeled “F” in schematic), where the center of RT is able to move up to 10bp left or right from 
its origin at the polymerase-competent configuration (red arrow indicates shuttling motion). The chart below the 
model shows the relationship between RT position and αslow (blue dotted line, right scale bar; value explained in 
text) and the position of RT, also corresponding to the model above it. The histograms represent the positional 
occupancy (i.e., mobility) of RT and were calculated from d), which shows the relationship between σ, the standard 
deviation of the position of RT on its T/P substrate, and the resulting anisotropy that would be observed according to 
the model in Figure 23. As indicated by dotted lines, σ values were interpolated from the experimental anisotropy 
values taken from the value at 66 nM RT (i.e., saturated binding) and the indicated conditions. αslow is a value which 
roughly indicates the odds of RT interacting with fluorescein, causing anisotropy resulting from slow tumbling to 
dominate, thereby raising absolute anisotropy (see Methods).  
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2.3.4 K103N RT is structurally resistant to efavirenz irrespective of binding affinity 
We next probed the effect of the concentration of EFV and Neviripine (NVP) on the mobility of 
WT and K103N RT and found a dose-dependent increase in absolute anisotropy due to presence 
of both NNRTIs (Figures 25 and 26, left).  WT RT plateaued at a higher anisotropy value in 
response to EFV than did K103N RT (Figure 25, left).  
 
Figure 25.  Binding of efavirenz to WT RT and K103N RT 
Left: Absolute anisotropy of the WT RT-T/P  (black circles) or K103N RT-T/P complex as a function of efavirenz 
concentration.  Right: The curves on the left are normalized and fit to a single-site binding hyperbola, and Kd  values 
from the fits to WT RT-T/P  (black) or K103N RT-T/P (red) are shown.  Points represent mean +/- s.e.m. values 
from n=3 separate experiments. 
 
Although K103N RT exhibited similar changes in mobility in the presence of both drugs, the 
mobility of WT RT was higher in the presence of EFV than with NVP (Figure 26, left). When 
normalized to fractional occupancy (Figure 25 and 26, right), we observed curves which fit well 
with single-site binding hyperbola (R
2 
> 95% for EFV and NVP), allowing us to extract Kd 
values of NNRTI binding.   
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Figure 26.  Binding of neviripine to WT RT and K103N RT 
Left: Absolute anisotropy of the WT RT-T/P  (black circles) or K103N RT-T/P complex as a function of neviripine 
concentration.  Right: The curves on the left are normalized and fit to a single-site binding hyperbola, and Kd  values 
from the fits to WT RT-T/P  (black) or K103N RT-T/P (red) are shown.  Points represent mean +/- s.e.m. values 
from n=3 separate experiments. 
 
In agreement with previous findings(Ren et al., 2000), K103N resulted in an ~11-fold 
reduction in binding affinity of NVP as compared to WT RT (Figure 26, right), supporting our 
conclusion that anisotropy can be used to accurately measure NNRTI binding.  Remarkably, the 
K103N mutation did not affect EFV binding at all (Figure 25, right).   
As expected, when we titrated dNTP into the WT RT-T/P complex, we saw an opposite 
effect from EFV on RT mobility (Figure 27, left, open circles), which also fit well to a single-site 
binding hyperbola. This trend persisted in the presence of saturating concentrations of EFV 
(Figure 27, left, closed circles), leading us to conclude that RT-T/P can incorporate EFV and 
dNTP simultaneously, and that these independently alter RT mobility.  In agreement with our 
PIFE data, K103N RT similarly responded to dNTP in the presence or absence of EFV (Figure 
27, left, open and closed triangles, respectively), but the magnitude of change in anisotropy 
arising from saturating EFV in the presence of dNTP was significantly lower than that of WT RT 
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(compare red fits to black fits).  Furthermore, the presence of EFV lowered the affinity of dNTP 
for WT RT-T/P by ~14-fold, whereas EFV affected the dNTP binding affinity to the K103N RT-
T/P complex by a modest ~3-fold.   Taken together, our results indicate that the K103N mutation 
allows RT to subvert the changes in RT-T/P dynamics seen with WT RT in response to EFV 
irrespective of EFV binding affinity. 
 
 
Figure 27.  Binding of dNTP to WT or K103N in the presence or absence of EFV 
Left: dNTP titrations are shown for WT (circles) or K103N (triangles) in the absence (no fill) or presence (fill) of 
EFV.  Hyperbolic fits consistent with a single-site binding model are shown (black: WT RT, red: K103N RT). 
Right: Kd of TTP for the indicated RT-T/P complex in the presence or absence of EFV.  Data represents mean +/- 
s.e.m. from n=3 experiments (left) and hyperbolic fits (right) each. 
2.3.5 K103N RT does not succumb to arthritis 
To understand the source of resistance to changes in shuttling dynamics conferred by K103N, we 
probed the conformational change of WT and K103N RT in response to EFV by monitoring the 
distance spanning the thumb and fingers subdomains of RT with single-molecule Förster 
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Resonance Energy Transfer (FRET) experiments on RT labeled with the Cy3-Cy5 FRET pair on 
the thumb (D250C-Cy3/5) and fingers (T139C-Cy3/5) domains (Figure 28a; see Methods) after 
allowing it to bind unlabeled, surface tethered T/P substrates.   
WT RT exhibited a FRET Eapp value of 0.74 ± 0.14 (mean ± std) and did not change 
appreciably in the presence of dNTP, with Eapp = 0.73 ± 0.13 (Figure 28b).  However, when EFV 
was added to RT, the thumb and fingers domains became noticeably further apart (Eapp = 0.57 ± 
0.15), even in the presence of dNTP, albeit slightly closer (Eapp = 0.64 ± 0.15).  The marked EFV-
dependent changes in Eapp distributions are entirely consistent with previous observations of 
“molecular arthritis” (see Table 1 for a summary of results and comparison expected values from 
crystal structures).   
 
Figure 28.  K103N does not succumb to arthritis. 
a) Schematic of the D250C/T139 FRET construct.  Shown are atomistic models of Cy3 (green) and Cy5 (red) built 
into the structure of the ternary complex (PDB ID: 1RTD).  Note that labeling can be either way, i.e., Cy3 could be 
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labeled on D250C and Cy5 on T139C, and the FRET signal in our experiments would stay the same.  Single-
molecule FRET histograms (see Methods) for b) WT RT and d) K103N are presented for the indicated complexes.  
d) Ratio of the average of the indicated FRET Eapp signal over the average FRET Eapp from the RT-T/P-dNTP 
(ternary) complex. 
 
 
 
FRET 
(Eapp ± STD) 
D250C-T139C 
FRET-derived 
distance  
(Å ± STD) 
D250-T139 
Cα-Cα 
crystal 
structure 
distance                         
(Å ± STD) 
(PDBID) 
WT RT 
WT RT-T/P 0.74 ± 0.14 45.6 ± 3.1 51.6 (2HMI) 
  
WT RT-T/P-dNTP 0.73 ± 0.13 45.7 ± 2.7 50.6 (1RTD) 
  
WT RT-T/P-EFV 0.57 ± 0.15 51.5 ± 1.7 56.2 (3V81) 
  
WT RT-T/P-dNTP-EFV 0.64 ± 0.15 49.2 ± 2.3 N/A 
K103N RT 
K103N RT-T/P 0.60 ± 0.19 50.4 ± 2.4 N/A 
  
K103N RT-T/P-dNTP 0.65 ± 0.14 48.8 ± 2.1 N/A 
  
K103N RT-T/P-EFV 0.46 ± 0.15 55.6 ± 1.2 N/A 
  
K103N RT-T/P-dNTP-EFV 0.62 ± 0.18 49.8 ± 2.5 N/A 
E138D RT  
E138D RT-T/P 0.69 ± 0.14 47.2 ± 2.6 N/A 
  
E138D RT-T/P-dNTP 0.66 ± 0.19 48.2 ± 3.1 N/A 
  
E138D RT-T/P-EFV 0.46 ± 0.12 55.6 ± 1.0 N/A 
  
E138D RT-T/P-dNTP-EFV 0.52 ± 0.13 53.3 ± 1.3 N/A 
 
Table 1. FRET-derived D250C-T139C distances and comparison to crystal structures. 
For all complexes indicated, the calculated Eapp values are shown, derived from the mean of fitted Gaussian 
functions to the observed Eapp data.  Projected D250C-T139 distances are shown.  When available, D250-T139 alpha 
carbon distances from crystallographic data are shown, with their respective PDBID indicated. 
 73 
Although FRET  was slightly lower in K103N RT  (Eapp = 0.60 ± 0.19) than in WT RT, the 
thumb-fingers distance in K103N RT also remained largely unchanged by presence of dNTP 
(Eapp = 0.65 ± 0.14) and showed a similar response to EFV as WT RT by shifting to a lower 
FRET  (Eapp = 0.46  ± 0.15), an Eapp change of  0.16 change for K103N RT vs. 0.15 for WT RT 
(Figure 28d).  In contrast to WT RT, however, K103N RT remained indistinguishable from both 
unliganded and dNTP-bound K103N RT when simultaneously incubated with dNTP and EFV 
(Eapp = 0.62 ± 0.18).  Thus, although the K103N RT-T/P-EFV complex experiences molecular 
arthritis in the presence of EFV, it maintains its grip on the T/P substrate in the presence of both 
dNTP and EFV and is likely polymerase competent, escaping the arthritis that WT RT-T/P-
dNTP-EFV experiences (Figure 28c; compare purple bars).  Since [TTP] in these experiments is 
well above the Kd calculated for both WT- and K103N-RT-T/P complexes in the presence or 
absence of EFV (Figure 27, right; see Methods), we conclude that cognate nucleotide can bind 
WT-RT-T/P complexes in the presence of EFV, yet, due to molecular arthritis, cannot be 
clamped by the fingers domain into a conformation compatible with primer extension.  On the 
other hand, K103N RT is able to overcome molecular arthritis and remain firmly clamped onto 
the T/P substrate in an extension-competent configuration. 
2.3.6 HIV-1 RT is a tunable molecular clutch 
With results indicating that the K103N mutation can alter RT-T/P dynamics and intramolecular 
conformation irrespective of EFV affinity, we compared the structures of WT and K103N RT 
bound to EFV and noted one striking difference in K103N RT: the disruption of a salt bridge 
between E138 on p51 and K101 on p66 likely removes the positive charge in K103 responsible 
for repelling K101 (Figure 29).   
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Figure 29.  K103N breaks the E138-K101 salt bridge 
The NNRTIBP of WT (darker) or K103N (lighter) is shown in ribbon representation.  p66 is colored in green, and 
p51 in grey. The distances between the Oε atom of E138 and the Nζ atom of K101are represented amidst red dotted 
lines.   
 
In published structures of WT RT (Kohlstaedt et al., 1992; Lansdon et al., 2010; Ren et 
al., 2000), the E138-K101 salt bridge (defined as a separation of < 4 Å between the Oε atom of 
E138 and the Nζ atom of K101; Donald et al., 2011) only exists in the presence of NNRTIs such 
as efavirenz, nevirapine, or rilpivirine.  Since E138-K101 resides at the hinge site between p51 
and p66, often implicated in the mechanism of RT inhibition by NNRTIs, we next engineered 
E138D-K101R into RT to form a stronger salt bridge by increasing its polarity, and examined its 
effects on EFV activity. We first noted that the binding affinity of EFV for E138D-K101R was 
increased by ~31-fold (Figure 30, left). Furthermore, the anisotropy-derived mobility of E138D-
K101R RT on the T/P substrate was constitutively higher than WT-RT and increased to a much 
higher degree in response to EFV than did WT RT (Figure 30, right).   
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Figure 30.  E138D/K101R binds and reacts strongly to EFV 
Left: Normalized binding curves of EFV to E138D/K101R are shown, with WT in black circles, and E138D/K101R 
in blue squares.  The data was normalized and fit similar to the binding curves presented in Figures 25 and 26. The 
indicated Kd values are derived from fits to the hyperbolic, single site binding curves. Right: dNTP titration with 
E138D/K101R in the presence (hollow squares) or absence (solid blue squares) of EFV are shown.  Fits to single 
site binding models are shown as blue lines.  Also shown are the fits from the analogous data from WT RT, i.e., 
from Figure 27, where the black dotted line is from WT RT-T/P and the solid black line is from WT RT-T/P-EFV. 
 
We next tested the E138D, K101R, and E138D-K101R mutations in two separate in vitro 
assays (see Methods) and found a respective 2.7 ± 0.2-, 1.3 ± 0.1-, and 2.7 ± 0.2-fold increase in 
susceptibility to EFV as measured by IC50, indicating that the changes observed in the E138D-
K101R salt bridge mutant largely arose from the presence of E138D.  We furthermore observed 
a 7.8 ± 4.6-fold increase in susceptibility of E138D-K101R RT (the other mutant viruses had no 
detectable activity) as measured by EC50 (see Table 2).  
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Table 2. IC50 and EC50 data for E138D, K101R, and K101R/E138D 
 
To quantify the effects of a stronger salt bridge on molecular arthritis, we next introduced 
the E138D mutation into our D250C/T139C thumb/fingers FRET construct.  Figure 6d illustrates 
that the distance between the thumb and fingers of the E138D-T/P complex (Eapp = 0.69  ± 0.14) 
was only slightly larger than that of WT, but responded in much greater magnitude to the 
presence of EFV than either WT or K103N RT did (Eapp = 0.46  ± 0.12, compare the FRET Eapp 
change of 0.24 for E138D vs. 0.15 and 0.16 for WT and K103N RT).   
 
Figure 31.  E138D RT is more arthritic than RT in the presence or absence of efavirenz 
FRET histograms for E138D RT-T/P (red) or WT-RT (black) both before (dotted) and after (solid) EFV. 
Genotype of 
RT or virus 
IC50 (nM) for inhibition of HIV-1 RT activity 
(Fold-resistance) 
EC50 (nM) for inhibition of HIV-1 replication 
(Fold-resistance) 
EFV NVP RIL ETV EFV NVP RIL ETV 
WT 
47.6±1.1 
 
2323.7±179.3 22.5±2.2 24.5±2.2 3.1±1.8 245±59.7 1.6±0.5 4.2±1.4 
E138D 
17.6±2.1 
(0.37) 
676.3±68.5 
(0.29) 
8.3±1.2 
(0.37) 
12.1±1.6 
(0.49) 
    
K101R 
37.4±1.8 
(0.78) 
2936.0±599.3 
(1.26) 
15.5±0.8 
(0.69) 
27.3±7.5 
(1.11) 
    
K101R/E138D 
17.5±2.4 
(0.37) 
1102.7±290.7 
(0.47) 
8.4±1.0 
(0.37) 
11.2±0.8 
(0.46) 
0.4±0.2 
(0.13) 
216±16.8 
(0.88) 
0.3±0.1 
(0.19) 
0.7±0.2 
0.17) 
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2.4 CONCLUSIONS 
We investigated mechanism(s) of inhibition of RT by Nonnucleoside RT Inhibitors (NNRTIs) 
and found that efavirenz (EFV), an NNRTI, did not significantly alter binding affinity of RT for 
its Template/Primer (T/P) substrate but substantially increased RT mobility on the T/P, reducing 
the time spent in the polymerase-competent position. In contrast, introduction of cognate dNTP 
resulted in an increased dwell time in the polymerase competent state in a manner independent of 
EFV, indicating distinct mechanisms of RT mobility modulation. Using a novel and extensible 
anisotropy-based assay of RT mobility, we also found that K103N, a drug resistance mutation in 
RT, reduced neviripine (NVP) affinity by ~10 fold but did not significantly affect EFV binding 
affinity.  Despite unaltered affinity of EFV, addition of EFV to K103N RT did not result in the 
increased shuttling we typically observed for WT RT, providing evidence that K103N confers 
structural resistance to EFV distinct from potential changes in the NNRTI binding 
pocket.  Furthermore, we showed that EFV addition results in a larger distance between the 
thumb and fingers domain of WT RT but not of K103N RT. After structural analysis revealed 
that NNRTIs generally result in the formation of a salt bridge between K101 and E138 of their 
respective p66 and p51 RT subunits and that this salt bridge is significantly disrupted in K103N 
RT, we engineered an electrostatically stronger salt bridge, E138D-K101R into RT and showed 
that this mutation resulted in an increase in NNRTI susceptibility accompanied by a large 
increase in T/P mobility and a persistently larger distance between the thumb and fingers domain 
than that of WT RT.  
Taken together, the results indicate that RT is akin to a tunable “molecular clutch” under 
partial control of the E138-K101 salt bridge, which modifies RT conformation through a crucial 
hinge site between p51 and p66.  EFV-induced molecular arthritis, greatly strengthened by the 
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salt bridge, is responsible for diminishing RT-T/P contacts, reducing the grip of RT on its T/P 
substrate and its ability to clamp down on the dNTP in the polymerase competent mode, 
permitting highly dynamic T/P translocation that is disruptive to DNA polymerization.  The 
K103N mutation alleviates molecular arthritis by breaking this crucial bridge and restoring the 
ability of RT to grip the T/P substrate in the presence of dNTP and EFV, conferring a structural 
workaround to the activity-reducing effects of EFV. 
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3.0  CHARACTERIZING THE INTRA-MOLECULAR DYNAMICS OF HIV-1 RT ON 
THE T/P SUBSTRATE IN THE ABSENCE AND PRESENCE OF NNRTI USING 
SPFRET AND MOLECULAR MODELLING 
3.1 INTRODUCTION 
HIV-1 Reverse Transcriptase (RT) is an attractive drug target as it is critical to the life cycle of 
HIV-1.  Nevertheless, there are major limits to our understanding about this important enzyme 
which impede the development of new and effective RT Inhibitors (RTIs).  Specifically, detailed 
information about drug- and/or substrate-induced changes in its structural dynamics and its 
substrate binding kinetics is lacking. In this chapter, we planned to address these deficits by 
developing methods that combine single-molecule fluorescence spectroscopy with molecular 
modeling.  Utilizing several inter-domain FRET pairs in RT, we propose to model equilibrium 
structures of RT in the presence of various substrate/drug combinations using spFRET. In 
addition, we will model the structural intermediates of RT during drug-induced conformational 
change, using a method under development called Structural Information from FRET (SIFF) that 
employs Bayesian methods to infer the most probable instantaneous structure in a trajectory from 
spFRET traces and structural sampling.  To obtain absolute, accurate FRET distances, all 
spFRET measurements will be complemented with data from atomistic MD simulations of our 
dye-labeled system of interest.   
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In the last 25 years there has been significant progress in understanding HIV-1 RT structure-
function relationships. To date, more than 100 different crystal structures of wild-type (WT) and 
mutant HIV-1 RTs have been solved in their unliganded forms or in complex with substrates 
[e.g., template/primer (T/P) and dNTP] or RTIs. These structures have highlighted the large 
intra-subunit, inter-domain conformational changes that can occur in HIV-1 RT upon substrate 
or drug binding (Ivetac and McCammon, 2009; Seckler et al., 2011; Sluis-Cremer et al., 2004; 
Temiz and Bahar, 2002). Biochemical studies have shed insight into the mechanisms associated 
with DNA polymerization, RNase H cleavage, RTI inhibition and drug resistance. Furthermore, 
recent single pair Förster Resonance Energy Transfer (spFRET) studies have revealed how 
nucleic acid sequence and RTI binding can influence the RT-T/P interaction (Abbondanzieri et 
al., 2008; Liu et al., 2008). For example, HIV-1 RT can flip its orientation 180° on a polypurine 
tract (PPT) T/P without dissociation upon NNRTI binding (Liu et al., 2008).    
Despite this wealth of available structural, biochemical and biophysical data, there remain 
significant knowledge gaps that have not been addressed. These include: 
i.     The structure and dynamics of RT in complex with substrates and RTIs; and 
ii.  The structural trajectories and transitions that occur in RT upon substrate or RTI 
binding; and  
iii.  The change in RT-T/P binding kinetics that occurs upon substrate or RTI binding   
Such information would have an immediate and profound impact on all levels of the 
biology of HIV-1 reverse transcription including structure-activity relationships, inhibition, drug 
resistance and drug discovery.   
To date, our ability to follow binding kinetics and to measure the intra-subunit 
conformational changes that occur in HIV-1 RT upon substrate and/or RTI binding has been 
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limited by technology.  In this regard, we aim to develop and apply single molecule fluorescence 
methods coupled with computational modeling to study the structural transitions in HIV-1 RT in 
vitro under physiologically relevant conditions. To this end, we proposed the following 
approaches: 
 
Approach 1: To develop an accurate method to generate structures of on-pathway 
transitional intermediates. We will observe several RT constructs bearing inter-domain FRET 
pairs with spFRET using a Scanning Confocal Fluorescence Microscope (Zheng et al., 2007) 
and/or a Total Internal Reflection Fluorescence Microscope (Graham et al., 2011; Roy et al., 
2008) equipped with a computer automated stopped-flow setup.  Equilibrium (i.e., “static”) 
atomistic RT structures will be modeled with multiple experimental distance constraints.  To 
model accurate, absolute distances (Allen and Paci, 2009; Corry and Jayatilaka, 2008; Iqbal et 
al., 2008a; Schroder, 2005; VanBeek et al., 2007), measurements will be complemented with 
data from atomistic simulations of dye-bound proteins, including orientation factor and linker 
flexibility. To model on-pathway structural intermediates between free drug-bound RT, drug 
induced conformational changes will be monitored by spFRET in real time during drug infusion. 
These inter-domain distance trajectories will in turn serve as inputs to a computational method 
called Structural Information from FRET (SIFF), which uses Bayesian particle filtering (Blake 
and Isard, 1998) methods to accurately recover and rank the likeliest atomistic structural 
trajectory responsible for the reported spFRET trace. Comparison of existing structural data with 
generated trajectories from subsequent SIFF calculations will provide a clear proof-of-concept 
for our method's ability to predict the proper conformation, cross-validating our experimental 
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(spFRET) and computational (SIFF) work and confirming its suitability to characterize less well-
studied systems. 
 
Approach 2: Characterize substrate- and RTI-induced conformational changes in RT. The 
primary goals of this Aim are to discover novel structures of RT complexed with various 
combinations of nucleic acid substrates (e.g., template/primer and/or NTPs) and/or drugs 
(NNRTIs, ncRTIs and RNHIs). Steady state traces of RT will be recorded, and equilibrium 
structures for each state will be modeled with FRET-derived distance constraints. To obtain 
structures of on-pathway intermediates during drug-induced conformational change, RT will be 
infused with ligand during real-time observation, and the resultant spFRET trajectories will be 
analyzed with techniques developed in Approach 1. 
 
3.1.1 Statement of Problem 
Although HIV-1 RT is one of the best studied viral polymerases, several knowledge gaps limit 
our ability to understand the structure and dynamics of enzyme function as well as the 
mechanisms of RT inhibitor (RTI) inhibition and drug resistance, specifically:  
 
i) While there are several crystal structures of HIV-1 RT in complex with substrates [e.g., 
T/P or T/P and dNTP] or RTIs [e.g., NNRTIs or RNase H inhibitors (RNHI)], there is no 
structural information for RT in complex with both substrates and RTIs. In this regard, 
the structural mechanisms associated with NNRTI inhibition of HIV-1 RT function have 
largely been deduced from RT-NNRTI binary complexes. Given that several kinetic 
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analyses have demonstrated that many NNRTIs preferentially bind to RT-T/P or RT-T/P-
dNTP complexes, the available structural information may not be entirely relevant.  It is 
crucial, then, that we find an alternate means to obtain structures of these target 
complexes.  
ii) Crystal structures of HIV-1 RT in complex with nonnucleoside RTIs (NNRTIs) reveal 
large conformational changes in the 66 kDa (p66) subunit of HIV-1 RT, but the nature 
and dynamics of the structural transitions and trajectories involved in these 
conformational changes are unknown.  While X-ray crystallography and NMR methods 
provide a wealth of structural information on low energy substates, they are insufficient 
for predicting transitional structures between two or more substates: interpolation 
between these structures is unsatisfactory since there is an astronomically large number 
of structural intermediates possible between different substates. Rational design of high-
affinity drugs may greatly benefit from reliable structural information from transitional 
intermediates; therefore, development of a means to identify these transitional 
intermediates is of critical importance.   
iii) It is unclear to what extent RTIs affect the on/off binding kinetics of the RT-T/P 
complex. Although bulk methods exist to measure kinetics of DNA-protein complexes, 
they can lead to artifacts from ensemble averaging and involve extensive instrumentation 
(e.g., stopped flow). Thus, our goal is to develop a means to directly measure the kinetics 
of DNA-protein reactions at the single-molecule level.  
 
We aimed to develop robust experimental and computational methods that will allow us to (i) 
model equilibrium structures of various RT complexes of interest and (ii) predict, with 
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unprecedented accuracy, structures of transitional intermediates during drug- and/or substrate-
induced conformational change in RT  
 
In this chapter, we propose coupling single-molecule fluorescence methods with 
computational modeling to study the structural dynamics and binding kinetics of RT.  spFRET is 
a powerful method, yielding high information content about the kinetics of individual molecules 
and relative changes between two or more states in the millisecond to minute timescale 
(Hohlbein et al., 2010; Joo et al., 2008; Lee et al., 2005; Lu, 2005; Michalet et al., 2006; Roy et 
al., 2008; Wang and Geva, 2005).  However, individual spFRET measurements significantly lack 
detailed structural information. Conversely, in silico atomistic simulations are atomically 
accurate but suffer from temporal sampling deficits. We therefore propose to integrate these two 
approaches to yield detailed, time-resolved atomistic information. In trying to push the limits of 
spFRET, we are attempting to optimize the accuracy of our experiments by optimizing s/n with 
rapidly evolving advances in the field (Chung et al., 2010; Iqbal et al., 2008b; Joo et al., 2008; 
Liu et al., 2010; Lu, 2005; Santoso et al., 2008; Wang and Geva, 2005; Wang and Lu, 2008; 
Watkins and Yang, 2004; Wozniak et al., 2008) and by complementing our results with 
molecular simulation of the system under study.  Furthermore, we are using the recently 
described phenomenon of fluorescence intensity enhancement (Hwang et al., 2011) to develop a 
powerful technique to record binding events and to accurately measure the on/off rates of 
molecular complexes, particularly important quantities as they provide information about the 
energy barrier of the reaction.  Notably, the methods developed in the proposed work will 
directly benefit the RT field and will be broadly applicable to other protein-ligand systems. 
 
 85 
3.1.2 Structural Information from FRET (SIFF) 
A computational tool under development in the lab of Chakra Chennubhotla (University of 
Pittsburgh), Structural Information from FRET (SIFF) recovers the instantaneous three-
dimensional structure of a natively fluctuating protein from spFRET data. Experimental spFRET 
methods capture molecular kinetics and relative distance changes between multiple 
conformational states with millisecond resolution. However, as one-dimensional dye-separation 
traces, spFRET measurements cannot resolve three-dimensional structural details; countless 
protein geometries could satisfy any single spFRET-derived distance. Molecular dynamics (MD) 
simulations make the opposite compromise: structural changes are sampled at atomistic 
resolution but with necessary temporal deficits; simulation timescales are orders of magnitude 
smaller than those accessible to spFRET. SIFF eliminates these tradeoffs by iteratively updating 
a structural ensemble at each spFRET-time point consistent with the reported spFRET distance 
and based on prior knowledge from the overall structural trajectory. The method is based on 
Bayesian filtering and predicts the time-evolution of a protein system that is constrained by 
incomplete (i.e., a single distance constraint) and imperfect (i.e., with quantifiable noise) 
experimental data; resulting (sequential) on-pathway intermediates agree with the inputted 
spFRET trace. Reconstructed dynamics are informed by atomistic and coarse-grained 
simulations, which quantify the three-dimensional conformational responses to reported spFRET 
distances. SIFF thus simultaneously removes the sampling deficits of molecular simulations and 
the structural deficits of spFRET experiments. Particularly suited to hinge proteins with large 
distance changes between domains, the method has already been validated for spFRET traces of 
apo Adenylate Kinase from Haw Yang’s lab. 
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3.2 PROPOSED STUDIES 
3.2.1 Development of a method to structurally characterize on-pathway transitional 
intermediates 
We plan to assess our technique using efavirenz and neviripine, FDA-approved NNRTIs, since 
the binding and kinetics of these drugs are well characterized.  Steady state spFRET experiments 
will be performed on free and NNRTI-bound RT bearing each FRET pair, and the data will be 
corrected for spectral crosstalk and variations in fluorophore quantum yield on a trace-by-trace 
basis to ensure accurate and precise FRET E values (McCann et al., 2010).  For each dye pair, 
distance distributions will be calculated from FRET E histograms and Ro as determined above.  
We will compare these inter-fluorophore distances to estimates from static X-ray structures (ΔE, 
Table 3), and from simulation (i.e., the distance between the dye-cloud centroids).  We will 
evaluate cross-correlation matrices from both atomistic and coarse grained simulations as inputs 
into SIFF, and we will assess several ways of incorporating dye structure into the model.  Next, 
we will process individual spFRET traces with the optimized SIFF algorithm, quantitatively 
comparing the resultant structural trajectories with crystallographic structures and simulation 
data.  This comparison will effectively cross-validate the accuracy of spFRET traces and of 
SIFF-derived structures and will allow us to make adjustments to either complimentary 
technique if necessary. 
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3.2.2 Discovering novel structures of RT complexes 
Despite the large number of RT structures deposited in the PDB, there is a conspicuous lack of 
structures in complex with more than one ligand.  To address this deficit, we plan to solve the 
structures of RT while in complex with various combinations of template/primer (T/P) 
substrates, NTPs, and drugs in the NNRTI, ncRTI, and RTI classes.  We will employ a T/P 
substrate commonly used in our lab: a 58mer template and a 26mer primer.  In some instances, 
the primer in the T/P substrate will be 3’-end terminated with a dideoxythiamine which lacks the 
3’OH necessary for elongation, denoted as T/PddT.  In other cases, the primer in the T/P substrate 
will be a synthetic polypurine tract (PPT), denoted as T/PPPT.  We will perform steady state 
spFRET experiments with TIRFM to record the interdomain distances of every binary, ternary, 
and quaternary complex outlined in Table 3.  Similar to the use of Nuclear Overhauser Effect 
(NOE) distance constraints in NMR structure determination, we will use multiple distance 
constraints derived from designed FRET pairs to model equilibrium RT structures.  We will 
incorporate absolute distance distributions from each FRET pair into our model which has been 
optimized to best describe the dye centroids.  Harmonic constraints will applied to the centroids 
of the dyes modeled on RT, accounting for the positional error of FRET due to protein dynamics, 
and structures will be globally optimized by simulated annealing and/or replica exchange 
molecular dynamics procedures.  The resultant structures will be exclusive, atomistic models of 
all of the various complexes outlined in Table 3, providing deep structural insight into the 
interplay between substrate and drug binding in RT.  Importantly, the success of the 
D250C/T139C FRET scheme in Chapter 2 provides proof-of-principle that these experiments 
will work. 
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Figure 32.  Proposed intra-RT FRET pairs. 
The proposed cysteines to be dye labeled are indicated in yellow spheres, where any pair within RT is a potential 
FRET pair. 
 
Table 3. Proposed distances between FRET pairs 
Distances between alpha carbons of the indicated FRET pairs in the NVP-free or –bound state.  Predicted FRET E is 
shown, and the predicted change in E upon complexing with NVP, ΔE, is shown. 
p66 Mutant State robs (Å) predicted predicted
FRET E ΔE
D67C/D250C free 19.5 1.00 0.05
bound 34.9 0.94
E6C/D67C   free 34.1 0.95 0.13
bound 43.2 0.83
E6C/E449C free 69.8 0.21 0.03
bound 72.3 0.18
E6C/D250C free 47.0 0.74 0.42
bound 63.5 0.32
D67C/ E449C free 61.2 0.37 0.13
bound 67.8 0.24
D250C/E449C free 48.6 0.70 0.09
bound 51.8 0.61
E6C/L560C free N/A N/A N/A
bound
D67C/L560C free N/A N/A N/A
bound
D250C/L560C free N/A N/A N/A
bound
E449C/L560C free N/A N/A N/A
bound
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3.2.3 Identification of transitional structures in RT during drug-induced conformational 
change 
We will monitor spFRET from various RT FRET pairs as several different drugs are infused into 
the system by stopped-flow.  We will start by testing Efavirenz and will move to novel 
compounds (ncRTIs, RHIs) discovered in our lab and in others in order to elucidate the 
mechanism of RT inhibition behind each drug. We will first perform experiments on FRET-
labeled T139C/D250C to see if we can monitor changes in molecular arthritis in real time.  We 
will next attempt to see conformational change within the other FRET pairs detailed in Table 3. 
Preliminary calculation (Table 3) suggests that the FRET pair between the thumb and the palm 
(C6/C250) will yield the highest FRET change upon Efavirenz binding.  Though the C67/C250 
(Fingers-Thumb) and C6/C449  (Fingers-RNase H) dye pairs are predicted to yield little to no 
FRET E change upon NNRTI binding, measuring E from both FRET pairs is worthwhile for 
providing more distance constraints and as an internal control against false-positive observations 
of transitions: the more FRET pairs that are sampled for each drug, the more information we get 
regarding conformational change and the more confidence we can have in our SIFF output.  We 
will first observe drug-induced transitions via TIRFM, since it can observe spFRET traces from 
hundreds of individual molecules at once, as opposed to our SCFM, which focuses on one 
molecule at a time.  At this stage we may decide to increase the temporal resolution of our 
TIRFM by speeding up the frame rate, sacrificing S/N by using smaller integration times.  We 
may also try pixel binning and/or reducing the effective area projected onto the CCD by 
acquiring sub-regions.  In this way, we could drive our TIRF microscope to acquire up to 1 
ms/frame (1 kHz), although we would only be watching 1-10 molecules (as opposed to 
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hundreds) at a time.  In order to sample the transition at higher speeds, we will next observe 
drug-induced conformational change with our SCFM setup. 
 
Figure 33.  Theoretical transitional FRET trace. 
A theoretical FRET trajectory before and after injection of NNRTI during observation.  In this scenario, molecular 
arthritis causes the thumb and fingers distance to become greater, decreasing the FRET value, while reducing the 
variability in the FRET signal due to stiffening of the domains relative to each other. 
 
Figure 30 illustrates an example of predicted experimental results.  In the depiction of an ideal 
FRET trace from an experiment using the C6/C250 dye pair as an example, NNRTI is infused 
some seconds after acquisition has started, inducing an observable state-to-state transition 
(depicted as a circle), indicating large conformational rearrangements in RT.  It has been 
reported that both Thumb and Finger domain mobilities are attenuated by NNRTI binding. The 
free and drug-bound states should hence be resolvable by quantifiable changes in FRET 
distribution width.  We hope to capture dozens of time-resolved drug binding events for every 
FRET-pair construct and drug combination.  We posit that sampling the unique structural 
trajectories of conformational change will significantly enhance rational drug design, so the 
ultimate goal will be capture as many structures of transitional intermediates as possible. 
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3.2.4 Investigation of the interplay between RT conformation and ligand affinity 
We hypothesize that, as the overall structure of RT begins to resemble the drug-bound structure 
during drug-induced conformational change, the affinity of drug for its binding site will increase.  
Moreover, we anticipate that, during a drug binding event, the spFRET traces should abide by 
the conformational selection hypothesis when undergoing a drug induced transition.  
Specifically, drug-bound conformations should be “reachable” from the unbound state by virtue 
of RT’s structurally encoded intrinsic dynamics.  If our efforts to sample structural trajectories of 
conformational change are successful, we will have a unique and exciting opportunity to test 
these hypotheses.   
 
Figure 34.  Theoretical effect of conformational change on ligand binding affinity 
The theoretical response of the calculated ligand binding free energy ΔGbind to docking to the structures along an on-
pathway transition from apo to holo forms, where blue represents a protein whose binding site shape is becoming 
more “ligand-like” as it makes the transition to a binding-competent conformation. 
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Using the structural trajectories we obtain, we will computationally dock the appropriate 
ligand onto each on-pathway intermediate using Autodock, which outputs an estimate of ligand 
binding free energy, ΔGbind for a  particular ligand/receptor pair (see Figure 34).   Also indicated 
in Figure 34, we will quantify the probability of a ligand-free conformation “reaching” a drug-
bound conformation from our simulations.  Independent of using transitional intermediates, we 
will perform similar experiments on the novel equilibrium structures from our modeling efforts.  
For instance, we can test the hypothesis that Efavirenz has a preference for binary and tertiary 
RT complexes while Nevirapine has a preference for free enzyme.   
 
3.2.5 Determining the role of conformational dynamics on polymerization activity 
The mechanism of polymerization by RT remains unclear.  Steady-state and pre-steady-state 
kinetics have pointed to the possibility that the rate-limiting step of polymerization is either 
nucleotide incorporation or T/P substrate dissociation.  Nucleotide incorporation is believed to 
take place in the polymerase active site as the p66 fingers domain clamps down on the incoming 
dNTP, precisely orienting the primer for elongation, followed by T/P translocation. In this 
paradigm, the rate limiting step of polymerization is the conformational dynamics of RT itself.  
Following RT:T/P complexes with spFRET, we will infuse dNTPs into the flow cell and observe 
conformational changes in the fingers domain relative to the thumb domain, attempting to relate 
the observed motions to the number of dNTP additions required for complete polymerization.  If 
this preliminary experiment is successful, we can easily move to combining dye-labeled T/P 
substrates with singly-labeled RT p66 (D250C, for instance) in order to watch stepwise changes 
in spFRET trajectories as the substrate is translocated, with the purpose of decoupling the 
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kinetics of translocation with those of dNTP addition.  If successful, the experiments will provide 
much needed insight into the structural dynamics of RT activity. 
 
3.2.6 Modeling accurate, absolute FRET distances with atomistic RT simulations 
Although it is reasonable to compare relative changes between two E measurements, inherent 
uncertainty in FRET E renders the method insufficient as an absolute quantitative ruler.  Using 
the equation for FRET Efficiency (E):      
                      E = 1/ (1+ (R0/r)
 6
)                                                    (3.1) 
we can directly calculate distance changes between single D-A pairs, r.  In the above equation, 
Ro is the Förster distance, or the distance at which E =0.5, and is defined as 
Ro = 8.8x10
-28
 κ2 η-4 Qo J                                               (3.2) 
where n is the refractive index, Q0 is the fluorescence quantum yield of the donor without 
acceptor, and J is the integral of the spectral overlap between the donor emission and acceptor 
excitation spectra.  In equation 2, κ2 is the orientation factor of the first excited state dipole and is 
calculated as 
                                                 κ2 = (sinθD sinθA cosΦ – 2 cosθD cosθA)
2                                            
 (3.3) 
where θD and θA are the angles between the transition dipole moments of donor and acceptor and 
the vector connecting the two dyes, and Φ is the angle between the planes of the fluorophores 
(see Figure 2). 
 94 
 
Figure 35.  Orientation factor and transition dipoles of FRET 
Left: vectors from the text are explained in schematic format.  The dipole of Cy3/donor are indicated as green vector 
and the dipole of Cy5/acceptor as red.  Right: The transition dipole moments of Cy3 and Cy5, projected onto the 
molecule. 
 
The value of κ2 can range from 0 to 4, depending on the relative dye orientations.  Most 
researchers assume a   κ2 value of 2/3 for isotropically tumbling dyes despite the fact that a high 
correlation between κ2 and Ro has been observed.
 
 In our system and in many others, the 
fluorophores are fixed to the system of interest with limited conformational freedom and are 
expected to display anisotropic behavior.  Clearly, uncertainty in FRET-derived distances 
(beyond measurement error from shot noise and dye-linker flexibility) largely stems from using 
an arbitrary value for Ro. Indeed, we typically use a commonly referenced Ro of 5.8 nm to 
approximate distances, calculated for the Cy3-Cy5 D-A pair assuming κ2 = 2/3 (Bastiaens and 
Jovin, 1996).  Thus, in order to calculate accurate absolute distances, i.e., distances which are not 
relative to another measurement, it is necessary to have an accurate estimate of κ2.  It is 
straightforward to calculate the instantaneous κ2 value from a snapshot of an MD simulation, so 
one can easily determine the mean κ2 value over the course of the simulation.  Currently, 
D
Ar
Φ
θD
θA
Cy3 Cy5
 95 
however, there are no publically available force field parameters for Cy3 and Cy5, so it was 
necessary to parameterize the dyes ourselves (see topology and parameter files in Appendix).   
In order to model the geometry of a fluorescing dye, one must model the excited state 
geometry of the molecule, which differs than that of the ground state.  Starting with previously 
optimized Cy3 and Cy5 coordinates courtesy of David Norman’s group (Iqbal et al., 2008b) 
(used to reduce computation time) and parameters courtesy of J. Spiriti (Spiriti et al., 2011),  we 
parameterized Cy3 and Cy5 with the CHARMM General Force Field (CGENFF) 
(Vanommeslaeghe et al., 2010).  Employing the newly parameterized Cy3 and Cy5 residues, we 
will perform explicit solvent Molecular Dynamics (MD) simulations of RT with either Cy3 or 
Cy5 residues on all of the four locations with known structure (residues 6, 67, 250, and 449).  
Using simple vectors between two atoms that best describe the excited state dipole, we can 
calculate mean κ2 as in eq. 3 and, for each time point in a given FRET trajectory, derive an 
absolute distance r from eqs. 3.2 and 3.1.   
 
3.3 RESULTS 
Preliminary simulations focused on obtaining a quantitative measurement of the accuracy of 
FRET simulations.   The first simulation we performed was on two tripeptides separated by 5 Å 
and fixed at the alpha carbon, in order to measure the distribution of FRET due to dye flexibility 
alone in the absence of protein domain motions (see Figure 36).  As a proof-of-principle, this 
experiment shows that we are able to measure FRET in silico with reasonable accuracy.  We 
were also able to measure Κ2 , which averaged 0.87 over the course of the 100 ns simulation.  
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This value is close to the expected value of 0.66 for the case of an isotropically tumbling dye, 
indicating that the dye linkers give sufficient flexibility per se, and that any gain in anisotropy is 
likely due to interaction with the protein.  Interaction of the dye with the protein is likely given 
(1) the results in Chapter 2 indicating that Cy3 nonspecifically associates with RT and (2) in our 
FRET experiments, the laser power must be cut very low (<2 mW) to avoid photobleaching 
compared to the power used for dye-labeled oligonucleotides. 
 
Figure 36.  Simulation of FRET 
FRET simulations for the two tripeptides held at 5 Å apart are presented. The top schematic indicates the positions of 
the dyes over the course of the trajectory (taken every 0.1 ns).  The bottom left is a histogram of all instantaneous 
FRET-derived distance values calculated over the trajectory.  The bottom right figure shows a histogram of Κ2 also 
calculated instantaneously for every frame of the simulation.   
 
 97 
Currently, we are running AMD simulations of the recent apo and holo structures of RT-T/P 
with or without NVP (Das et al., 2012) (PDB IDs 3VD6 and 3V81), bound to Cy3 and Cy5 at 
D250C and T139C on the respective thumb and fingers domains (as shown in Figure 28a)  which 
required removal of the DNA-fingers crosslink and the terminal AZT on the primer, and also 
required parameterization of NVP (using CGENFF) and Cy3- and Cy5-maleimides.  As of the 
time of this writing, the simulations have reached about 200 ns each and are gaining ~4.5 ns/day 
each.  We then intend to carry out the experiments outlined in 3.2.3, using our stopped-flow 
apparatus to inject NVP during observation time. 
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4.0  CONCLUSIONS 
HIV-1 RT must form a stable ternary RT-T/P-dNTP complex to facilitate phosphodiester 
bond formation and elongation of the DNA primer. Our data shows that EFV substantially 
increases the sliding of RT on the T/P, which effectively reduces the enzyme’s dwell time in the 
polymerase-competent ternary complex. EFV was also found to decrease the affinity of dNTP 
for the RT-T/P complex. The observed increase in RT sliding and decrease in dNTP binding 
provide a plausible mechanism by which EFV (and other NNRTIs) inhibit HIV-1 reverse 
transcription. In pre-steady-state kinetic studies, the EFV-bound RT-T/P complex exhibits an 
increase in dNTP affinity. However, it should be noted that the anisotropy and pre-steady-state 
kinetic assays measure different events. In the anisotropy assays we assess dNTP binding to an 
RT-T/P complex that cannot undergo catalysis because the DNA primer is chain-terminated. As 
such, we likely capture both productive and non-productive dNTP binding. In contrast, the Kd 
determined from pre-steady-state kinetic studies only measures productive dNTP binding to an 
RT-T/P complex actively undergoing catalysis. Unexpectedly, we found that the K103N 
mutation in RT does not prevent EFV from binding to the RT-T/P complex but allows the 
enzyme to form a stable polymerase-competent RT-T/P-dNTP ternary complex. However, the 
K103N mutation did decrease the affinity of NVP for the RT-T/P complex. In comparison to 
NVP, EFV is a smaller drug and can reposition itself within the pocket, whereas the bulky fused 
ring system of NVP remains relatively rigidly in place and no such rearrangements are possible.  
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Overall, this is consistent with earlier predictions from crystallographic data (Ren et al., 2000). 
The single-molecule FRET data unambiguously shows that the K103N mutation relieves the 
molecular arthritis in the fingers and thumb sub-domains of RT such that it can form a stable RT-
T/P-dNTP complex. The molecular arthritis phenotype is likely driven by the formation of salt 
bridge between K101 and E138 at the hinge region of the RT dimer interface. Of note, RIL is 
active against HIV-1 containing K103N, and our anisotropy studies reveal that the drug 
efficiently binds to and mobilizes K103N RT. Interestingly, in the structure of K103N RT in 
complex with rilpivirine the salt bridge between K101 and E138 is intact (Lansdon et al., 2010).  
In this structure, the central, electrostatically positive nitrogenous ring of the three ring 
diarylpryimidine moiety appears to be responsible for repositioning K101 into a salt bridge-
competent configuration in the structure of K103N bound to rilpivirine (Lansdon et al., 2010).  
Taken together with our data, this observation suggests that a positive interloping substituent can 
take place of K103, whose purpose in the context of NNRTI activity is to precisely position 
K101 into register to constitute the E138-K101 salt bridge. 
In addition to sampling on-pathway transitional intermediates in NNRTI-induced 
conformational change, we plan to use the simulation results from Chapter 3 to directly monitor 
the connection between E138-K101 salt bridge integrity and thumb/finger dynamics, with the 
working hypothesis that the two are directly related.  Since it is possible that the E138-K101 salt 
bridge is only partially responsible for the overall effect of NNRTI, this analysis will directly 
demonstrate the magnitude of interdependence of the global dynamics of RT on the NNRTI-
induced salt bridge. 
Our data highlights an unexpected and novel mechanism of HIV-1 resistance to NNRTIs 
and will be critical in transforming NNRTI drug design from a shotgun/library-based approach to 
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a rational approach which incorporates molecular mechanism(s) of action as well as resistance 
mechanism(s).  Since using our unique combination of techniques to probe the mechanism of a 
single NNRTI resistance mutation yielded much needed insight into the mechanism of NNRTIs 
as well as the mechanism of NNRTI resistance, essential to this future endeavor into rational 
NNRTI design will be the understanding of other resistance mutations in the context of other 
NNRTIs.  For instance, we have begun to investigate the effects of RIL on RT T/P dynamics and 
intradomain conformation, and are interested in the mechanism of various RIL resistance 
mutations such as E138A/G/K/Q/R and/or K101E/P, which appear to target the salt bridge and 
its effects on RT dynamics.  Results from these studies will be critical in the design of novel, 
effective inhibitors against an ever-emerging battery of NNRTI resistance mutations in HIV-1 
RT. 
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APPENDIX A 
MATLAB SCRIPTS USED FOR DATA ANALYSIS 
**************** ********************* PIFE.m ******************************* 
function PIFE (fname,m,n) 
%% usage: redlaser ('fname',n) 
 
%where fname is root file name: i.e. for example_1, example_2, etc. 
%usage is redlaser ('example',1) 
 
workdir= 'F:\PIFE\130328.traces\'  %where the .traces file exists 
timeunit=0.015; %define CCD frame increment in seconds 
fold_intensity=0; %set this to 1 to convert intensity histograms to "fold" histograms via the 
PIFE_fit routine. 
 
 
%set "high" to be divisible by bin_number 
bin_number=25; %number of bins to be used in all histograms 
high=2000; low = 0; bin_interval = (high-low)/bin_number; %define upper/lower limit of intensity 
values 
PIFE_space=low:bin_interval:high; 
 
%FILTERING AND CORRECTION 
filter=0;  %set to 1 to use savitsky-golay filter on FRET signal 
filter_window=5; %must be odd number >1 
number_polys=2; 
 
vb_cat='y';   %Use this to go through multiple regions, pressing 'v' and taking regions 
close all;  
cd(workdir); 
%for n=startn:endn 
%% Definitions 
           global base_mean; 
           donor_count=0; 
           vb_count=0;   
           donor_regions_all_points=0; 
           vb_regions_all_points=0; 
           vb_struct={}; 
                       
                    if nargin==1  
                        n=0; manyregions='n'; 
                    elseif nargin==2 | nargin==3 
                        manyregions='y';  %multi-region (static histogram) run 
                    end 
 
%% For every slide region      
for region=m:n   
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        if nargin==2 | nargin==3 
            fnames=[fname '_' num2str(region)]; 
        elseif nargin==1 
            fnames= fname; 
        end 
 
                   
        fid=fopen([fnames '.traces'],'r'); 
        len=fread(fid,1,'int32'); 
        time=timeunit:timeunit:len*timeunit; 
        Ntraces=fread(fid,1,'int16'); 
        disp(['Slide region ' num2str(region) ': Number of time traces: ' num2str(Ntraces/2) ', 
Number of frames is ' num2str(len),', framerate = ' num2str(timeunit),'s']) 
        raw=fread(fid,Ntraces*len,'int16'); 
        fclose(fid); 
        tracker=['./traces/' fnames '_track.dat']; 
        fname_fret_reg_tally=['./traces/' fnames '_reg_FRET.dat']; 
        fname_vbFRET=['./traces/' fnames '_vbFRET.mat']; 
        fname_PIFE=['./traces/' fnames '_PIFE.mat']; 
      %% convert into donor traces 
  
      index=(1:Ntraces*len); 
      Data=zeros(Ntraces,len); 
      donor=zeros(Ntraces/2,len);  
%       vb_donor=zeros(Ntraces/2,len); 
%       vb_acceptor=ones(Ntraces/2,len); 
      vbFRET_scale_factor=zeros(Ntraces/2); 
      vbFRET_acceptor=zeros(Ntraces/2,len); 
      vbFRET_donor=zeros(Ntraces/2,len); 
      track=zeros(len+1,2); 
      Data(index)=raw(index); 
   
  for i=1:(Ntraces/2) 
      for j=1:len 
          donor(i,j)=Data(i*2-1,j); % + beta*donor(i,:) 
%           vb_donor(i,j)=donor(i,j)+1;%trying to trick vbFRET; failed. 
%           vb_FRET(i,j)=(1/(vb_donor(i,j)-1))^-1; 
      end 
                 
%       vbFRET_acceptor(i,:)=vb_FRET(i,:); 
%       vbFRET_donor(i,:)=1-vbFRET_acceptor(i,:);  %trying to trick vbFRET; failed.   
         
        vbFRET_scale_factor(i)=max(donor(i,:)); 
        vbFRET_acceptor (i,:) = donor(i,:)/vbFRET_scale_factor(i); %scale to 1 for 
vbFRET.vbFRET_acceptor=vb_FRET; 
           
  end 
   
        vbFRET_donor = 1-vbFRET_acceptor;  %just a requirement of vbFRET 
     
                  if (region==0) | (region==m) 
                       PIFE_all_regions=donor; 
                  else 
                       PIFE_all_regions=vertcat(PIFE_all_regions,donor); 
                  end     
       
   
  %% calculate, plot and save AVERAGE traces 
   
   dAvg=sum(donor,1)/Ntraces*2; 
   
   figure(1); %hdl1=gcf; figure(hdl1); 
   plot(time,dAvg,'g'); 
   title('Average donor'); 
   zoom on; 
   avgOutput=[time' dAvg']; 
   avgFileName=[fnames '_avg.dat']; 
   save(avgFileName,'avgOutput','-ascii'); 
 
  if manyregions=='n' 
      figure(2) 
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      title('Avg intensity of all traces for first 100 frames'); 
      subplot(1,2,1); 
      hist(dAvg(1:100),20,'FaceColor','g','EdgeColor','k'); 
      legend(['donor average= ' num2str(mean(dAvg(1:100)))]) 
      subplot(1,2,2); 
      hist(dAvg(1:100),20,'FaceColor','r','EdgeColor','k'); 
      legend(['acceptor average= ' num2str(mean(dAvg(1:100)))]) 
  end 
   
  MSGID =  'MATLAB:MKDIR:DirectoryExists'; warning ('off',MSGID); 
 
       
%% Define trajectory regions for multiple slide regions 
if manyregions=='n' || vb_cat=='y' 
mkdir traces;  
rk = 0; lkb = 0; lknb = 0; lk2= 0; lk = 0; i=0; saved=0; k=0;  
 
% Enter trace window.  needs while loop (not for loop).  
while i <((Ntraces/2)),  
 
i=i+1; 
 
figure(3);  %%TRACE window 
 
subplot(2,1,1); %D trace 
   plot(time,donor(i,:),'g');    
   line([0 max(time)],[0.1 0.1], [0,0], 'Color','r', 'linewidth',2);  
   
   temp=axis; 
   
  temp(3)=min( min(donor(i,:))) ; temp(4)=max( max(donor(i,:))) ;  
  grid on; zoom on; axis(temp); 
  title(['Molecule ' num2str(i)]); 
   
subplot(2,1,2);% donor histogram 
  hist(donor(i,:),25); 
  temp=axis; title(['Intensity histogram for trace ' num2str(i)]); 
 
%% MAKE A SELECTION 
ans=input('save([),pass(CR),back(p), or (e)nd?','s'); 
switch lower(ans) 
    case 'e' 
            break                
       
    case 'p' 
        i=i-2; 
       
     
    case 'g'  %GOTO molecule 
     nml = input('which molecule?'); 
     i=nml - 1; 
  
    case 'f' 
         
      donor(i,:)=sgolayfilt(donor(i,:),number_polys,filter_window); 
      i=i-1; 
       
    case 'r' %define region.  should do this after 'b' and 'c'.  save to array 
         
         clear X Y click_first click_last mollength ginput started; 
         [X, Y, mousebutton]= ginput; 
        
        mollength= length(X); 
         
        if mollength==2 %if 2 clicks, define regionp 
            
            for clk=1:mollength     
              if clk==1 
                    totalclickfirst_reg= X(clk); 
                    totalclickfirst_reg= fix(totalclickfirst_reg/timeunit); 
                elseif clk==2 
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                    totalclicklast_reg= X(clk); 
                    totalclicklast_reg= fix(totalclicklast_reg/timeunit); 
              end 
              end 
             
            totalclicktime_reg= abs(totalclicklast_reg - totalclickfirst_reg)'; 
                       
          clear time_reg donor_reg  %reload region variables each time since dimensions will vary           
            time_reg= time(totalclickfirst_reg:totalclicklast_reg);  %+1 
            donor_reg=donor(i,totalclickfirst_reg:totalclicklast_reg); 
                      
      i = i -1;        
      end 
         
  case 'x' 
        %region=region+1 
        clear X Y click_first click_last mollength ginput started; 
        [X, Y, mousebutton]= ginput; 
        click_first= 0; 
        click_last= 0; 
        started=0; 
 
        mollength= length(X); 
 
        if (mod(mollength,2)==0) & (mollength > 0) 
 
            for clk=1:mollength 
 
                if started==0 
                    click_first= click_first+1; 
                    totalclickfirst(click_first)= X(clk); 
                    totalclickfirst= fix(totalclickfirst/timeunit); 
                    totalclickfirst 
 
                    started=1; 
 
                else 
                    click_last= click_last+1; 
                    totalclicklast(click_last)= X(clk); 
                    totalclicklast= totalclicklast; 
                    totalclicklast= fix(totalclicklast/timeunit); 
                    totalclicklast 
                    started=0; 
                end 
            end 
            totalclicktime= abs(totalclicklast- totalclickfirst)'; 
            totalclicktime 
 
 
           %%%%%%%%%%%%%%save the picked traces%%%%%%%%%%%%%%%% 
 
            fname2=['./traces/' fnames '_tr_' num2str(i) '_region.dat']; 
            output=[time(1:totalclicktime+1)' donor(i,totalclickfirst:totalclicklast)']; 
            save(fname2,'output','-ascii') ; 
           %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
        end 
         
case 's' 
        save (fname_vbFRET,'-struct', 'vb_struct');  %temporary save (good if you crash the 
program a lot by e.g. clicking outside of the region); 
 
case {'v', '['} 
          clear X Y click_first click_last mollength ginput started; 
         [X, Y, mousebutton]= ginput; 
        
        mollength= length(X); 
         
        if mollength==1 %if 1 clicks, define region and save as vbFRET input 
            for clk=1:mollength     
              if clk==1 
                    totalclickfirst_reg= timeunit; 
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                    totalclickfirst_reg= fix(totalclickfirst_reg/timeunit); 
                    totalclicklast_reg= X(clk); 
                    totalclicklast_reg= fix(totalclicklast_reg/timeunit); 
              end 
              end 
             
            totalclicktime_reg= abs(totalclicklast_reg - totalclickfirst_reg)'; 
             
            if totalclicktime_reg > len; 
                disp ('You clicked outside of the region') 
                %clear clear totalclickfirst_reg; clear totalclicklast_reg; 
                i=i-1; 
                 
               
            end 
             
            clear time_reg donor_reg donor_intensity  %reload region variables each time since 
dimensions will vary           
             
            if totalclicktime_reg <len 
               time_reg= time(totalclickfirst_reg:totalclicklast_reg);  %+1 
            
            %for fetching later 
          
                         
            %these regions are for vbFRET.. weirdness to feed Id as E 
            donor_reg=vbFRET_donor(i,totalclickfirst_reg:totalclicklast_reg); 
            acceptor_reg=vbFRET_acceptor(i,totalclickfirst_reg:totalclicklast_reg);             
             
            %this region is for PIFE_fit 
            donor_region = donor(i,totalclickfirst_reg:totalclicklast_reg); 
                   
                       
            %clear output_vbFRET; 
            output_vbFRET=[donor_reg' acceptor_reg']; 
            vb_count=vb_count+1; 
             
          end                
       elseif mollength==2   % if you just press enter, save the whole trace    
             
            output_vbFRET=[vbFRET_donor(i,:)' vbFRET_acceptor(i,:)']; 
            vb_count=vb_count+1; 
        elseif mollength==0 
        end  
          
f fold_intensity==1;         
    %now make a histogram and send it to be curve fit 
    figure(10); 
     
    s=size(donor_region,2); 
      
     xlim= donor_region<=high;  
     donor_region=donor_region(xlim); 
     xlim2= donor_region >= low; 
     donor_region=donor_region(xlim2); 
    
 
        [freq,x_data]=hist(donor_region,PIFE_space); 
        x_data=x_data'; 
        y_data=(freq./s(1,1))'; 
        PIFE_fit(x_data,y_data);      
 
        
        
ans2= input('Choose PIFE 1-fold value: Use (;,l)owest peak mean, (d)efine, or (p)oint to 
it?','s'); 
      switch lower(ans2)        
          case {'l',';'} 
              donor_region=donor_region./base_mean; 
              figure(11); 
              hist(donor_region,bin_number); 
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          case 'd'     
              ans3=input('Enter base value: '); 
              donor_region=donor_region./ans3; 
              figure(11); 
              hist(donor_region,bin_number); 
          
          case 'p'  %you align the x-axis with the noise to define bckgnd 
             figure(3); 
              
              
             [Xb,Yb] = ginput; 
             if numel(Yb)==0;break;end 
             donor_base = Yb(1); 
             donor_region=donor_region./donor_base; 
             figure(11); 
             hist(donor_region,bin_number);        
             
      end 
end 
            %Creat a structure called PIFE with labels, donor intensity, 
            %normalized (fold) intensity, and the fold-factor required to divide the intensity to 
get the  
            %fold value.  Saved as fname_PIFE.m 
            PIFE.labels{vb_count}= [fnames '_mol_'  num2str(i)]; 
            PIFE.Cy3_intensity{vb_count}=donor(i,:); 
            PIFE.fold_intensity{vb_count}=donor_region; 
            
PIFE.fold_factor{vb_count}=PIFE.Cy3_intensity{vb_count}(:,1)./PIFE.fold_intensity{vb_count}(:,1);  
                         
            %Create a structure called vb_struct with labels and corrected 
            %donor/acceptor intensity required to spoof vbFRET into 
            %thinking the trace is FRET.  Feed directly to vbFRET. 
            vb_struct.data{vb_count}= output_vbFRET; 
            vb_struct.labels{vb_count} = [fnames '_mol_'  num2str(i)]; 
            vb_struct.scale_factor_intensity{vb_count}=vbFRET_scale_factor(i); %corrects vbFRET E 
to Intensity 
            
vb_struct.scale_factor_fold{vb_count}=(vb_struct.data{vb_count}(1,2).*vb_struct.scale_factor_inte
nsity{vb_count})./PIFE.fold_factor{vb_count}; %corrects vbFRET E to Fold I 
             
            if vb_count==1 
                vb_regions_all_points=output_vbFRET; 
                donor_regions_all_points=donor_region'; 
            else 
                vb_regions_all_points=[vb_regions_all_points; output_vbFRET]; 
                donor_regions_all_points=[donor_regions_all_points; donor_region'];          
            end 
             
        %Ntraces=0; continue; 
 
   end %end switch 
end 
 
elseif manyregions=='y' 
close all 
continue 
 
end 
    
 end 
  
%% makes total histogram of all slide regions 
 if size(PIFE_all_regions)>=1; 
    mkdir all_points_hist; 
       
      PIFE_all_regions=reshape(PIFE_all_regions,1,[]); 
      s=size(PIFE_all_regions,2); 
      
           xlim= PIFE_all_regions<=high;  
      PIFE_all_regions=PIFE_all_regions(xlim); 
             xlim2= PIFE_all_regions >= low; 
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      PIFE_all_regions=PIFE_all_regions(xlim2); 
                       
      [freq,xout]=hist(PIFE_all_regions,PIFE_space); 
      histdata=[xout' (freq./s(1,1))']; 
      figure (4); 
      bar(xout,freq./s(1,1),1,'w'); %plot normalized histogram 
      xlabel ('I'); 
      labn=['p ' '(n=' num2str(s(1,1)) ')'] ; 
      ylabel (labn); 
      titulo=['All points histogram' workdir '\' fname]; 
      title (titulo,'interpreter','none'); %suppress latex interpretation in title 
      savefile=[workdir 'all_points_hist\' fname '_all_points_hist.dat']; %save hist data as 
fname_hist.dat 
      save(savefile, 'histdata', '-ascii', '-tabs'); %tab delimited 
end 
 
%% vbREGions are tallied using "["), makes a histogram of these regions. 
 
if vb_count >= 1 
       save (fname_vbFRET,'-struct', 'vb_struct'); 
       save (fname_PIFE,'-struct','PIFE'); 
        
       %   
mkdir vb_regions_hist; 
%% vbHist      
     s=size(vb_regions_all_points,2); 
         xlim= vb_regions_all_points<=high;  
     vb_regions_all_points=vb_regions_all_points(xlim); 
     xlim2= vb_regions_all_points >= low; 
     vb_regions_all_points=vb_regions_all_points(xlim2); 
    
 
        [freq,xout]=hist(vb_regions_all_points,PIFE_space); 
        histdata=[xout' (freq./s(1,1))']; 
        figure (5); 
        bar(xout,freq./s(1,1),1,'w'); %plot normalized histogram 
 
        xlabel ('I'); labn=['p ' '(n=' num2str(s(1,1)) ')'] ; 
        ylabel (labn); 
        titulo=['Regions histogram: ' workdir '\' fname]; title (titulo,'interpreter','none'); 
%suppress latex interpretation in title 
        savefile=[workdir 'vb_regions_hist\' fname '_vb_regions_hist.dat']; %save hist data as 
fname_hist.dat 
        save(savefile, 'histdata', '-ascii', '-tabs'); %tab delimited 
 
 %% donor region hist (normalized to 1) 
figure(8); 
hist(donor_regions_all_points,50);  
  
fold_bin_number=50; %number of bins to be used in all histograms 
     fold_low=0; fold_high = 6; fold_bin_interval = (fold_high - fold_low)/fold_bin_number; 
%define upper/lower limit of intensity values  
 
s=size(donor_regions_all_points,1); 
         xlim= donor_regions_all_points<=fold_high;  
     donor_regions_all_points=donor_regions_all_points(xlim); 
     xlim2= donor_regions_all_points >= fold_low; 
     donor_regions_all_points=donor_regions_all_points(xlim2); 
    
          
     donor_space=fold_low:fold_bin_interval:fold_high; 
 
        [freq,xout]=hist(donor_regions_all_points,donor_space); 
        histdata=[xout' (freq./s(1,1))']; 
        figure (6); 
        bar(xout,freq./s(1,1),1,'w'); %plot normalized histogram 
 
        xlabel ('fold increase in intensity'); labn=['p ' '(n=' num2str(s(1,1)) ')'] ; 
        ylabel (labn); 
        titulo=['Fold histogram: ' workdir '\' fname]; title (titulo,'interpreter','none'); 
%suppress latex interpretation in title 
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        %SKELETOR 
%saves fname_fold_hist.dat for later use 
        savefile=[workdir 'traces\' fname '_fold_hist.dat']; %save hist data as fname_hist.dat 
        save(savefile, 'histdata', '-ascii', '-tabs'); %tab delimited 
        
end  
%% 
if manyregions=='y' 
       % PIFE_histogram(workdir,fname,n); 
end 
 
****************PIFE_fit.m**************************************************** 
 
function pife_fit(x_data,y_data) 
global cf1; global cf2; global base_mean; 
%close all; 
 
n=2; 
 
if n==2 
cf1 = fit(x_data,y_data,'gauss2'); 
 zero_means=[abs(cf1.b1),abs(cf1.b2)]; 
  if min(zero_means)==cf1.b1 
            a=cf1.a1;b=cf1.b1;c=cf1.c1; 
        elseif min(zero_means)==cf1.b2 
            a=cf1.a2;b=cf1.b2;c=cf1.c2; 
  end 
 
 
 
%disp(['b2=',num2str(cf1.b2)]); 
if cf1.b1<cf1.b2 
    base_mean=cf1.b1; 
elseif cf1.b1>cf1.b2 
    base_mean=cf1.b2; 
end 
 
disp(['mean=',num2str(base_mean)]); 
%    
% kill=a*exp(-((x_data-b)/c).^2); 
% killed=y_data-kill; 
%  
% cf2=fit(x_data,killed,'gauss1'); 
 
%figure (10); 
plot(x_data,y_data,'bo') 
hold all 
plot(cf1,'r') 
%plot(x_data,killed,'bx') 
%plot(cf2,'g') 
 
legend('data', 'gauss2')    
hold off 
 
elseif n==3; 
cf1 = fit(x_data,y_data,'gauss3'); % "natural" fit 
 
zero_means=[abs(cf1.b1),abs(cf1.b2),abs(cf1.b3)];         
 
        if min(zero_means)==cf1.b1 
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            a=cf1.a1;b=cf1.b1;c=cf1.c1; 
        elseif min(zero_means)==cf1.b2 
            a=cf1.a2;b=cf1.b2;c=cf1.c2; 
        elseif min(zero_means)==cf1.b3 
            a=cf1.a3;b=cf1.b3;c=cf1.c3; 
        end 
                         
kill=a*exp(-((x_data-b)/c).^2); 
killed=y_data-kill; 
 
cf2=fit(x_data,killed,'gauss2'); 
 
%figure (10); 
plot(x_data,y_data,'bo') 
hold all 
plot(cf1,'r') 
plot(x_data,killed,'bx') 
plot(cf2,'g') 
 
legend('original data', 'gauss3','minus zero peak','gauss2')  
hold off 
 
cftool(x_data,y_data); 
end 
 
***********************path_fit.m********************************************* 
function path_fit (fname); 
%Fit vbFRET PATH files to low/high dwell time distributions & on/off rates 
workdir= 'F:\PIFE\130126.traces\'   ;  %use "\" at end! 
timeunit=0.015;  %CCD integration time 
std_threshold=3;  %outside of this STDEV range = outlier 
rounds_outlier_removal=2; %number of iterations of outlier removal  
n_bins_tao=100;  %specify the number of bins.   
exp_trunc=20;  %usually this is too many bins, so only use the first exp_trun to fit w/ 
exponential 
n_bins_k=15;  %this was 15 
 
cd(workdir); 
fid=([fname '.dat']); %need the beginning space? 
tao_filename=(['tao_' fname '.dat']); %name of savefile 
raw=load(fid); 
n=raw(end,1); %number of PIFE traces saved 
begin=raw(1,1); 
%total_frames=size(raw,1); 
 
total_transition_count=0; dumped=0;  
for i=begin:n;  %start looping through molecules  
  mol_index=find(raw(:,1)==i);   
  mol_dat=raw(mol_index,2);   %mol_dat is a 1-column vector of 2 states for every molecule 
   
  low_state=min(mol_dat);  %define low/high states 
  high_state=max(mol_dat); 
   
  %transition_count=0;  
  low_to_high_transition_count=0;high_to_low_transition_count=0; 
  low_run_length=1; high_run_length=1; %initialize 
   
  for j=1:size(mol_dat,1)-1;  %find contiguous states 
   
              if mol_dat(j) == mol_dat(j+1) && j < size(mol_dat,1)  %if the next one is the same 
                    if mol_dat(j)==low_state 
                       low_run_length=low_run_length+1; 
                    else 
                       high_run_length=high_run_length+1; 
                    end 
               elseif mol_dat(j) ~= mol_dat (j+1) && j < size(mol_dat,1) 
         %transition_count = transition_count+1;  
         total_transition_count=total_transition_count+1; 
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         if mol_dat(j)==low_state 
             low_to_high_transition_count=low_to_high_transition_count+1;              
             tao.low(low_to_high_transition_count,i)=timeunit*low_run_length; 
         end 
                 if low_to_high_transition_count == 0 
                   tao.low(1,i)=0;    %this was happening by default but not if the first or last 
only had 1 transition. 
                 end 
          
          
          
         if mol_dat(j)==high_state  
             high_to_low_transition_count= high_to_low_transition_count+1; 
             tao.high(high_to_low_transition_count,i)=timeunit*high_run_length; 
         end 
                   if high_to_low_transition_count == 0 
                      tao.high(1,i)=0;    %this was happening by default but not if the first or 
last only had 1 transition. 
                   end 
          
          
         %tao.high_cat(high_to_low_transiton_count,1)=timeunit*high_run_length;  %1 column vector 
of concatenated taos (because the structure was adding zeros and I didn't feel like picking them 
out of each column) 
         %tao.low_cat(low_to_high_transition_count,1)=timeunit*low_run_length;        
          
         low_run_length=1; high_run_length=1;             
               end 
                
  tao.transitions(i)=low_to_high_transition_count + high_to_low_transition_count;              
  end 
     
end 
tao.high_cat(:,1)=nonzeros(tao.high); 
tao.low_cat(:,1)=nonzeros(tao.low); 
     
%Remove traces w/out a transition    
zero_ind=find(tao.transitions==0); 
%if vbFRET only found one state, revise the number 
       tao.low(:,zero_ind)=[]; 
       tao.high(:,zero_ind)=[]; 
       tao.transitions(:,zero_ind)=[]; 
n2=n-size(zero_ind,2); 
 
 
for i=1:n2 
tao.frames_kon(1,i)=size(nonzeros(tao.low(:,i)),1);  
tao.frames_koff(1,i)=size(nonzeros(tao.high(:,i)),1); 
%tao_dwell (A or B) = total time in A or B)/(number of transitions) 
%i.e., tao=average of all state dwell times, rate k=1/tao 
 
%kon=1/tao_low 
%tao.kon(1,i)=1./(sum(nonzeros(tao.low(:,i)))./tao.transitions(1,i)); 
tao.kon(1,i)=1./(mean(nonzeros(tao.low(:,i))));   %average rate for each molecule, 1 per column 
%tao.kon_errors(2,i)=std(1./(nonzeros(tao.low(:,i)))); 
%tao.kon2(1,i)=mean(1./nonzeros(tao.low(:,i))) 
 
%koff=1/tao_high 
%tao.koff(1,i)=1./(sum(nonzeros(tao.high(:,i)))./tao.transitions(1,i)); 
tao.koff(1,i)=1./(mean(nonzeros(tao.high(:,i)))); %average rate for each molecule, 1 per column 
%tao.koff_errors(2,i)=std(1./(nonzeros(tao.high(:,i)))); 
%tao.koff2(1,i)=mean(1./nonzeros(tao.high(:,i)));   
 
%not utilized, just for comparison 
tao.kon_total=1./(sum(tao.low_cat)/total_transition_count);   
tao.koff_total=1./(sum(tao.high_cat)./total_transition_count); 
end     
 
tao.kon_mean=mean(tao.kon); 
tao.koff_mean=mean(tao.koff); 
tao.kon_mean_std=std(tao.kon); 
 111 
tao.koff_mean_std=std(tao.koff); 
 
tao.kon_ave=1./(mean(nonzeros(tao.low(:))));  %non-weighted average of ALL tao, 1/<tao> 
tao.koff_ave=1./(mean(nonzeros(tao.high(:)))); 
tao.koff_ave_std=std(nonzeros(tao.low(:))); 
tao.kon_ave_std=std(nonzeros(tao.high(:))); 
 
%now I have a distribution of all calculated rates, but a singular average of these 
%rates needs to be weighted by total observation time.  NOTE: STDEV's are 
% weighted using an ubiased estimator.   
%See en.wikipedia.org/wiki/Weighted_mean#Weighted_sample_variance 
%For the distributions I will plot all of them along with a distribution  
%after discarding the half of the data with the lowest observation time 
  total_frames_kon=sum(tao.frames_kon); total_frames_koff=sum(tao.frames_koff); 
  kon_weight= tao.frames_kon./total_frames_kon;  
  koff_weight= tao.frames_koff./total_frames_koff; 
   
  %weighted_kon(1,i)= tao.kon(1,i)*kon_weight(1,i); 
  %weighted_koff(1,i)=tao.koff(1,i)*koff_weight(1,i); 
  weighted_kon=tao.kon.*kon_weight; 
  weighted_koff=tao.koff.*koff_weight; 
   
  tao.kon_outliers=tao.kon; 
  tao.koff_outliers=tao.koff; 
  %weighted_kon(1,i)=tao.kon(1,i).* ( size(nonzeros(tao.low(:,i)),1) ./ size(tao.low_cat,1) ) ;     
  %weighted_koff(1,i)=tao.koff(1,i).* (size(nonzeros(tao.high(:,i)),1)./ size(tao.low_cat,1)  );  
 
 
tao.kon_weighted_mean=sum(weighted_kon); 
tao.koff_weighted_mean=sum(weighted_koff);  
 
%Weighted STD w/ unbiased estimator.  Use these ones. 
v2_on=sum(kon_weight.^2); v2_off=sum(kon_weight.^2); %used for unbiased estimate 
tao.kon_weighted_std_unbiased= (1./(1-v2_on)) .* (sqrt(sum(kon_weight.*((tao.kon - 
tao.kon_weighted_mean).^2)))); 
tao.koff_weighted_std_unbiased= (1./(1-v2_off)) .* (sqrt(sum(koff_weight.*((tao.koff - 
tao.koff_weighted_mean).^2)))); 
 
for i=1:rounds_outlier_removal; 
 
%Grubb's Z score 
Z_kon=abs(tao.kon_weighted_mean-tao.kon)./tao.kon_weighted_std_unbiased; 
Z_koff=abs(tao.koff_weighted_mean-tao.koff)./tao.koff_weighted_std_unbiased; 
 
outlier_index_kon=find(Z_kon>std_threshold); 
outlier_index_koff=find(Z_koff>std_threshold); 
outlier_index_master=unique([outlier_index_kon outlier_index_koff]); 
 
%Throw out the outliers, if any (~typically 1 or 2).   
tossed_koff=size(outlier_index_koff,2); tossed_kon=size(outlier_index_kon,2); 
tossed_total=size(outlier_index_master,2); 
 
tao.kon(:,outlier_index_master)=[]; tao.koff(:,outlier_index_master)=[]; 
tao.low(:,outlier_index_master)=[]; tao.high(:,outlier_index_master)=[]; 
tao.frames_kon(:,outlier_index_master)=[]; 
tao.frames_koff(:,outlier_index_master)=[]; 
 
disp(['Round ' num2str(i) ':']) 
disp(['Detected ' num2str(tossed_kon) ' kon  values outside of ' num2str(std_threshold) ' STDEVs 
(' num2str(tao.kon_weighted_std_unbiased,2) ')' char(10) 'Detected ' num2str(tossed_koff) ' koff 
values outside of ' num2str(std_threshold) ' STDEVs (' num2str(tao.koff_weighted_std_unbiased,2)  
')' char(10) 'Tossed ' num2str(tossed_total) ' traces total']); 
 
 
%Recalculate weighted mean/std 
 
    clear kon_weight koff_weight  
    %tao.kon_weighted_mean tao.koff_weighted_mean tao.kon_weighted_std tao.koff_weighted_std 
     
    total_frames_no_outliers_kon=sum(tao.frames_kon); 
    total_frames_no_outliers_koff=sum(tao.frames_koff); 
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    kon_weight= tao.frames_kon./total_frames_no_outliers_kon; 
    koff_weight=tao.frames_koff./total_frames_no_outliers_koff; 
     
    weighted_kon= tao.kon.*kon_weight; 
    weighted_koff=tao.koff.*koff_weight; 
     
    tao.kon_weighted_mean_post=sum(weighted_kon); 
    tao.koff_weighted_mean_post=sum(weighted_koff); 
     
    v2_on=sum(kon_weight.^2); v2_off=sum(kon_weight.^2); %used for unbiased estimate 
    tao.kon_weighted_std_unbiased_post= (1/(1-v2_on)) .* (sqrt(sum(kon_weight.*((tao.kon - 
tao.kon_weighted_mean_post).^2)))); 
    tao.koff_weighted_std_unbiased_post= (1/(1-v2_off)) .* (sqrt(sum(koff_weight.*((tao.koff - 
tao.koff_weighted_mean_post).^2)))); 
 
    tao.kon_mean_post=mean(tao.kon); 
    tao.koff_mean_post=mean(tao.koff); 
    tao.kon_mean_std_post=std(tao.kon); 
    tao.koff_mean_std_post=std(tao.koff); 
         
    tao.kon_ave_post=1./(mean(nonzeros(tao.low(:))));  %non-weighted average of tao, POST STD 
FILTERING 
    tao.koff_ave_post=1./(mean(nonzeros(tao.high(:)))); 
    tao.koff_ave_std_post=std(nonzeros(tao.low(:))); 
    tao.kon_ave_std_post=std(nonzeros(tao.high(:))); 
 
 
end 
%% frequency histograms 
% 
 
MSGID =  'MATLAB:MKDIR:DirectoryExists'; warning ('off',MSGID); 
mkdir tao; mkdir cdf; 
s_tao_low=size(tao.low_cat,1);  %total number of low states 
s_tao_high=size(tao.high_cat,1);%total number high states 
s_k=size(tao.kon,2);  %total number of molecules      
 
 
fname_tao=[workdir 'tao\' fname '_TAO.mat']; 
save (fname_tao,'-struct', 'tao'); 
 
close all; 
 
        %TAO_LOW 
        [freq,xout]=hist(tao.low_cat,n_bins_tao); 
        yout=freq./s_tao_low(1,1); %change to frequency 
        histdata=[xout' yout']; 
        xout_fit=xout(1:exp_trunc); 
        yout_fit=yout(1:exp_trunc); 
        options=fitoptions('exp1'); 
        set(options,'Robust','Off','MaxIter',5000); 
        [cf,gof]=fit(xout_fit',yout_fit','exp1',options);  
        x_curve=0:0.01:10; 
        fit_low=cf.a.*exp(x_curve'.*cf.b); 
        figure (1); 
        %plot(xout,yout); 
        bar(xout(1:50),yout(1:50),1,'w'); %plot normalized histogram 
        hold all; plot(x_curve,fit_low,'r','LineWidth',2); %plot exponential fit 
        xlim([0 4]); 
        ylim([0 1.1*max(yout)]); 
        %axes; 
        %set(axes_handle,'XLim',[0 2]) 
        xlabel ('tao (s)'); labn=['p ' '(n=' num2str(s_tao_low(1,1)) ')'] ; 
        ylabel (labn); 
        kon_pre_exp=cf.a; 
        kon_exp=abs(cf.b); 
        text(0.5,0.1, ['kon=' num2str(kon_exp)]); 
        titulo=['Low state dwell times: ' workdir '\' fname char(10) char(10) 'kon=' 
num2str(kon_exp) ', rsquare= ' num2str(gof.rsquare)]; title (titulo,'interpreter','none'); 
%suppress latex interpretation in title 
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        savefile=[workdir 'tao\' fname '_tao_low_hist.dat']; %save hist data as fname_hist.dat 
        save(savefile, 'histdata', '-ascii', '-tabs'); %tab delimited 
        assignin('base','low_hist',histdata); 
        clear freq xout yout cf histdata ; 
               
   %TAO_HIGH 
        [freq,xout]=hist(tao.high_cat,n_bins_tao); 
        yout=freq./s_tao_high(1,1); 
        histdata=[xout' yout']; 
        xout_fit=xout(1:exp_trunc); 
        yout_fit=yout(1:exp_trunc); 
        options=fitoptions('exp1'); 
        set(options,'Robust','Off','MaxIter',5000); 
        [cf,gof]=fit(xout_fit',yout_fit','exp1',options);  
        x_curve=0:0.01:10; 
        fit_high=cf.a.*exp(x_curve'.*cf.b);         
        figure (2); 
        bar(xout(1:50),yout(1:50),1,'w'); %plot normalized histogram 
        hold all; plot(x_curve,fit_high,'r','Linewidth',2); %plot exponential fit 
        xlim([0 4]);  
        ylim([0 1.1*max(yout)]) 
        xlabel ('tao (s)'); labn=['p ' '(n=' num2str(s_tao_high(1,1)) ')'] ; 
        ylabel (labn); 
        koff_pre_exp=cf.a; 
        koff_exp=abs(cf.b); 
        text(0.5,0.3, ['koff=' num2str(koff_exp)]); 
        titulo=['High state dwell times: ' workdir '\' fname char(10) char(10) 'koff=' 
num2str(koff_exp) ', rsquare= ' num2str(gof.rsquare)]; title (titulo,'interpreter','none'); 
%suppress latex interpretation in title 
        savefile=[workdir 'tao\' fname '_tao_high_hist.dat']; %save hist data as fname_hist.dat 
        save(savefile, 'histdata', '-ascii', '-tabs'); %tab delimited 
        assignin('base','high_hist',histdata); 
        clear freq xout yout cf histdata ; 
        assignin('base','koff_cat',tao.low_cat); 
         
        %KON 
        [freq,xout]=hist(tao.kon,n_bins_k); 
        histdata=[xout' (freq./s_k(1,1))']; 
        figure (3); 
        bar(xout,freq./s_k(1,1),1,'w'); %plot normalized histogram 
        hold on; bar(tao.kon_weighted_mean,max(freq./s_k),0.2,'k') 
        xlabel ('kon (s^-^1)'); labn=['p ' '(n=' num2str(s_k(1,1)) ')'] ; 
        ylabel (labn); 
        %text(1,(0.95*max(freq./s_k)),['Weighted mean= ' num2str(tao.kon_weighted_mean,3) ' +/- ' 
num2str(tao.kon_weighted_std_unbiased,3)])  
        titulo=['kon: ' workdir '\' fname char(10) char(10) 'Weighted mean= ' 
num2str(tao.kon_weighted_mean,3) ' +/- ' num2str(tao.kon_weighted_std_unbiased,3)]; title 
(titulo,'interpreter','none'); %suppress latex interpretation in title 
        figure(12); title ('kon'); 
        [a,a2]=ecdf(tao.kon); 
        cdf_data=[a2,a]; 
        stairs(a2,a);   
        savefile=[workdir 'tao\' fname '_kon_hist.dat']; %save hist data as fname_hist.dat 
        save(savefile, 'histdata', '-ascii', '-tabs'); %tab delimited 
        clear freq xout histdata   
        savefile=[workdir 'cdf\' fname '_kon_CDF.dat']; 
        save(savefile, 'cdf_data', '-ascii', '-tabs'); %tab delimited 
         
        %KOFF 
        [freq,xout]=hist(tao.koff,n_bins_k); 
        histdata=[xout' (freq./s_k(1,1))']; 
        figure (4); 
        bar(xout,freq./s_k(1,1),1,'w'); %plot normalized histogram 
        hold on; bar(tao.koff_weighted_mean,max(freq./s_k),0.2,'k')    
        xlabel ('koff (s^-^1)'); labn=['p ' '(n=' num2str(s_k(1,1)) ')'] ; 
        ylabel (labn); 
        %text(1,(0.95*max(freq./s_k)),['Weighted mean= ' num2str(tao.koff_weighted_mean,3) ' +/- 
' num2str(tao.koff_weighted_std_unbiased,3)])  
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        titulo=['koff: ' workdir '\' fname char(10) char (10) 'Weighted mean= ' 
num2str(tao.koff_weighted_mean,3) ' +/- ' num2str(tao.koff_weighted_std_unbiased,3)]; title 
(titulo,'interpreter','none'); %suppress latex interpretation in title 
        figure(11);title ('koff'); 
        [a,a2]=ecdf(tao.koff);  
        cdf_data=[a2 a]; 
        stairs(a2,a);         
        savefile=[workdir 'tao\' fname '_koff_hist.dat']; %save hist data as fname_hist.dat 
        save(savefile, 'histdata', '-ascii', '-tabs'); %tab delimited 
        savefile=[workdir 'cdf\' fname '_koff_CDF.dat']; 
        save(savefile, 'cdf_data', '-ascii', '-tabs'); %tab delimited 
         
        clear freq xout histdata  
         
         
        %TRANSITIONS HISTOGRAM 
        [freq,xout]=hist(tao.transitions,20); 
        histdata=[xout' (freq./s_k(1,1))']; 
        figure (3); 
        bar(xout,freq./s_k(1,1),1,'w'); %plot normalized histogram 
        hold on; bar(tao.kon_weighted_mean,max(freq./s_k),0.2,'k') 
        xlabel ('# transitions per molecule'); labn=['p ' '(n=' num2str(s_k(1,1)) ')'] ; 
        ylabel (labn); 
        %text(1,(0.95*max(freq./s_k)),['Weighted mean= ' num2str(tao.kon_weighted_mean,3) ' +/- ' 
num2str(tao.kon_weighted_std_unbiased,3)])  
        titulo=['Transitions: ' workdir '\' fname char(10) char(10) 'Mean= ' 
num2str(mean(tao.transitions),3) ' +/- ' num2str(std(tao.transitions),3)]; title 
(titulo,'interpreter','none'); %suppress latex interpretation in title 
                
        savefile=[workdir 'tao\' fname '_transitions_hist.dat']; %save hist data as 
fname_hist.dat 
        save(savefile, 'histdata', '-ascii', '-tabs'); %tab delimited 
        clear freq xout histdata  
        %savefile= [workdir 'tao\' fname '_koff_hist.dat']; 
 
%% Send a variable to the workspace 
%First row contains : 1)weighted k 2) k from exp fit 3) k from all dwell times and 4) non-
weighted average of all k's.  
 
kon=[tao.kon_mean tao.kon_mean_post tao.kon_weighted_mean , tao.kon_weighted_mean_post , 
tao.kon_ave , tao.kon_ave_post , kon_exp];  
kon(2,:)=[tao.kon_mean_std tao.kon_mean_std_post tao.kon_weighted_std_unbiased , 
tao.kon_weighted_std_unbiased_post , tao.kon_ave_std , tao.kon_ave_std_post , kon_pre_exp]; 
 
koff=[tao.koff_mean tao.koff_mean_post tao.koff_weighted_mean tao.koff_weighted_mean_post 
tao.koff_ave tao.koff_ave_post koff_exp];  
koff(2,:)=[tao.koff_mean_std tao.koff_mean_std_post tao.koff_weighted_std_unbiased 
tao.koff_weighted_std_unbiased_post tao.koff_ave_std tao.koff_ave_std_post koff_pre_exp]; 
 
assignin('base','kon',kon); 
assignin('base','koff',koff); 
 
 
*****************************tiffdir.m*********************************** 
function tiffdir (workdir) 
%% TiffDir 
Give it the directory name and it will mop up any and all spooled output from Solis.  
% Images are rotated, and if they're split into two (X1,X2), they are sewn together. 
% Assumes you spool to disk in Solis using "basename," which is incremented automatically e.g. 
 
% basename   ---> rot_basename_0 
% basename_1 ---> rot_basename_1 
% basename_2 ---> rot_basename_2    etc., and for long files: 
 
% longfile_basename 
% longfile_basename_X2   ------> rot_longfile_basename_0 
% longfile_basename_1 
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% longfile_basename_1_X2 ------> rot_longfile_basename_1   
% longfile_basename_2 
% longfile_basename_2_X2 ------> rot_longfile_basename_2  etc. 
 
% IMPORTANT NOTES:  
% 1) MAKE SURE to remove all index/ghost files (i.e. <1kb tif from spool). 
% 2) NEVER use an "X" when you name your files.   
% 3) DO NOT end a spool file name with a number or a symbol (or else you have to add "0" to the 
name of the first file after processing, useful for processing with redlaser_dir) 
% 4) tiffdir will crash if folder contains tiffs with different pixel dimensions (i.e. 512x512 
and 512x256)   
% 5) Program assumes it only goes to X2. This is the case for our system: spooling splits files 
% after ~4000 frames, and we have a rough 8000 frame limit since we can't address >4gb RAM  
% with the current LibTiff.  Future versions of Matlab will support BigTiff. 
%  
% Copyleft Grant Schauer 05/10 
auto_delete='y'; 
 
if nargin==0  %if you don't give it an argument, it will let you select it in a GUI  
  
workdir2=uigetdir('J:\Sean\10-8') 
workdir=[workdir2 '\']; 
end 
if workdir == 0  %if you write "redlaser 0" at the command line it will use these in/out 
directories: 
 workdir='I:\Grant\PIFE\120812\';  %add the '\' at the end 
 outdir= 'J:\Grant\PIFE\120812\'; 
 mkdir (outdir); 
else  
    outdir=workdir; 
end 
cd(workdir); 
list=ls(workdir);  %list of all files in directory including "." and ".." (always 1 and 2). 
no_files=size(list,1); %number of files, including "." and ".." 
x_ind=zeros(no_files,1); 
count=0; 
nframes_total=0;    
all_x=0;  
%% START WITH THE X1/X2 files 
disp(['Total number of files: ' num2str(no_files-2)]) 
total_time=tic; 
for i=1:no_files   %for every file, 
   
   current_file=list(i,:); 
   count=count+1; 
   hi= find(current_file=='X'); %find all thefiles with an "X" 
    if hi>0  
      x_ind(count,:) = find(current_file=='X'); %column vector, containing 0 if no X, and n if X 
where n= coulumn # of 'X' 
    end 
     
end 
count=0; 
filenum_x=find(x_ind); %rows that contain files w/ "X" 
   
for i=1:size(filenum_x,1);  %for all X files, find partner and concatentate 
       
            j=x_ind(filenum_x(i)); %the character position of the actual "X" 
       
      %Solis will name e.g. filename and filename_X2 
      current_x_file=list(filenum_x(i),:); 
       
      %Define the name of X1 based on the name of X2 (discovered by "X" in the filename) 
      x2_file=current_x_file;    
      x1_file=[x2_file(1:j-2),x2_file(j+2:end)];  %subtract the "_X2_" out of the name 
       
      all_x(i,1:size(x1_file,2))=x1_file(1,:);  %keep track of all X-files you found 
      all_x=char(all_x);  %final all_x is a list of all X1 files. 
 
x_time=tic;           
  for x = 1:2;  % Start processing X1/X2 files 
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        if x==2  
          tifname=x2_file; 
        else 
          tifname=x1_file; 
        end 
     
       if isletter(current_x_file(j-2))==0 %if the X1 file is numbered, keep it as is     
          outfile=[outdir 'rot_', x1_file]; 
       else    
          outfile =[outdir 'rot_' current_x_file(1:j-2),'_0', current_x_file(j+2:end)]; %if not, 
add a 0 
       end 
    info=imfinfo(tifname); 
    nFrames=(numel(info)); % grab number of frames  
 
                if x==1 
                    disp([num2str(nFrames) ' frames in X1: ' tifname ])  
                else 
                    disp([num2str(nFrames) ' frames in X2: ' tifname ]) 
                end 
     
        for frame=1:nFrames   
           %unfortunately A cannot be pre-allocated.          
           A(:,:) = flipud(rot90(imread(tifname, frame, 'Info',info),3)); 
           if frame==1 && x==1; 
             imwrite(A,outfile, 'tif', 'Compression','none') 
           else 
             imwrite(A,outfile, 'tif', 'Compression','none','WriteMode','append'); 
           end 
         
        end 
    
  nframes_total=nframes_total+nFrames; 
 
  end 
     
  disp([num2str(nframes_total),'-frame rotated/appended file written to ' outfile ]) 
  nframes_total=0; 
   t(1)=toc(x_time); 
   disp(['Time elapsed= ' num2str(t) ' seconds.']) 
  disp(' ') 
 
clear A;   
end 
     
%% Now do the rest of them. 
%If you tallied any X's, that row position in variable 'check' will be 0. 
 
check=ones(no_files,1);  %indexes all X's as 0's. 
 
check(find(x_ind),1)=0; %X2=0 
 
if all_x > 0  % has to be here or else strtrim below complains 
 for i = 1:no_files;    
  for j = 1:size(all_x,1); 
      length=size(all_x(j),2); 
     
      if isequal(strtrim(list(i,:)),strtrim(all_x(j,:)))==1; 
        check(i)=0;  %X1=0 
      end 
  end 
 end 
end 
     
filenum_nonx = find(check==1);  %vector of all row #'s without an X (or an implicit X1). 
 
for i=3:size(filenum_nonx,1);  %start at 3 to avoid (./..) 
nox_time=tic; 
tifname=list(filenum_nonx(i),:); 
dot_location=find(tifname=='.'); 
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           if isletter(tifname(dot_location-1))==0      
              outfile=[outdir 'rot_', tifname]; 
           end 
 
           if isletter(tifname(dot_location-1))==1 
              outfile =[outdir 'rot_' tifname(1:dot_location-1),'_0.tif'];  
           end 
 
  if strcmp('rot',tifname(1,1:3))==0  %don't process rot files (if you run this more than once). 
 
    info=imfinfo(tifname); 
    nFrames=numel(info); % grab number of frames  
    disp([num2str(nFrames) ' frames in ' tifname]);  
 
    %read each frame, rotate clockwise and upside-down, write to rot_file  
       for frame=1:nFrames 
            A(:,:) = flipud(rot90(imread(tifname, frame, 'Info',info),3)); 
            if frame==1; 
               imwrite(A,outfile,'tif','Compression','none') 
            else 
               imwrite(A,outfile,'tif','Compression','none','WriteMode','append'); 
            end 
 
       end 
       disp([num2str(nFrames) '-frame rotated file written to ' outfile ]) 
       t(1)=toc(nox_time); 
       disp(['Time elapsed= ' num2str(t) ' seconds.  ' num2str(size(filenum_nonx,1)-i) ' files 
and ~' num2str((size(filenum_nonx,1)-i)*t/3600) ' hours left']) 
       disp(' ');     
   % delete(tifname); 
 
  else 
  end 
 
end 
t=toc(total_time); 
disp(['Processed ' num2str(no_files-2) ' files in ' num2str(t./60) ' minutes']); 
disp(' '); 
clear A; 
%% delete files part 
beep2(990,0.8) 
 
if auto_delete~='y'; 
    disp('Would you like to delete all of the original files?'); 
    reply=input('(y)es or (n)o? ','s'); 
    if isempty(reply) 
        ans = 'n'; 
    end 
    switch lower(reply) 
    case {'y','yes','sure','ok','fine','why not?'} 
        for i = 3:no_files 
            if strcmp('rot',strtrim(list(i,1:3)))==0  %don't delete rot files if run twice.       
              delete(strtrim(list(i,:))) 
            else 
             continue 
            end 
        end    
    otherwise 
    end 
     
elseif auto_delete=='y' 
     for i = 3:no_files 
            if strcmp('rot',strtrim(list(i,1:3)))==0  %don't delete rot files if run twice.       
              delete(strtrim(list(i,:))) 
            else 
             continue 
            end 
     end    
end 
 
end    
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APPENDIX B 
CYANINE PARAMETERS 
Cy3 and Cy5 CHARMM Topology files (can be streamed with CHARMM top file) 
 
RESI CY5         +1.000 ! 
!!Will not use sulfonate groups 
!GROUP            ! SULFONATE B 
!ATOM SB     SG3O1   1.350 !    0.620 
!ATOM OSB1   OG2P1  -0.651 !    0.000 
!ATOM OSB2   OG2P1  -0.651 !    0.000 
!ATOM OSB3   OG2P1  -0.651 !    0.000 
!GROUP            ! SULFONATE A 
!ATOM SA     SG3O1   1.350 !    0.620 
!ATOM OSA4   OG2P1  -0.651 !    0.000 
!ATOM OSA5   OG2P1  -0.651 !    0.000 
!ATOM OSA6   OG2P1  -0.651 !    0.000 
 
 
GROUP !from residue 3HIN, with charge adjustments from BSAT.   
!(3H-indole with adjustments for benzenesulfonate, rather than explicitly using sulfonate).  
ATOM N1A   NG2R52  -0.11 ! +0.50 added to this charge, atom type changed 
ATOM C2A   CG2R52   0.29 
ATOM C3A   CG3C50   0.09 !              H5 
ATOM C4A   CG2RC0   0.25 !     \       / \\ 
ATOM C5A   CG2R61  -0.36 ! H32--C3---C4   C6--H6 
ATOM H5A   HGR61    0.20 !      |    ||    | 
ATOM C6A   CG2R61  -0.22 !      C2   C9   C7--H7 
ATOM H6A   HGR61    0.21 
ATOM C7A   CG2R61  -0.21 !   H2   N1    C8 
ATOM H7A   HGR61    0.21 !              | 
ATOM C8A   CG2R61  -0.34 !              H8   
ATOM H8A   HGR61    0.26 
ATOM C9A   CG2RC0   0.23 
 
GROUP !common methyl group from other compounds 
ATOM CM1A   CG331   -0.27 ! 
ATOM HM1A  HGA3     0.09 ! 
ATOM HM2A  HGA3     0.09 ! 
ATOM HM3A  HGA3     0.09 ! 
GROUP  
ATOM CM2A   CG331   -0.27 ! 
ATOM HM4A  HGA3     0.09 ! 
ATOM HM5A  HGA3     0.09 ! 
ATOM HM6A  HGA3     0.09 ! 
 
GROUP  
ATOM CM3B   CG331   -0.27 ! 
ATOM HM7B  HGA3     0.09 ! 
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ATOM HM8B  HGA3     0.09 ! 
ATOM HM9B  HGA3     0.09 ! 
 
GROUP !this is the linker chain between the two rings, from 1,3,5-hexatriene, HEP3 
ATOM CX1   CG2DC2 -0.15 !          /    \    / 
ATOM HX1  HGA4    0.15 !        H31     C5=C6 
GROUP 
ATOM CX2   CG2DC2 -0.15 !               /    \ 
ATOM HX2  HGA4    0.15 !             H51     H62 
GROUP 
ATOM CX3   CG2DC2 -0.15 !               /    \ 
ATOM HX3  HGA4    0.15 !             H51     H62 
GROUP 
ATOM CX1A   CG2DC2 -0.15 
ATOM HX1A   HGA4    0.15 
GROUP 
ATOM CX1B   CG2DC2 -0.15 
ATOM HX1B   HGA4    0.15 
 
GROUP !AROMATIC system B from residue 3HIN, with charge adjustments from BSAT 
ATOM N1B   NG2R52  -0.11 ! +0.50 added to this charge, atom type changed 
ATOM C2B   CG2R52   0.29 
ATOM C3B   CG3C50   0.09 !              H5 
ATOM C4B   CG2RC0   0.25 !     \       / \\ 
ATOM C5B   CG2R61  -0.36 ! H32--C3---C4   C6--H6 
ATOM H5B   HGR61    0.20 !      |    ||    | 
ATOM C6B   CG2R61  -0.22 !      C2   C9   C7--H7 
ATOM H6B   HGR61    0.21 
ATOM C7B   CG2R61  -0.21 !   H2   N1    C8 
ATOM H7B   HGR61    0.21 !              | 
ATOM C8B   CG2R61  -0.34 !              H8   
ATOM H8B   HGR61    0.26 
ATOM C9B   CG2RC0   0.23 
GROUP 
ATOM CM1B   CG331   -0.27 ! 
ATOM HM1B  HGA3     0.09 ! 
ATOM HM2B  HGA3     0.09 ! 
ATOM HM3B  HGA3     0.09 ! 
GROUP 
ATOM CM2B   CG331   -0.27 ! 
ATOM HM4B  HGA3     0.09 !scrab 
ATOM HM5B  HGA3     0.09 ! 
ATOM HM6B  HGA3     0.09 ! 
 
 
!GROUP !modified from spiriti. this is the linker chain to DNA, from n-propanol 
 
GROUP !(the only unmodified group from Spiriti)  
ATOM CL3B  CG324    -0.18  !this atom type changed b/c next to partially + nitrogen 
ATOM H31B  HGA2      0.09 
ATOM H32B  HGA2      0.09 
 
 
!!!!!!!!!!!!!!!!!!!!! 
!MALEIMIDE LINKER 
 
GROUP !this is the linker chain to DNA, from n-propanol 
!ATOM OL1A  OG311    -0.65  !spiriti 
!ATOM HO1A  HGP1      0.42  !spiriti 
ATOM CL1A CG321 -0.18 
!ATOM CL1A  CG321     0.05  
ATOM H11A  HGA2      0.09 
ATOM H12A  HGA2      0.09   
 
GROUP 
ATOM CL2A  CG321    -0.18  
ATOM H21A  HGA2      0.09  
ATOM H22A  HGA2      0.09 
 
GROUP 
ATOM CL3A   CG324    -0.18  !this atom type changed b/c next to partially + nitrogen 
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ATOM H31A  HGA2      0.09 
ATOM H32A  HGA2      0.09 
 
***new additions below**      PENALTY 
 
GROUP 
ATOM CL4    CG321  -0.18 !    0.228 
ATOM H1     HGA2    0.090 !    0.000 
ATOM H2     HGA2    0.090 !    0.000 
 
GROUP 
ATOM CL5    CG321  -0.18 !    0.427 
ATOM H3     HGA2    0.090 !    0.000 
ATOM H4     HGA2    0.090 !    0.000 
 
GROUP !From Correy C37/041/N40/HAF 
ATOM CL6    CG2O1   0.73 !    1.616 
ATOM O3     OG2D1  -0.49 !    0.000 
ATOM NL1    NG2S1  -0.58 !    3.147 
ATOM H5     HGP1    0.34 !    0.563 
 
             
GROUP 
ATOM CL7    CG321  -0.18 !   11.279 
ATOM H6     HGA2    0.090 !    0.850 
ATOM H7     HGA2    0.090 !    0.850 
 
GROUP 
ATOM CL8    CG321  -0.18 !   15.198                              O1 
ATOM H8     HGA2    0.090 !    0.835 
ATOM H9     HGA2    0.090 !    0.835 
 
 
GROUP !maleimide group from Correy et al 
ATOM NL2    NG2R51 -0.20 !                                 | 
ATOM CL9    CG2R53  0.58 !       H1  H3  O3      H6  H8    CL12 
ATOM CL12   CG2R53  0.58 !       |   |   |       |   |    /    \ 
ATOM CL11   CG2R51 -0.18 !       CL4-CL5-CL6-NL1-CL7-CL8-NL2    CL11-H10 
ATOM CL10   CG2R51 -0.18 !       |   |       |   |   |    \     / 
ATOM O1     OG2D1  -0.48 !      H2  H4      H5  H7  H9    CL9-CL10-H11 
ATOM O2     OG2D1  -0.48 !                                 | 
ATOM H10    HGR51   0.18 !    
ATOM H11    HGR51   0.18 !                                O2 
 
 
!BOND SB   OSB1 
!BOND SB   OSB2 
!BOND SB   OSB3 
!BOND SB   C6B  
!BOND SA   OSA4 
!BOND SA   OSA5 
!BOND SA   OSA6 
!BOND SA   C6A  
!^NO sulfonate 
 
!BOND CX2  CX1  
BOND HX3  CX3  
BOND HX2  CX2  
BOND HX1  CX1  
BOND HX1A CX1A 
BOND HX1B CX1B 
 
BOND CX1 CX1A 
BOND CX1A CX1B 
BOND CX1B CX2 
 
 
BOND N1B  C9B  
BOND N1B  CL3B 
BOND CX3  CX2  
BOND C9B  C8B  
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BOND C4B  C9B  
BOND C4B  C5B  
BOND C8B  H8B  
BOND C8B  C7B  
BOND C7B  H7B  
BOND C6B  H6B 
BOND C6B  C7B  
BOND C5B  C6B  
BOND C5B  H5B  
BOND C3B  C4B  
BOND C3B  CM1B 
BOND C3B  CM2B 
BOND CM1B HM4B 
BOND CM1B HM5B 
BOND CM1B HM6B 
BOND CM2B HM1B 
BOND CM2B HM2B 
BOND CM2B HM3B 
BOND C2B  N1B  
BOND C2B  CX3  
BOND C2B  C3B  
BOND CL3B H31B 
BOND CL3B H32B 
BOND CL3B CM3B 
BOND CM3B HM7B 
BOND CM3B HM8B 
BOND CM3B HM9B 
BOND N1A  C9A  
BOND N1A  CL3A 
BOND CX1  C2A  
BOND C9A  C4A  
BOND C9A  C8A  
BOND C4A  C5A  
BOND C8A  H8A  
BOND C8A  C7A  
BOND C7A  H7A  
BOND C7A  C6A  
BOND C5A  C6A 
BOND C6A  H6A  
BOND C5A  H5A  
BOND C3A  C4A  
BOND C3A  CM2A 
BOND C3A  CM1A 
BOND CM2A HM4A 
BOND CM2A HM5A 
BOND CM2A HM6A 
BOND CM1A HM1A 
BOND CM1A HM2A 
BOND CM1A HM3A 
BOND C2A  N1A  
BOND C2A  C3A  
BOND CL3A CL2A 
BOND CL2A CL1A 
BOND CL1A CL4  
BOND CL4  CL5  
BOND CL5  CL6  
BOND CL6  NL1  
BOND CL6  O3   
BOND NL1  CL7  
BOND CL7  CL8  
BOND CL8  NL2  
BOND NL2  CL9  
BOND NL2  CL12 
BOND CL9  CL10 
BOND CL9  O2   
BOND CL12 CL11 
BOND CL12 O1   
BOND CL11 H10  
BOND CL10 CL11 
BOND CL10 H11  
BOND H31A CL3A 
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BOND H32A CL3A 
BOND H21A CL2A 
BOND H22A CL2A 
BOND H11A CL1A 
BOND H12A CL1A 
BOND H1   CL4  
BOND H2   CL4  
BOND H3   CL5  
BOND H4   CL5  
BOND H5   NL1  
!BOND H6 NL1 
BOND H6   CL7  
BOND H7   CL7  
BOND H8   CL8  
BOND H9   CL8  
 
 
 
IMPR CL6    CL5    NL1    O3   !used to maintain planarity    
IMPR CL9    CL10   NL2    O2   ! used to maintain planarity  
IMPR CL12   CL11   NL2    O1    !used to maintain planarity;  
 
RESI CY3         +1.000 ! 
!!Will not use sulfonate groups 
!GROUP            ! SULFONATE B 
!ATOM SB     SG3O1   1.350 !    0.620 
!ATOM OSB1   OG2P1  -0.651 !    0.000 
!ATOM OSB2   OG2P1  -0.651 !    0.000 
!ATOM OSB3   OG2P1  -0.651 !    0.000 
!GROUP            ! SULFONATE A 
!ATOM SA     SG3O1   1.350 !    0.620 
!ATOM OSA4   OG2P1  -0.651 !    0.000 
!ATOM OSA5   OG2P1  -0.651 !    0.000 
!ATOM OSA6   OG2P1  -0.651 !    0.000 
 
 
GROUP !from residue 3HIN, with charge adjustments from BSAT.   
!(3H-indole with adjustments for benzenesulfonate, rather than explicitly using sulfonate).  
ATOM N1A   NG2R52  -0.11 ! +0.50 added to this charge, atom type changed 
ATOM C2A   CG2R52   0.29 
ATOM C3A   CG3C50   0.09 !              H5 
ATOM C4A   CG2RC0   0.25 !     \       / \\ 
ATOM C5A   CG2R61  -0.36 ! H32--C3---C4   C6--H6 
ATOM H5A   HGR61    0.20 !      |    ||    | 
ATOM C6A   CG2R61  -0.22 !      C2   C9   C7--H7 
ATOM H6A   HGR61    0.21 
ATOM C7A   CG2R61  -0.21 !   H2   N1    C8 
ATOM H7A   HGR61    0.21 !              | 
ATOM C8A   CG2R61  -0.34 !              H8   
ATOM H8A   HGR61    0.26 
ATOM C9A   CG2RC0   0.23 
 
GROUP !common methyl group from other compounds 
ATOM CM1A   CG331   -0.27 ! 
ATOM HM1A  HGA3     0.09 ! 
ATOM HM2A  HGA3     0.09 ! 
ATOM HM3A  HGA3     0.09 ! 
GROUP  
ATOM CM2A   CG331   -0.27 ! 
ATOM HM4A  HGA3     0.09 ! 
ATOM HM5A  HGA3     0.09 ! 
ATOM HM6A  HGA3     0.09 ! 
 
GROUP  
ATOM CM3B   CG331   -0.27 ! 
ATOM HM7B  HGA3     0.09 ! 
ATOM HM8B  HGA3     0.09 ! 
ATOM HM9B  HGA3     0.09 ! 
 
GROUP !this is the linker chain between the two rings, from 1,3,5-hexatriene, HEP3 
ATOM CX1   CG2DC2 -0.15 !          /    \    / 
 123 
ATOM HX1  HGA4    0.15 !        H31     C5=C6 
GROUP 
ATOM CX2   CG2DC2 -0.15 !               /    \ 
ATOM HX2  HGA4    0.15 !             H51     H62 
GROUP 
ATOM CX3   CG2DC2 -0.15 !               /    \ 
ATOM HX3  HGA4    0.15 !             H51     H62 
 
 
GROUP !AROMATIC system B from residue 3HIN, with charge adjustments from BSAT 
ATOM N1B   NG2R52  -0.11 ! +0.50 added to this charge, atom type changed 
ATOM C2B   CG2R52   0.29 
ATOM C3B   CG3C50   0.09 !              H5 
ATOM C4B   CG2RC0   0.25 !     \       / \\ 
ATOM C5B   CG2R61  -0.36 ! H32--C3---C4   C6--H6 
ATOM H5B   HGR61    0.20 !      |    ||    | 
ATOM C6B   CG2R61  -0.22 !      C2   C9   C7--H7 
ATOM H6B   HGR61    0.21 
ATOM C7B   CG2R61  -0.21 !   H2   N1    C8 
ATOM H7B   HGR61    0.21 !              | 
ATOM C8B   CG2R61  -0.34 !              H8   
ATOM H8B   HGR61    0.26 
ATOM C9B   CG2RC0   0.23 
GROUP 
ATOM CM1B   CG331   -0.27 ! 
ATOM HM1B  HGA3     0.09 ! 
ATOM HM2B  HGA3     0.09 ! 
ATOM HM3B  HGA3     0.09 ! 
GROUP 
ATOM CM2B   CG331   -0.27 ! 
ATOM HM4B  HGA3     0.09 !scrab 
ATOM HM5B  HGA3     0.09 ! 
ATOM HM6B  HGA3     0.09 ! 
 
 
!GROUP !modified from spiriti. this is the linker chain to DNA, from n-propanol 
 
GROUP !(the only unmodified group from Spiriti)  
ATOM CL3B  CG324    -0.18  !this atom type changed b/c next to partially + nitrogen 
ATOM H31B  HGA2      0.09 
ATOM H32B  HGA2      0.09 
 
 
!!!!!!!!!!!!!!!!!!!!! 
!MALEIMIDE LINKER 
 
GROUP !this is the linker chain to DNA, from n-propanol 
!ATOM OL1A  OG311    -0.65  !spiriti 
!ATOM HO1A  HGP1      0.42  !spiriti 
ATOM CL1A CG321 -0.18 
!ATOM CL1A  CG321     0.05  
ATOM H11A  HGA2      0.09 
ATOM H12A  HGA2      0.09   
 
GROUP 
ATOM CL2A  CG321    -0.18  
ATOM H21A  HGA2      0.09  
ATOM H22A  HGA2      0.09 
 
GROUP 
ATOM CL3A   CG324    -0.18  !this atom type changed b/c next to partially + nitrogen 
ATOM H31A  HGA2      0.09 
ATOM H32A  HGA2      0.09 
 
***new additions below**      PENALTY 
 
GROUP 
ATOM CL4    CG321  -0.18 !    0.228 
ATOM H1     HGA2    0.090 !    0.000 
ATOM H2     HGA2    0.090 !    0.000 
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GROUP 
ATOM CL5    CG321  -0.18 !    0.427 
ATOM H3     HGA2    0.090 !    0.000 
ATOM H4     HGA2    0.090 !    0.000 
 
GROUP !From Correy C37/041/N40/HAF 
ATOM CL6    CG2O1   0.73 !    1.616 
ATOM O3     OG2D1  -0.49 !    0.000 
ATOM NL1    NG2S1  -0.58 !    3.147 
ATOM H5     HGP1    0.34 !    0.563 
 
             
GROUP 
ATOM CL7    CG321  -0.18 !   11.279 
ATOM H6     HGA2    0.090 !    0.850 
ATOM H7     HGA2    0.090 !    0.850 
 
GROUP 
ATOM CL8    CG321  -0.18 !   15.198                              O1 
ATOM H8     HGA2    0.090 !    0.835 
ATOM H9     HGA2    0.090 !    0.835 
 
 
GROUP !maleimide group from Correy et al 
ATOM NL2    NG2R51 -0.20 !                                 | 
ATOM CL9    CG2R53  0.58 !       H1  H3  O3      H6  H8    CL12 
ATOM CL12   CG2R53  0.58 !       |   |   |       |   |    /    \ 
ATOM CL11   CG2R51 -0.18 !       CL4-CL5-CL6-NL1-CL7-CL8-NL2    CL11-H10 
ATOM CL10   CG2R51 -0.18 !       |   |       |   |   |    \     / 
ATOM O1     OG2D1  -0.48 !      H2  H4      H5  H7  H9    CL9-CL10-H11 
ATOM O2     OG2D1  -0.48 !                                 | 
ATOM H10    HGR51   0.18 !    
ATOM H11    HGR51   0.18 !                                O2 
 
 
!BOND SB   OSB1 
!BOND SB   OSB2 
!BOND SB   OSB3 
!BOND SB   C6B  
!BOND SA   OSA4 
!BOND SA   OSA5 
!BOND SA   OSA6 
!BOND SA   C6A  
!^NO sulfonate 
 
BOND CX2  CX1  
BOND N1B  C9B  
BOND N1B  CL3B 
BOND CX3  CX2  
BOND C9B  C8B  
BOND C4B  C9B  
BOND C4B  C5B  
BOND C8B  H8B  
BOND C8B  C7B  
BOND C7B  H7B  
BOND C6B  H6B 
BOND C6B  C7B  
BOND C5B  C6B  
BOND C5B  H5B  
BOND C3B  C4B  
BOND C3B  CM1B 
BOND C3B  CM2B 
BOND CM1B HM4B 
BOND CM1B HM5B 
BOND CM1B HM6B 
BOND CM2B HM1B 
BOND CM2B HM2B 
BOND CM2B HM3B 
BOND C2B  N1B  
BOND C2B  CX3  
BOND C2B  C3B  
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BOND CL3B H31B 
BOND CL3B H32B 
BOND CL3B CM3B 
BOND CM3B HM7B 
BOND CM3B HM8B 
BOND CM3B HM9B 
BOND N1A  C9A  
BOND N1A  CL3A 
BOND CX1  C2A  
BOND C9A  C4A  
BOND C9A  C8A  
BOND C4A  C5A  
BOND C8A  H8A  
BOND C8A  C7A  
BOND C7A  H7A  
BOND C7A  C6A  
BOND C5A  C6A 
BOND C6A  H6A  
BOND C5A  H5A  
BOND C3A  C4A  
BOND C3A  CM2A 
BOND C3A  CM1A 
BOND CM2A HM4A 
BOND CM2A HM5A 
BOND CM2A HM6A 
BOND CM1A HM1A 
BOND CM1A HM2A 
BOND CM1A HM3A 
BOND C2A  N1A  
BOND C2A  C3A  
BOND CL3A CL2A 
BOND CL2A CL1A 
BOND CL1A CL4  
BOND CL4  CL5  
BOND CL5  CL6  
BOND CL6  NL1  
BOND CL6  O3   
BOND NL1  CL7  
BOND CL7  CL8  
BOND CL8  NL2  
BOND NL2  CL9  
BOND NL2  CL12 
BOND CL9  CL10 
BOND CL9  O2   
BOND CL12 CL11 
BOND CL12 O1   
BOND CL11 H10  
BOND CL10 CL11 
BOND CL10 H11  
BOND H31A CL3A 
BOND H32A CL3A 
BOND H21A CL2A 
BOND H22A CL2A 
BOND H11A CL1A 
BOND H12A CL1A 
BOND H1   CL4  
BOND H2   CL4  
BOND H3   CL5  
BOND H4   CL5  
BOND H5   NL1  
!BOND H6 NL1 
BOND H6   CL7  
BOND H7   CL7  
BOND H8   CL8  
BOND H9   CL8  
BOND HX3  CX3  
BOND HX2  CX2  
BOND HX1  CX1  
IMPR CL6    CL5    NL1    O3   !used to maintain planarity    
IMPR CL9    CL10   NL2    O2   ! used to maintain planarity  
IMPR CL12   CL11   NL2    O1    
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* CY3/CY5 parameters.   
* Generated by G.Schauer from CGENFF/paramchem/iqbal/spiriti(!)/correy(!) 
* 
BONDS  !All were checked 3/22/11 
CG2R51 CG2R53  360.00     1.4000 ! CY3_MAL_ , from CG2R51 CG2R52, penalty= 5  !CL9/Cl12 
CG321  NG2R51  400.00     1.4580 ! CY3_MAL_ , from CG331 NG2R51, penalty= 6  !NL2-CL8 
!^can't find CT2-NH2 in correy (?) 
CG324  NG2R52  300.00     1.4330 ! RETINOL SCH2, Schiff's base, protonated #eq# !equilibrium dist 
redcuced to agree better with iqbal 
CG331  CG3C50  222.50     1.5280 ! TF2M, viv, methylcyclopentane 
CG2RC0 CG3C50  305.00     1.5200 ! 3HIN, 3H-indole 
CG2R52 CG3C50  350.00     1.5050 ! 2PRZ, 2-pyrazoline 
CG2RC0 NG2R52  310.00     1.3650 ! NA G, adm jr. 11/97 
CG2R52 CG2DC2  450.00     1.3000 ! mode 13, RETINOL 13DB, Butadiene @@@@@ Kenno: 1.47 --> 1.45 
@@@@@ 
 
!**NEW bonds*** !bonds from NL1/NL2 (NG2S1/NG2R51) are missing b/c of improper/planar designation 
CG321  NG2R52  263.00     1.4740 ! CY3_MAL_ , from CG321 NG311, penalty= 20 
!CG321  NG3C51  263.00     1.4740 ! CY3_MAL_ , from CG321 NG311, penalty= 20 
 
CG2R52 NG2R52  420.00     1.3550 ! CY3_MAL_ , from CG2R52 NG311, penalty= 20 
!CG2R52 NG3C51  420.00     1.3550 ! CY3_MAL_ , from CG2R52 NG311, penalty= 20 
 
!from PRES SAX 
SM   CS    205.000     1.740  
 
!CS CG2R53  360.00     1.4000 ! CY3_MAL_ , from CG2R51 CG2R52, penalty= 5  !CL9/Cl12 
CG2R53   CS    305.000     1.52 
!CC CS 
 
CG2R51   CS    305.000     1.33 
!CA CS 
ANGLES 
CG2DC2 CG2R52 CG3C50   10.00     123.50 !25.30    123.50 ! RETINOL MECH !vib calc, mode 9. from 
spriti.  paramchem says 60, 122 
 
CG2R52 NG2R52 CG2RC0   60.00    107.20 ! copied from 3HIN, 3H-indole !equilibrium angle changed 
to agree better with iqbal 
!^CG2R52 NG2R52 CG2RC0  145.00    108.00 ! CY3_MAL_ , from CG2R51 NG2R52 CG2R53, penalty= 2 
!^^ iqbal's angle is 120.54 
 
CG2R52 CG3C50 CG2RC0  105.00    105.00 ! 3HIN, 3H-indole, mode 13  
CG2RC0 CG2RC0 CG3C50  143.00    110.00 ! 3HIN, 3H-indole, mode 13  
CG2R61 CG2RC0 CG3C50   60.00    130.00 ! 3HIN, 3H-indole 
 
CG3C50 CG2R52 NG2R52  170.00    112.00 !copied from 2PRZ, 2-pyrazoline; 3HPR, 3H-pyrrole N2-C3-C4 
!^CG3C50 CG2R52 NG2R52   45.80    122.00 ! CY3_MAL_ , from CG321 CG2R51 NG2R52, penalty= 10 
 
CG2RC0 NG2R52 CG324    62.30    112.30 ! PROT 107.5->120.0 to make planar Arg (KK) !modified 
equilibrium 
!^iqbal ~120 
 
CG2R52 NG2R52 CG324    62.30    140.50 ! PROT 107.5->120.0 to make planar Arg (KK) !modified 
equilibrium 
!^CG2R52 NG2R52 CG324   101.00    111.90 ! CY3_MAL_ , from CG2R52 NG2R52 CG3C54, penalty= 1.2 
!^iqbal ~120 
 
CG2R61 CG2RC0 NG2R52  130.00    120.5 ! modified to match iqbal 
!^spiriti CG2R61 CG2RC0 NG2R52  130.00    130.00 ! copied from ZIMI, benzimidazole 
 
CG3C50 CG331 HGA3     33.43    110.10   22.53   2.17900 ! RETINOL TMCH/MECH 
CG2DC2 CG2DC2 CG2DC2   17.30    123.00 ! RETINOL 13DP, Pentadiene @@@@@ Kenno: 123.5-->123.0 
@@@@@ ! vib calc, mode 3 
CG2DC2 CG2DC2 CG2R52   40.00    123.00 ! RETINOL 13DP, Pentadiene @@@@@ Kenno: 123.5-->123.0 
@@@@@ ! vib calc, mode 3 
 
CG2DC2 CG2R52 NG2R52   10.00    125.60 !12.40    125.60 ! RETINOL SCH3, Schiff's base, protonated 
!vib calc, mode 9 
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!^iqbal says 129.04 
 
CG2R52 CG3C50 CG331    32.00    112.20 ! RETINOL MECH 
CG2RC0 CG3C50 CG331    32.00    112.20 ! RETINOL MECH 
!^CG2RC0 CG3C50 CG331    65.00    108.20 ! CY3_MAL_ , from CG2RC0 CG3C52 CG3C52, penalty= 16 
 
!CG331 CG3C52 CG331    58.35    113.50   11.16   2.561 ! RETINOL TMCH/MECH, also neopentane 
CG331  CG3C50 CG331    58.35    113.50   11.16   2.561 ! RETINOL TMCH/MECH, also neopentane 
 
CG2RC0 CG2RC0 NG2R52  100.00    105.70 ! CY3_MAL_ , from CG2RC0 CG2RC0 NG2R51, penalty= 25 
!^spiriti says CG2RC0 CG2RC0 NG2R52  100.00    110.00 ! NA Ade 5R) bridgeC5... but above matches 
iqubal angle 
 
NG2R52 CG321  HGA2     33.43    110.10 ! NA FOR 9-M-G(C), adm jr. 
 
NG2R52 CG324  HGA2     42.00    110.10 ! CY3_MAL_ , from NG2P1 CG324 HGA2, penalty= 2 
!spiriti NG2R52 CG324  HGA2     33.43    110.10 ! NA FOR 9-M-G(C), adm jr. 
 
CG2R52 CG2DC2 HGA4     25.50    119.00 ! RETINOL BTE2, 2-butene !vib calc 
 
CG321  CG324  NG2R52   70.00    113.70 ! NA 9-E-G, adm jr. !this angle must be above 110.0 or 
causes severe problems 
 
!unused spiriti CG321  CG324  NG2R52   70.00    113.70 ! NA 9-E-G, adm jr. !this angle must be 
above 110.0 or causes severe problems 
!unused spiriti NG2R52 CG331  HGA3     33.43    110.10 ! NA FOR 9-M-G(C), adm jr. 
****new angles***** 
CG2DC2 CG2R52 NG2R52   10.00    125.60 !12.40    125.60 ! RETINOL SCH3, Schiff's base, protonated 
!vib calc, mode 9 
!CG2DC2 CG2R52 NG3C51   60.00    122.00 ! CY3_MAL_ , from CG2DC2 CG2R52 NG311, penalty= 3 
 
!CG3C50 CG2R52 NG3C51   60.00    122.00 ! CY3_MAL_ , from CG2D1 CG2R52 NG311, penalty= 67 
CG3C50 CG2R52 NG2R52  170.00    112.00 !copied from 2PRZ, 2-pyrazoline; 3HPR, 3H-pyrrole N2-C3-C4 
 
CG2R51 CG2R51 CG2R53   90.00    106.00 ! CY3_MAL_ , from CG2R51 CG2R51 CG2R52, penalty= 1 
CG2R53 CG2R51 HGR51    15.00    127.60 ! CY3_MAL_ , from CG2R52 CG2R51 HGR51, penalty= 1 
 
CG2DC2 CG2R52 CG3C50   10.00     123.50 !25.30    123.50 ! RETINOL MECH !vib calc, mode 9 
!CG2DC1 CG2R52 CG3C50  115.00    109.00 ! CY3_MAL_ , from CG2R51 CG2R51 CG3C52, penalty= 28.7 
 
CG2DC2 CG2R52 NG2R52   10.00    125.60 !12.40    125.60 ! RETINOL SCH3, Schiff's base, protonated 
!vib calc, mode 9 
!CG2DC1 CG2R52 NG2R52  121.00    110.00 ! CY3_MAL_ , from CG2R51 CG2R52 NG2R52, penalty= 22.5 
 
 
! Starting with some of the maleimide linkers from Correy: 
CG2R51 CG2R53 NG2R51 70.00 105.60 
!CG2R51 CG2R53 NG2R51  130.00    106.00 ! CY3_MAL_ , from CG2R51 CG2R51 NG2R51, penalty= 15 
!NH2  CC   CA     70.000   105.6000  (correy) 
 
CG2R51 CG2R53 OG2D1 80.00 131.50 
!CG2R51 CG2R53 OG2D1    55.00    125.50 ! CY3_MAL_ , from CG2DC1 CG2R53 OG2D1, penalty= 22.5 
!O    CC   CA     80.000   131.5000 (correy) 
 
CG321  CG321  NG2R51   50.00    113.00  
!CG321  CG321  NG2R51   70.00    113.50 ! CY3_MAL_ , from CG321 CG321 NG2S1, penalty= 11 
!NH2  CT2  CT2    50.000   113.0000 
 
CG321  CG321  NG2R52   43.70    112.20 ! CY3_MAL_ , from CG331 CG321 NG311, penalty= 3.9 
!CG321  CG321  NG3C51   43.70    112.20 ! CY3_MAL_ , from CG331 CG321 NG311, penalty= 3.9 
 
NG2R52 CG321  HGA2     33.43    110.10 ! NA FOR 9-M-G(C), adm jr. 
!NG2R52 CG321  HGA2     32.40    109.50   50.00   2.13000 ! CY3_MAL_ , from NG311 CG321 HGA2, 
penalty= 3 
!NG3C51 CG321  HGA2     32.40    109.50   50.00   2.13000 ! CY3_MAL_ , from NG311 CG321 HGA2, 
penalty= 3 
 
CG331  CG324  NG2R52   67.70    110.00 ! CY3_MAL_ , from CG321 CG324 NG2P1, penalty= 2.9 
 
CG2R52 CG3C50 CG2RC0  105.00    105.00 ! 3HIN, 3H-indole, mode 13  
!CG2R52 CG3C50 CG2RC0   70.00    105.00 ! CY3_MAL_ , from CG2R52 CG3C52 CG2RC0, penalty= 10 
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CG2R52 CG3C50 CG2RC0  105.00    105.00 ! 3HIN, 3H-indole, mode 13  
!CG2R52 CG3C50 CG331    80.00     99.00 ! CY3_MAL_ , from CG2R52 CG3C52 CG3C52, penalty= 16 
 
CG2R53 NG2R51 CG2R53 110.0 111.43 
!CG2R53 NG2R51 CG2R53  130.00    107.50 ! CY3_MAL_ , from CG2R51 NG2R51 CG2R53, penalty= 3 
!CC   NH2  CC    110.000   111.4300 (correy) 
 
CG2R53 NG2R51 CG321  50.00 123.20 
!CG2R53 NG2R51 CG321    70.00    127.80 ! CY3_MAL_ , from CG2R53 NG2R51 CG331, penalty= 0.9 
!CC   NH2  CT2    50.000   124.2000 (correy) 
 
CG2R52 NG2R52 CG2RC0   60.00    107.20 ! copied from 3HIN, 3H-indole !equilibrium angle changed 
to agree better with iqbal 
!CG2R52 NG3C51 CG2RC0   40.00    109.00 ! CY3_MAL_ , from CG2R61 NG311 CG2R61, penalty= 42.5 
 
CG2RC0  NG2R52  CG321    62.30    112.30 ! PROT 107.5->120.0 to make planar Arg (KK) !modified 
equilibrium 
!CG2RC0 NG3C51 CG321    60.00    106.90 ! CY3_MAL_ , from CG2RC0 NG3C51 CG3C52, penalty= 6 
 
CG2R52  NG2R52  CG321    62.30    140.50 ! PROT 107.5->120.0 to make planar Arg (KK) !modified 
equilibrium 
!CG2R52 NG3C51 CG321    45.00    104.80 ! CY3_MAL_ , from CG2R51 NG3C51 CG3C52, penalty= 28.5 
 
CG2R52 NG2R52 CG324   101.00    111.90 ! CY3_MAL_ , from CG2R52 NG2R52 CG3C54, penalty= 1.2 
!CG2R52  NG2R52  CG324    62.30    140.50 ! PROT 107.5->120.0 to make planar Arg (KK) !modified 
equilibrium 
 
CG2RC0 NG2R52 CG324   101.00    111.90 ! CY3_MAL_ , from CG2R52 NG2R52 CG3C54, penalty= 4.2 
!CG2RC0  NG2R52  CG324    62.30    112.30 ! PROT 107.5->120.0 to make planar Arg (KK) !modified 
equilibrium 
 
NG2R51 CG321 HGA2  44.000   107.9000 
!NH2  CT2  HA     44.000   107.9000 
 
!from PRES SAX 
CS   SM   CT2    55.000   100.00 
 
SM   CS   CG2R53     40.000   118.80 
!SM   CS   CC     40.000   118.80 
 
SM   CS   CG2R51     40.000   133.25 
!SM   CS   CA     40.000   133.25 
 
CS CG2R53 OG2D1   80.000   126.75 
!CS   CC   O      80.000   126.75 
 
CG2R51 CS CG2R53  52.000   108.00 
!CA   CS   CC     52.000   108.00 
 
CS CG2R53 NG2R51  70.000   106.12 
!CS   CC   NH2    70.000   106.12 
 
CG2R53 CG2R51 CS  52.000   108.56 
!CS   CA   CC     52.000   108.56 
 
CS CG2R51 HGR51   30.000   129.92 
!CS   CA   HP     30.000   129.92 
 
DIHEDRALS 
! 
!V(dihedral) = Kchi(1 + cos(n(chi) - delta)) 
!     
!Kchi: kcal/mole 
!n: multiplicity 
!delta: degrees 
!delta=180: minimum at 0, delta at 0, minimum at 180 
!delta=180: minimum at 0, delta at 0, minimum at 180 
!for mult = 2, delta at 180 = min at 0,180,  delta = 0 means min at 90 
 
!the next two may be duplicative as sch2 has only one of these dihedrals 
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!I use !! to describe unneeeded dihedrals from Spiriti (GDS) 
 
CG2DC2 CG2R52 NG2R52  CG324      1.0000  2   180.00 ! RETINOL SCH2, Schiff's base, protonated 
!vib calc mode 4 
!CG2DC2 CG2R52 NG2R52 CG324      6.0000  2   180.00 ! CY3_MAL_ , from CG2R51 CG2R52 NG2R52 
CG3C54, penalty= 23.7 
!CG2DC1 CG2R52 NG2R52 CG324      6.0000  2   180.00 ! CY3_MAL_ , from CG2R51 CG2R52 NG2R52 
CG3C54, penalty= 23.7 
 
CG2DC2 CG2R52 NG2R52  CG2RC0  1.5000  2   180.00 ! RETINOL SCH2, Schiff's base, protonated !vib 
calc mode 4 
!CG2DC2 CG2R52 NG3C51 CG2RC0     0.5000  2   180.00 ! CY3_MAL_ , from CG2DC2 CG2R52 NG311 CG2R52, 
penalty= 44 
 
HGA4   CG2DC2 CG2R52  NG2R52     0.5000  2   180.00 ! RETINOL SCH3, Schiff's base, protonated 
!vib calc mode 4 
!HGA4   CG2DC1 CG2R52 NG2R52     0.6000  2   180.00 ! CY3_MAL_ , from HGA4 CG2DC1 CG2R61 CG2R61, 
penalty= 77 
 
 
CG3C50  CG2R52  NG2R52  CG324    1.0000  2   180.00 ! RETINOL SCH2, Schiff's base, protonated 
!vib calc mode 4 
!CG3C50 CG2R52 NG2R52 CG324      6.0000  2   180.00 ! CY3_MAL_ , from CG2R51 CG2R52 NG2R52 
CG3C54, penalty= 72.7 
 
HGA2   CG324  NG2R52  CG2R52     0.1500  3   180.00 ! RETINOL SCH2, Schiff's base, protonated 
!HGA2   CG324  NG2R52 CG2R52     0.1500  3   180.00 ! CY3_MAL_ , from HGA3 CG334 NG2P1 CG2D1, 
penalty= 48 
 
HGA2   CG324  NG2R52  CG2RC0     0.1500  3   180.00 ! RETINOL SCH2, Schiff's base, protonated 
!HGA2   CG324  NG2R52 CG2RC0     0.1500  3   180.00 ! CY3_MAL_ , from HGA3 CG334 NG2P1 CG2D1, 
penalty= 48 
 
!from mech, retinol anlaogs 
!double all constants for half mode 2 
 
!CG3C50  CG2R52 CG2DC2 CG2DC2     0.9000  1     0.00 ! RETINOL MECH 
 
CG3C50  CG2R52 CG2DC2 CG2DC2     2.1000  2   180.00 ! RETINOL MECH 
!CG3C50 CG2R52 CG2DC2 CG2DC1     1.5000  1   180.00 ! CY3_MAL_ , from OG301 CG2R52 CG2DC2 CG2DC1, 
penalty= 42 
 
CG3C50  CG2R52 CG2DC2 CG2DC2     0.2200  3     0.00 ! RETINOL MECH 
CG3C50  CG2R52 CG2DC2 CG2DC2     0.2500  5   180.00 ! RETINOL MECH 
!CG3C50 CG2R52 CG2DC2 CG2DC1     1.5000  1   180.00 ! CY3_MAL_ , from OG301 CG2R52 CG2DC2 CG2DC1, 
penalty= 42 
!CG3C50 CG2R52 CG2DC2 CG2DC1    15.0000  2   180.00 ! CY3_MAL_ , from OG301 CG2R52 CG2DC2 CG2DC1, 
penalty= 42 
 
 
CG3C50  CG2R52 CG2DC2 CG2DC2     0.1000  6     0.00 ! RETINOL MECH 
!CG3C50  CG2R52 CG2DC2 CG2DC2     0.7000  1     0.00 ! RETINOL MECH 
!CG3C50  CG2R52 CG2DC2 CG2DC2     1.7000  2   180.00 ! RETINOL MECH 
!CG3C50  CG2R52 CG2DC2 CG2DC2     0.1700  3     0.00 ! RETINOL MECH 
!CG3C50  CG2R52 CG2DC2 CG2DC2     0.2000  5   180.00 ! RETINOL MECH 
!CG3C50  CG2R52 CG2DC2 CG2DC2     0.0800  6     0.00 ! RETINOL MECH 
 
CG3C50  CG2R52 CG2DC2 HGA4       0.5000  2   180.00 ! RETINOL MECH !vib calc mode 4 
!CG3C50 CG2R52 CG2DC2 HGA4       3.0000  2   180.00 ! CY3_MAL_ , from OG301 CG2R52 CG2DC2 HGA4, 
penalty= 42 
 
NG2R52 CG2R52 CG3C50  CG331      0.5000  2     0.00 ! RETINOL TMCH !vib calc mode 4 
NG2R52 CG2R52 CG3C50  CG331      0.4000  3     0.00 ! RETINOL TMCH !vib calc mode 4 
!NG2R52 CG2R52 CG3C50 CG331      2.8000  3   180.00 ! CY3_MAL_ , from NG2R50 CG2R52 CG3C52 
CG3C52, penalty= 42 
 
CG2DC2 CG2R52 CG3C50  CG331      0.3000  3     0.00 ! RETINOL MECH !vib calc mode 4 
!CG2DC2 CG2R52 CG3C50 CG331      0.1000  2   180.00 ! CY3_MAL_ , from CG2DC2 CG2R52 NG301 CG3C51, 
penalty= 306.4 
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CG2RC0 CG2RC0 CG3C50  CG331      0.5000  2     0.00 ! RETINOL TMCH !this one causes "almost 
linear" errors 
CG2RC0 CG2RC0 CG3C50  CG331      0.4000  3     0.00 ! RETINOL TMCH !this one causes "almost 
linear" errors 
!CG2RC0 CG2RC0 CG3C50 CG331      1.0300  3   180.00 ! CY3_MAL_ , from CG2RC0 CG2RC0 CG3C52 
CG3C52, penalty= 16 
 
CG2R61 CG2RC0 CG3C50  CG331      0.5000  2     0.00 ! RETINOL TMCH !half mode 2 
CG2R61 CG2RC0 CG3C50  CG331      0.4000  3     0.00 ! RETINOL TMCH !half mode 2 
!CG2R61 CG2RC0 CG3C50 CG331      3.0000  2   180.00 ! CY3_MAL_ , from CG2R61 CG2RC0 CG3C52 
CG3C52, penalty= 16 
 
CG2R52 CG3C50  CG331  HGA3       0.1600  3     0.00 ! RETINOL TMCH 
!CG2R52 CG3C50  CG331  HGA3       0.1600  3     0.00 ! RETINOL TMCH 
!HGA3   CG331  CG3C50 CG2R52     0.1600  3     0.00 ! CY3_MAL_ , from CG2D1 CG321 CG331 HGA3, 
penalty= 68 
 
CG2RC0 CG3C50  CG331  HGA3       0.1600  3     0.00 ! RETINOL TMCH 
!CG2RC0 CG3C50  CG331  HGA3       0.1600  3     0.00 ! RETINOL TMCH 
!HGA3   CG331  CG3C50 CG2RC0     0.1600  3     0.00 ! CY3_MAL_ , from CG2R51 CG321 CG331 HGA3, 
penalty= 66 
 
HGA3   CG331  CG3C50 CG331      0.1600  3     0.00 ! CY3_MAL_ , from HGA3 CG331 CG3C51 CG3C52, 
penalty= 12 
!CG331  CG3C50  CG331  HGA3       0.1600  3     0.00 ! RETINOL TMCH 
!HGA3   CG331  CG3C50 CG331      0.1600  3     0.00 ! CY3_MAL_ , from HGA3 CG331 CG3C51 CG3C52, 
penalty= 12 
 
CG2DC2 CG2R52 CG3C50  CG2RC0      0.0000  3     0.00 ! RETINOL MECH !vib calc, mode 4, the 5 
member ring is more rigid than the 6 member. 
!CG2DC2 CG2R52 CG3C50 CG2RC0     0.5000  2   180.00 ! CY3_MAL_ , from CG2DC2 CG2R52 NG311 CG2R52, 
penalty= 319 
 
!from 3HIN 
NG2R52 CG2R52 CG3C50 CG2RC0     1.3000  3   180.00 ! 3HIN, 3H-indole !vib calc, mode 4-5 
!NG2R52 CG2R52 CG3C50 CG2RC0     3.5000  3   180.00 ! CY3_MAL_ , from NG2R50 CG2R52 CG3C52 
CG2RC0, penalty= 36 
 
CG3C50 CG2R52 NG2R52 CG2RC0     6.0000  2   180.00 ! 3HIN, 3H-indole !vib calc, mode 4-5 
!CG3C50 CG2R52 NG2R52 CG2RC0     2.5000  2   180.00 ! CY3_MAL_ , from CG321 CG2R51 NG2R52 CG2R53, 
penalty= 14 
 
CG2R61 CG2R61 CG2RC0 CG3C50     0.0000  2   180.00 ! 3HIN, 3H-indole 
!CG2R61 CG2R61 CG2RC0 CG3C50     0.0000  2   180.00 ! CY3_MAL_ , from CG2R61 CG2R61 CG2RC0 
CG3C52, penalty= 1.2 
 
CG2R61 CG2R61 CG2RC0 NG2R52     1.5000  2   180.00 ! ZIMI, benzimidazole 
!CG2R61 CG2R61 CG2RC0 NG2R52     3.0000  2   180.00 ! CY3_MAL_ , from CG2R61 CG2R61 CG2RC0 
NG2R51, penalty= 25 
 
CG2R61 CG2RC0 CG2RC0 CG3C50     2.5000  2   180.00 ! 3HIN, 3H-indole !vib calc mode 5 
!CG2R61 CG2RC0 CG2RC0 CG3C50     6.5000  2   180.00 ! CY3_MAL_ , from CG2R61 CG2RC0 CG2RC0 
CG3C52, penalty= 1.2 
 
CG2RC0 CG2RC0 CG3C50 CG2R52     0.5000  3   180.00 ! 3HIN, 3H-indole !vib calc mode 5 
!CG2RC0 CG2RC0 CG3C50 CG2R52     1.0000  3   180.00 ! CY3_MAL_ , from CG2RC0 CG2RC0 CG3C52 
CG2R51, penalty= 32.5 
 
CG2R61 CG2RC0 NG2R52 CG2R52     4.0000  2   180.00 ! 3HIN, 3H-indole 
!CG2R61 CG2RC0 NG2R52 CG2R52    12.0000  2   180.00 ! CY3_MAL_ , from CG2R51 CG2R51 NG2R52 
CG2R53, penalty= 40 
 
CG2R61 CG2RC0 CG3C50 CG2R52     3.5000  3     0.00 ! 3HIN, 3H-indole 
!CG2R61 CG2RC0 CG3C50 CG2R52     0.9000  3     0.00 ! CY3_MAL_ , from CG2R61 CG2RC0 CG3C52 
CG2R51, penalty= 32.5 
!CG2R61 CG2RC0 CG3C50 CG2R52     3.5000  3     0.00 ! CY3_MAL_ , from CG2R61 CG2RC0 CG3C52 
CG2R52, penalty= 10 
 
CG2RC0 CG2RC0 NG2R52 CG2R52     4.0000  2   180.00 ! 3HIN, 3H-indole !half mode 2 
!CG2RC0 CG2RC0 NG2R52 CG2R52    12.0000  2   180.00 ! CY3_MAL_ , from CG2R51 CG2R51 NG2R52 
CG2R53, penalty= 32 
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CG3C50 CG2RC0 CG2RC0 NG2R52     6.5000  2   180.00 ! 3HIN, 3H-indole !vib calc mode 4-5 
!CG3C50 CG2RC0 CG2RC0 NG2R52     6.5000  2   180.00 ! CY3_MAL_ , from CG3C52 CG2RC0 CG2RC0 
NG2R50, penalty= 27.2 
 
CG2R61 CG2RC0 CG2RC0 NG2R52     1.5000  2   180.00 ! ZIMI, benzimidazole 
!CG2R61 CG2RC0 CG2RC0 NG2R52     1.5000  2   180.00 ! CY3_MAL_ , from CG2R61 CG2RC0 CG2RC0 
NG2R51, penalty= 25 
 
HGR61  CG2R61 CG2RC0 NG2R52     0.8000  2   180.00 ! ZIMI, benzimidazole 
!HGR61  CG2R61 CG2RC0 NG2R52     3.0000  2   180.00 ! CY3_MAL_ , from HGR61 CG2R61 CG2RC0 NG2R51, 
penalty= 25 
 
HGR61  CG2R61 CG2RC0 CG3C50     0.0000  2   180.00 ! 3HIN, 3H-indole 
!HGR61  CG2R61 CG2RC0 CG3C50     0.0000  2   180.00 ! CY3_MAL_ , from HGR61 CG2R61 CG2RC0 CG3C52, 
penalty= 1.2 
 
!9-ethyl-guanine 
CG2RC0 CG2RC0 NG2R52 CG324      9.0000  2   180.00 ! 9MAD, 9-Methyl-Adenine, kevo for gsk/ibm, 
half mode 4 
!CG2RC0 CG2RC0 NG2R52 CG324      6.0000  2   180.00 ! CY3_MAL_ , from CG2R51 CG2R52 NG2R52 
CG3C54, penalty= 37.2 
 
CG2R61 CG2RC0 NG2R52 CG324      9.0000  2   180.00 ! 9MAD, 9-Methyl-Adenine, kevo for gsk/ibm, 
half mode 4 
!CG2R61 CG2RC0 NG2R52 CG324      6.0000  2   180.00 ! CY3_MAL_ , from CG2R51 CG2R52 NG2R52 
CG3C54, penalty= 45.2 
 
!others 
 
HGA3   CG331  CG3C50 CG331      0.1600  3     0.00 ! CY3_MAL_ , from HGA3 CG331 CG3C51 CG3C52, 
penalty= 12 
!CG331  CG3C50  CG331  HGA3       0.1600  3     0.00 ! RETINOL TMCH 
 
NG2R52 CG324  CG331  HGA3       0.1950  3     0.00 ! CY3_MAL_ , from HGA2 CG321 CG324 NG2P1, 
penalty= 8 
 
CG2RC0 CG2RC0 CG3C50 CG2R52     0.5000  3   180.00 ! 3HIN, 3H-indole !vib calc mode 5 
!CG2RC0 CG2RC0 CG3C50 CG2R52     2.0000  3   180.00 ! CY3_MAL_ , from CG2RC0 CG2RC0 CG3C52 
CG2R52, penalty= 10 
 
!to match vib freqs I had to make these so soft, might get isomerization 
CG2R52 CG2DC2 CG2DC2 CG2DC2     0.5600  1   180.00 ! RETINOL HEP3, 1,3,5-heptatriene 
CG2R52 CG2DC2 CG2DC2 CG2DC2     4.0000  2   180.00 ! RETINOL HEP3, 1,3,5-heptatriene !mode 1-2, 
vib calc 
!CG2DC2 CG2DC1 CG2DC1 CG2R52     0.5600  1   180.00 ! CY3_MAL_ , from CG2DC2 CG2DC1 CG2DC1 
CG2DC2, penalty= 22.5 
!CG2DC2 CG2DC1 CG2DC1 CG2R52     7.0000  2   180.00 ! CY3_MAL_ , from CG2DC2 CG2DC1 CG2DC1 
CG2DC2, penalty= 22.5 
 
!use the same one to make about C2A-CX1 for more double bond character 
NG2R52 CG2R52 CG2DC2 CG2DC2     0.5600  1   180.00 ! RETINOL HEP3, 1,3,5-heptatriene 
NG2R52 CG2R52 CG2DC2 CG2DC2     9.0000  2   180.00 ! RETINOL HEP3, 1,3,5-heptatriene !mode 1-2, 
vib calc 
!CG2DC1 CG2DC1 CG2R52 NG2R52     3.0000  2   180.00 ! CY3_MAL_ , from CG2D1O CG2DC1 CG2R53 
NG2R51, penalty= 38 
 
!All 4 bonds across the linker are as stiff as the central bond in 1,3,5-hexatriene.  
!This probably makes the linker too stiff but it's better than being too floppy in this case. 
CG2DC2 CG2DC2 CG2DC2 HGA4       5.2000  2   180.00 ! RETINOL 13DB, 1,3-Butadiene !modes 1-2, vib 
calc 
CG2R52 CG2DC2 CG2DC2 HGA4       5.2000  2   180.00 ! RETINOL 13DB, 1,3-Butadiene !modes 1-2, vib 
calc 
!CG2R52 CG2DC1 CG2DC1 HGA4       5.2000  2   180.00 ! CY3_MAL_ , from CG2DC2 CG2DC1 CG2DC1 HGA4, 
penalty= 22.5 
 
CG2RC0 CG2R61 CG2R61 SG3O1      3.1000  2   180.00 ! based on toluene, adm jr., 3/7/92 
!CG2RC0 CG2R61 CG2R61 SG3O1      3.1000  2   180.00 ! CY3_MAL_ , from CG2R61 CG2R61 CG2R61 SG3O1, 
penalty= 1.5 
!spiriti didn't use S03 
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!arginine 
!!HGA2   CG321  CG324  NG2R52     0.1950  3     0.00 ! PROT alkane update, adm jr., 3/2/92 
 
!HGA2   CG324  NG2R52  CG2R52      0.0000  6   180.00 ! PROT methylguanidinium, adm jr., 3/26/92 
!HGA2   CG324  NG2R52  CG2RC0   0.0000  6   180.00 ! PROT methylguanidinium, adm jr., 3/26/92 
 
!These are especially important as they are along the angles we wish to study. 
!!CG321  CG321  CG324  NG2R52     0.1950  3     0.00 ! PROT alkane update, adm jr., 3/2/92 
(arginine) 
!!CG321  CG324  NG2R52  CG2R52   2.2500  1     0.00 ! PROT methylguanidinium, adm jr., 
3/26/92  !B3LYP/6-31+g(d,p) dihedral scan 
!!CG321  CG324  NG2R52  CG2R52   0.9000  2   180.00 ! PROT methylguanidinium, adm jr., 
3/26/92 
!!CG321  CG324  NG2R52  CG2RC0   2.2500  1   180.00 ! PROT methylguanidinium, adm jr., 
3/26/92 
!!CG321  CG324  NG2R52  CG2RC0   0.9000  2   180.00 ! PROT methylguanidinium, adm jr., 
3/26/92 
 
!these are not from arginine but also along the linker. 
!!CG324  CG321  CG321  OG303      0.1950  3     0.00 ! PROT alkane update, adm jr., 3/2/92 
!!CG324  CG321  CG321  OG311      0.1950  3     0.00 ! PROT alkane update, adm jr., 3/2/92 
!!CG324  CG321  CG321  ON2        0.1950  3     0.00 ! PROT alkane update, adm jr., 3/2/92 
 
!NG3C51=NG2R52 
 
CG2RC0 CG2RC0 NG2R52 CG321      1.9600  3     0.00 ! CY3_MAL_ , from CG2RC0 CG2RC0 NG3C51 CG3C52, 
penalty= 6 
!CG2RC0 CG2RC0 NG3C51 CG321      1.9600  3     0.00 ! CY3_MAL_ , from CG2RC0 CG2RC0 NG3C51 
CG3C52, penalty= 6 
 
CG2R61 CG2RC0 NG2R52 CG321      4.0000  2   180.00 ! CY3_MAL_ , from CG2R61 CG2RC0 NG3C51 CG3C52, 
penalty= 6 
!CG2R61 CG2RC0 NG2R52 CG324      9.0000  2   180.00 ! 9MAD, 9-Methyl-Adenine, kevo for gsk/ibm, 
half mode 4 
 
CG321  CG321  CG321  NG2R52     1.0000  3     0.00 ! CY3_MAL_ , from CG321 CG321 CG324 NG3P2, 
penalty= 16 
!CG321  CG321  CG324  NG2R52     0.1950  3     0.00 ! PROT alkane update, adm jr., 3/2/92 
(arginine) 
!CG321  CG321  CG321  NG3C51     1.0000  3     0.00 ! CY3_MAL_ , from CG321 CG321 CG324 NG3P2, 
penalty= 16 
 
CG3C50 CG2RC0 CG2RC0 NG2R52     6.0000  2   180.00 ! CY3_MAL_ , from CG3C52 CG2RC0 CG2RC0 NG3C51, 
penalty= 1.2 
!CG3C50 CG2RC0 CG2RC0 NG3C51     6.0000  2   180.00 ! CY3_MAL_ , from CG3C52 CG2RC0 CG2RC0 
NG3C51, penalty= 1.2 
 
CG2DC2 CG2R52 NG2R52  CG2RC0  1.5000  2   180.00 ! RETINOL SCH2, Schiff's base, protonated !vib 
calc mode 4 
!CG2DC2 CG2R52 NG3C51 CG2RC0     0.5000  2   180.00 ! CY3_MAL_ , from CG2DC2 CG2R52 NG311 CG2R52, 
penalty= 44 
!CG2DC2 CG2R52 NG2R52  CG2RC0  1.5000  2   180.00 ! RETINOL SCH2, Schiff's base, protonated !vib 
calc mode 4 
 
CG2DC2 CG2R52 NG2R52 CG321       1.0000  2   180.00  
!CG2DC2 CG2R52 NG3C51 CG321      0.1000  2   180.00 ! CY3_MAL_ , from CG2DC2 CG2R52 NG301 CG3C51, 
penalty= 31.4 
!CG2DC2 CG2R52 NG2R52  CG324      1.0000  2   180.00 ! RETINOL SCH2, Schiff's base, protonated 
!vib calc mode 4 
 
CG3C50 CG2R52 NG2R52 CG2RC0     6.0000  2   180.00 ! 3HIN, 3H-indole !vib calc, mode 4-5 
!CG3C50 CG2R52 NG3C51 CG2RC0     0.1000  2   180.00 ! CY3_MAL_ , from CG2D1 CG2R52 NG311 CG2R52, 
penalty= 108 
!CG3C50 CG2R52 NG2R52 CG2RC0     6.0000  2   180.00 ! 3HIN, 3H-indole !vib calc, mode 4-5 
 
CG3C50  CG2R52  NG2R52  CG324    1.0000  2   180.00 ! RETINOL SCH2, Schiff's base, protonated 
!vib calc mode 4 
!CG3C50 CG2R52 NG3C51 CG321      0.1000  2   180.00 ! CY3_MAL_ , from CG2D1 CG2R52 NG301 CG3C51, 
penalty= 95.4 
!CG3C50  CG2R52  NG2R52  CG324    1.0000  2   180.00 ! RETINOL SCH2, Schiff's base, protonated 
!vib calc mode 4 
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HGA2   CG324  NG2R52  CG2R52     0.1500  3   180.00 ! RETINOL SCH2, Schiff's base, protonated 
!HGA2   CG321  NG3C51 CG2R52     0.0000  3   180.00 ! CY3_MAL_ , from HGA3 CG331 NG311 CG2N1, 
penalty= 58 
!HGA2   CG324  NG2R52  CG2R52     0.1500  3   180.00 ! RETINOL SCH2, Schiff's base, protonated 
 
HGA2   CG324  NG2R52  CG2RC0     0.1500  3   180.00 ! RETINOL SCH2, Schiff's base, protonated 
!HGA2   CG321  NG3C51 CG2RC0     0.0000  3   180.00 ! CY3_MAL_ , from HGA3 CG331 NG311 CG2N1, 
penalty= 59 
!HGA2   CG324  NG2R52  CG2RC0     0.1500  3   180.00 ! RETINOL SCH2, Schiff's base, protonated 
 
CG2R61 CG2RC0 NG2R52 CG2R52     4.0000  2   180.00 ! 3HIN, 3H-indole 
!CG2R61 CG2RC0 NG3C51 CG2R52     0.4400  2     0.00 ! CY3_MAL_ , from CG2R61 CG2R61 NG311 CG2R61, 
penalty= 61! 
!CG2R61 CG2RC0 NG2R52 CG2R52     4.0000  2   180.00 ! 3HIN, 3H-indole 
 
CG2RC0 CG2RC0 NG2R52 CG2R52     4.0000  2   180.00 ! 3HIN, 3H-indole !half mode 2 
!CG2RC0 CG2RC0 NG3C51 CG2R52     0.4400  2     0.00 ! CY3_MAL_ , from CG2R61 CG2R61 NG311 CG2R61, 
penalty= 62.5 
!CG2RC0 CG2RC0 NG2R52 CG2R52     4.0000  2   180.00 ! 3HIN, 3H-indole !half mode 2 
 
NG3C51 CG321  CG321  HGA2       0.1600  3     0.00 ! CY3_MAL_ , from NG311 CG321 CG331 HGA3, 
penalty= 9 
 
NG2R52 CG2R52 CG2DC2 CG2DC2     0.5600  1   180.00 ! RETINOL HEP3, 1,3,5-heptatriene 
!NG3C51 CG2R52 CG2DC2 CG2DC1     2.5000  2   180.00 ! CY3_MAL_ , from NG311 CG2R52 CG2DC2 CG2O1, 
penalty= 32 
!NG2R52 CG2R52 CG2DC2 CG2DC2     0.5600  1   180.00 ! RETINOL HEP3, 1,3,5-heptatriene 
 
NG2R52 CG2R52 CG3C50 CG2RC0     1.3000  3   180.00 ! 3HIN, 3H-indole !vib calc, mode 4-5 
!NG3C51 CG2R52 CG3C50 CG2RC0     0.1000  2   180.00 ! CY3_MAL_ , from CG2D1 CG2R52 NG311 CG2R52, 
penalty= 383 
!NG2R52 CG2R52 CG3C50 CG2RC0     1.3000  3   180.00 ! 3HIN, 3H-indole !vib calc, mode 4-5 
 
NG2R52 CG2R52 CG3C50  CG331      0.5000  2     0.00 ! RETINOL TMCH !vib calc mode 4 
!NG3C51 CG2R52 CG3C50 CG331      0.1000  2   180.00 ! CY3_MAL_ , from CG2D1 CG2R52 NG301 CG3C51, 
penalty= 370.4 
!NG2R52 CG2R52 CG3C50  CG331      0.5000  2     0.00 ! RETINOL TMCH !vib calc mode 4 
 
CG321  CG321  NG2R52  CG2R52   2.2500  1     0.00 ! PROT methylguanidinium, adm jr., 3/26/92  
!B3LYP/6-31+g(d,p) dihedral scan 
!CG321  CG321  NG3C51 CG2R52     0.0500  3   180.00 ! CY3_MAL_ , from CG3C52 CG3C52  CG2R51, 
penalty= 108.5 
!CG321  CG324  NG2R52  CG2R52   2.2500  1     0.00 ! PROT methylguanidinium, adm jr., 3/26/92  
!B3LYP/6-31+g(d,p) dihedral scan 
 
CG321  CG321  NG2R52  CG2RC0     0.9000  2   180.00 ! PROT methylguanidinium, adm jr., 3/26/92 
!CG321  CG324  NG2R52  CG2RC0    0.9000  2   180.00 ! PROT methylguanidinium, adm jr., 3/26/92 
!CG321  CG321  NG3C51 CG2RC0     1.4500  3   180.00 ! CY3_MAL_ , from CG3C52 CG3C52 NG3C51 
CG2RC0, penalty= 86 
 
!!NG3C51 CG2R52 CG2DC2 HGA4       3.0000  2   180.00 ! CY3_MAL_ , from OG301 CG2R52 CG2DC2 HGA4, 
penalty= 33 
!!duplicate of HGA4 CG2DC2 CG2R52  NG2R52     0.5000  2   180.00 ! RETINOL SCH3, Schiff's base, 
protonated !vib calc mode 4 
 
!CG2DC1=CG2DC2 
 
HGA4   CG2DC1 CG2R52 CG3C50      0.5000  2   180.00 
!HGA4   CG2DC1 CG2R52 CG3C50     0.6000  2   180.00 ! CY3_MAL_ , from HGA4 CG2DC1 CG2R61 CG2R61, 
penalty= 110 
!CG3C50  CG2R52 CG2DC2 HGA4       0.5000  2   180.00 ! RETINOL MECH !vib calc mode 4 
 
CG2DC2 CG2R52 CG3C50  CG331      0.3000  3     0.00 ! RETINOL MECH !vib calc mode 4 
!CG2DC2 CG2R52 CG3C50  CG331      0.3000  3     0.00 ! RETINOL MECH !vib calc mode 4 
!CG2DC1 CG2R52 CG3C50 CG331      0.0500  3   180.00 ! CY3_MAL_ , from CG2R51 CG2R51 CG3C52 
CG3C52, penalty= 43.5 
 
CG2DC2 CG2R52 CG3C50  CG2RC0      0.0000  3     0.00 ! RETINOL MECH !vib calc, mode 4, the 5 
member ring is more rigid than the 6 member. 
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!CG2DC1 CG2R52 CG3C50 CG2RC0     1.5000  3   180.00 ! CY3_MAL_ , from CG2R51 CG2R51 CG3C52 
CG2RC0, penalty= 37.5 
!CG2DC2 CG2R52 CG3C50  CG2RC0      0.0000  3     0.00 ! RETINOL MECH !vib calc, mode 4, the 5 
member ring is more rigid than the 6 member. 
 
CG3C50  CG2R52 CG2DC2 CG2DC2     0.9000  1     0.00 ! RETINOL MECH 
CG3C50  CG2R52 CG2DC2 CG2DC2     2.1000  2   180.00 ! RETINOL MECH 
CG3C50  CG2R52 CG2DC2 CG2DC2     0.2200  3     0.00 ! RETINOL MECH 
CG3C50  CG2R52 CG2DC2 CG2DC2     0.2500  5   180.00 ! RETINOL MECH 
CG3C50  CG2R52 CG2DC2 CG2DC2     0.1000  6     0.00 ! RETINOL MECH 
!CG2DC1 CG2DC1 CG2R52 CG3C50     3.0000  2   180.00 ! CY3_MAL_ , from CG2D1O CG2DC1 CG2R53 
NG2R51, penalty= 83 
 
NG2R52 CG2R52 CG2DC2 CG2DC2     9.0000  2   180.00 ! RETINOL HEP3, 1,3,5-heptatriene !mode 1-2, 
vib calc 
!CG2DC1 CG2DC1 CG2R52 NG2R52     3.0000  2   180.00 ! CY3_MAL_ , from CG2D1O CG2DC1 CG2R53 
NG2R51, penalty= 38 
!NG2R52 CG2R52 CG2DC2 CG2DC2     9.0000  2   180.00 ! RETINOL HEP3, 1,3,5-heptatriene !mode 1-2, 
vib calc 
 
!duplicate CG2DC2 CG2R52 NG2R52  CG324      1.0000  2   180.00 ! RETINOL SCH2, Schiff's base, 
protonated !vib calc mode 4 
!CG2DC1 CG2R52 NG2R52 CG324      6.0000  2   180.00 ! CY3_MAL_ , from CG2R51 CG2R52 NG2R52 
CG3C54, penalty= 23.7 
!CG2DC2 CG2R52 NG2R52  CG324      1.0000  2   180.00 ! RETINOL SCH2, Schiff's base, protonated 
!vib calc mode 4 
 
 
CG2R52 CG2DC2 CG2DC2 CG2DC2     0.5600  1   180.00 ! RETINOL HEP3, 1,3,5-heptatriene 
CG2R52 CG2DC2 CG2DC2 CG2DC2     4.0000  2   180.00 ! RETINOL HEP3, 1,3,5-heptatriene !mode 1-2, 
vib calc 
!CG2DC2 CG2DC1 CG2DC1 CG2R52     0.5600  1   180.00 ! CY3_MAL_ , from CG2DC2 CG2DC1 CG2DC1 
CG2DC2, penalty= 22.5 
!CG2DC2 CG2DC1 CG2DC1 CG2R52     7.0000  2   180.00 ! CY3_MAL_ , from CG2DC2 CG2DC1 CG2DC1 
CG2DC2, penalty= 22.5 
 
CG321  CG321  CG324  NG2R52     0.1950  3     0.00 ! PROT alkane update, adm jr., 3/2/92 
(arginine) 
 
HGA2   CG321  CG324  NG2R52     0.1950  3     0.00 ! PROT alkane update, adm jr., 3/2/92 
 
CG321  CG324  NG2R52  CG2R52   2.2500  1     0.00 ! PROT methylguanidinium, adm jr., 3/26/92  
!B3LYP/6-31+g(d,p) dihedral scan 
 
CG321  CG324  NG2R52  CG2RC0   2.2500  1   180.00 ! PROT methylguanidinium, adm jr., 3/26/92 
CG321  CG324  NG2R52  CG2RC0   0.9000  2   180.00 ! PROT methylguanidinium, adm jr., 3/26/92 
 
!matched to correy 
HGA2   CG321  NG2R51 CG2R53     0.0000  3     0.00 ! CY3_MAL_ , from HGA3 CG331 NG2R51 CG2R53, 
penalty= 6 
!HA   CT2  NH2  CC       0.0000  3      0.00 
 
CG2R53 CG2R51 CG2R51 HGR51       4.200   2    180.00 
!CG2R53 CG2R51 CG2R51 HGR51      2.6000  2   180.00 ! CY3_MAL_ , from CG2R52 CG2R51 CG2R51 HGR51, 
penalty= 1 
!CC   CA   CA   HP       4.200   2    180.00 
 
CG2R53 CG2R51 CG2R51 CG2R53     3.1000   2   180.00 
!CG2R53 CG2R51 CG2R51 CG2R53    15.0000  2   180.00 ! CY3_MAL_ , from CG2R51 CG2R51 CG2R51 
CG2R51, penalty= 6 
!CC   CA   CA   CC       3.1000  2    180.00  
 
CG2R51 CG2R53 NG2R51 CG2R53     3.1      2   180.00 
!CC   NH2  CC   CA              3.1000  2    180.00 
 
CG2R51 CG2R53 NG2R51 CG321      0.0000  1     0.00 ! CY3_MAL_ , from CG2R51 CG2R51 NG2R51 CG3C51, 
penalty= 21.4 
!CT2  NH2  CC   CA              2.5000  2    180.00 
 
CG2R51 CG2R51 CG2R53 NG2R51      3.1000  2    180.00 
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!CG2R51 CG2R51 CG2R53 NG2R51     4.0000  2   180.00 ! CY3_MAL_ , from CG2R51 CG2R51 CG2R51 
NG2R51, penalty= 15 
!NH2  CC   CA   CA               3.1000  2    180.00 
 
NG2R51 CG321  CG321  HGA2       0.1950  3     0.00 ! CY3_MAL_ , from NG2S1 CG321 CG321 HGA2, 
penalty= 11 
!^can't find this dihedral 
 
OG2D1  CG2R53 NG2R51 CG2R53      3.1000  2   180.00 
!OG2D1  CG2R53 NG2R51 CG2R53     2.5000  2   180.00 ! CY3_MAL_ , from OG2D1 CG2R53 NG2R51 CG2RC0, 
penalty= 7 
!O    CC   NH2  CC               3.1000  2    180.00  
 
CG2R51 CG2R51 CG2R53 OG2D1       3.1000  2   0.00 
!CG2R51 CG2R51 CG2R53 OG2D1      8.5000  2   180.00 ! CY3_MAL_ , from CG2R51 CG2R51 CG2R51 
OG2R50, penalty= 39 
!O    CC   CA   CA               3.1000  2    0.00  
 
CG321  CG321  NG2R51 CG2R53      0.2000  1    180.00 
!CG321  CG321  NG2R51 CG2R53     1.8000  1     0.00 ! CY3_MAL_ , from CG321 CG311 NG2R53 CG2R53, 
penalty= 64 
!CT2  CT2  NH2  CC               0.2000  1    180.00  
 
CG2R52 CG3C50  CG331  HGA3       0.1600  3     0.00 ! RETINOL TMCH 
!HGA3   CG331  CG3C50 CG2R52     0.1600  3     0.00 ! CY3_MAL_ , from CG2D1 CG321 CG331 HGA3, 
penalty= 68 
!CG2R52 CG3C50  CG331  HGA3       0.1600  3     0.00 ! RETINOL TMCH 
!HGA3   CG331  CG3C50 CG2R52     0.1600  3     0.00 ! CY3_MAL_ , from CG2R51 CG321 CG331 HGA3, 
penalty= 67 
 
 
CG2RC0 CG3C50  CG331  HGA3       0.1600  3     0.00 ! RETINOL TMCH 
!HGA3   CG331  CG3C50 CG2RC0     0.1600  3     0.00 ! CY3_MAL_ , from CG2R51 CG321 CG331 HGA3, 
penalty= 66 
!CG2RC0 CG3C50  CG331  HGA3       0.1600  3     0.00 ! RETINOL TMCH 
 
OG2D1  CG2R53 NG2R51 CG321       2.5000  2    180.00 
!OG2D1  CG2R53 NG2R51 CG321     11.0000  2   180.00 ! CY3_MAL_ , from NG2R50 CG2R53 NG2R51 CG331, 
penalty= 46.9 
!O    CC   NH2  CT2      2.5000  2    180.00  
 
CG331  CG324  NG2R52  CG2R52   2.2500  1     0.00 ! PROT methylguanidinium, adm jr., 3/26/92  
!B3LYP/6-31+g(d,p) dihedral scan 
CG331  CG324  NG2R52  CG2R52   0.9000  2   180.00 ! PROT methylguanidinium, adm jr., 3/26/92 
!CG331  CG324  NG2R52 CG2R52     0.0000  6   180.00 ! CY3_MAL_ , from CG321 CG324 NG2P1 CG2N1, 
penalty= 53.9 
!!CG321  CG324  NG2R52  CG2R52   2.2500  1     0.00 ! PROT methylguanidinium, adm jr., 
3/26/92  !B3LYP/6-31+g(d,p) dihedral scan 
!!CG321  CG324  NG2R52  CG2R52   0.9000  2   180.00 ! PROT methylguanidinium, adm jr., 
3/26/92 
 
CG331  CG324  NG2R52  CG2RC0   2.2500  1   180.00 ! PROT methylguanidinium, adm jr., 3/26/92 
CG331  CG324  NG2R52  CG2RC0   0.9000  2   180.00 ! PROT methylguanidinium, adm jr., 3/26/92 
!CG331  CG324  NG2R52 CG2RC0     0.0000  6   180.00 ! CY3_MAL_ , from CG321 CG324 NG2P1 CG2N1, 
penalty= 53.9 
!!CG321  CG324  NG2R52  CG2RC0   2.2500  1   180.00 ! PROT methylguanidinium, adm jr., 
3/26/92 
!!CG321  CG324  NG2R52  CG2RC0   0.9000  2   180.00 ! PROT methylguanidinium, adm jr., 
3/26/92 
 
 
!!CG321  CG321  CG324  NG2R52     0.1950  3     0.00 ! PROT alkane update, adm jr., 3/2/92 
(arginine) 
 
NG2R51 CG2R53 CG2R51 HGR51  4.2000  2  180.00 
!NH2  CC   CA   HP       4.2000  2    180.00 
 
!HERE Is the new dihedral for Cy5 
 
CG2DC2 CG2DC2 CG2DC2 CG2DC2     0.5600  1   180.00  
CG2DC2 CG2DC2 CG2DC2 CG2DC2     7.0000  2   180.00  
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!CG2DC2 CG2DC1 CG2DC1 CG2DC2     0.5600  1   180.00 ! RETINOL HEP3, 1,3,5-heptatriene 
!CG2DC2 CG2DC1 CG2DC1 CG2DC2     7.0000  2   180.00 ! RETINOL HEP3, 1,3,5-heptatriene 
 
 
!HERE are the new dihedrals for the linker: 
CG2O1  CG321  CG321  CG321      0.1950  3     0.00 ! CY3_MAL_ , from CG2O1 CG321 CG321 CG311, 
penalty= 0.6 
NG2R51 CG321  CG321  NG2S1      0.1900  3     0.00 ! CY3_MAL_ , from CG2R61 CG321 CG321 NG2S1, 
penalty= 47 
 
!!and HERE are the dihedrals created by PRES SAX 
CS   SM   CT2  HA       0.158   3      0.0 
!DIHE 1HB1 1CB 1SG 2CL10 
!DIHE 1HB2 1CB 1SG 2CL10 
 
CT2  SM   CS   CG2R51       2.4     2    180.0  
!DIHE 1CB 1SG 2CL10 2CL11 
 
CT2  SM   CS   CG2R53       2.4     2    180.0 
!DIHE 1CB 1SG 2CL10 2CL9 
 
SM   CS   CG2R53   OG2D1        3.1     2    180.0 
!DIHE 2O2 2CL9 2CL10 1SG 
 
SM   CS   CG2R53   NG2R51      3.1     2    180.0 
!DIHE NL2 2CL9 2CL10 1SG 
 
SM   CS   CG2R51   HGR51       2.4     2    180.0 
!DIHE 2H10 2C11 2CL10 1SG 
 
SM   CS   CG2R51   CG2R53       3.1     2    180.0 
!DIHE 2CL12 2CL11 2CL10 1SG 
 
CS   SM   CT2  CT1      0.31    3      0.0 
!DIHE 1CA 1CB 1SG 2CL10  !(added/GDS) 
 
CS CG2R51 CG2R53 OG2D1   3.1     2    180.0  
!CS   CA   CC   O        3.1     2    180.0 
 
CG2R51 CS CG2R53 OG2D1   3.1     2    180.0 
!O    CC   CS   CA       3.1     2    180.0 
 
CG2R53 CS CG2R51 CG2R53  3.1     2    180.0 
!CC   CA   CS   CC       3.1     2    180.0 
 
CG2R53 CS CG2R51 HGR51   4.2     2    180.0 
!HP   CA   CS   CC       4.2     2    180.0 
 
CG321 NG2R51 CG2R53 CS   2.5     2    180.0 
!CS   CC   NH2  CT2      2.5     2    180.0 
 
NG2R51  CG2R53  CG2R51  CS  3.1   2  180.0 
!CS   CA   CC   NH2      3.1     2    180.0 
 
NG2R51 CG2R53 CS CG2R51  3.1     2    180.0 
!CA   CS   CC   NH2      3.1     2    180.0 
 
CG2R53 NG2R51 CG2R53 CS  3.1     2    180.0 
!CS   CC   NH2  CC       3.1     2    180.0 
 
OG2D1 CG2R53 CG2R51 HGR51    4.2000   2    180.00 
!O    CC   CA   HP       4.2000  2    180.00  
 
IMPROPERS 
CG2R53 CG2R51 NG2R51 OG2D1     90.0000  0     0.00 ! CY3_MAL_ , from CG2R53 CG2DC1 NG2R51 OG2D1, 
penalty= 57 
CG2R53 CS NG2R51 OG2D1     90.0000  0     0.00 ! CY3_MAL_ , from CG2R53 CG2DC1 NG2R51 OG2D1, 
penalty= 57 
 
NONBONDED 
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